id	sid	tid	token	lemma	pos
iajs-2011	1	1	microsoft	microsoft	PROPN
iajs-2011	1	2	word	word	PROPN
iajs-2011	1	3	63	63	NUM
iajs-2011	1	4	-	-	SYM
iajs-2011	1	5	69	69	NUM
iajs-2011	1	6	chemistry	chemistry	NOUN
iajs-2011	1	7	|	|	ADP
iajs-2011	1	8	63	63	NUM
iajs-2011	1	9	ibn	ibn	PROPN
iajs-2011	1	10	al	al	PROPN
iajs-2011	1	11	-	-	PUNCT
iajs-2011	1	12	haitham	haitham	PROPN
iajs-2011	1	13	jour	jour	X
iajs-2011	1	14	.	.	PROPN
iajs-2011	2	1	for	for	ADP
iajs-2011	2	2	pure	pure	ADJ
iajs-2011	2	3	&	&	CCONJ
iajs-2011	2	4	appl	appl	PROPN
iajs-2011	2	5	.	.	PUNCT
iajs-2011	3	1	sci	sci	PROPN
iajs-2011	3	2	.	.	PROPN
iajs-2011	3	3	ihjpas	ihjpa	VERB
iajs-2011	3	4	https://doi.org/10.30526/31.3.2011	https://doi.org/10.30526/31.3.2011	X
iajs-2011	3	5	vol	vol	NOUN
iajs-2011	3	6	.	.	PROPN
iajs-2011	4	1	31	31	NUM
iajs-2011	4	2	(	(	PUNCT
iajs-2011	4	3	3	3	NUM
iajs-2011	4	4	)	)	SYM
iajs-2011	4	5	2018	2018	NUM
iajs-2011	4	6	comparison	comparison	NOUN
iajs-2011	4	7	study	study	NOUN
iajs-2011	4	8	of	of	ADP
iajs-2011	4	9	the	the	DET
iajs-2011	4	10	effect	effect	NOUN
iajs-2011	4	11	of	of	ADP
iajs-2011	4	12	erlotinib	erlotinib	NOUN
iajs-2011	4	13	as	as	ADP
iajs-2011	4	14	a	a	DET
iajs-2011	4	15	tyrosine	tyrosine	NOUN
iajs-2011	4	16	kinase	kinase	NOUN
iajs-2011	4	17	inhibitor	inhibitor	NOUN
iajs-2011	4	18	on	on	ADP
iajs-2011	4	19	electrolyte	electrolyte	ADJ
iajs-2011	4	20	levels	level	NOUN
iajs-2011	4	21	in	in	ADP
iajs-2011	4	22	type2	type2	PROPN
iajs-2011	4	23	diabetic	diabetic	ADJ
iajs-2011	4	24	and	and	CCONJ
iajs-2011	4	25	diabetic	diabetic	ADJ
iajs-2011	4	26	nephropathy	nephropathy	NOUN
iajs-2011	4	27	zainab	zainab	PROPN
iajs-2011	4	28	mahdi	mahdi	PROPN
iajs-2011	4	29	abed	abed	PROPN
iajs-2011	4	30	al	al	PROPN
iajs-2011	4	31	-	-	PUNCT
iajs-2011	4	32	khdhairi	khdhairi	PROPN
iajs-2011	4	33	bushra	bushra	PROPN
iajs-2011	4	34	h.	h.	PROPN
iajs-2011	4	35	ali	ali	PROPN
iajs-2011	4	36	department	department	PROPN
iajs-2011	4	37	of	of	ADP
iajs-2011	4	38	chemistry	chemistry	NOUN
iajs-2011	4	39	,	,	PUNCT
iajs-2011	4	40	college	college	NOUN
iajs-2011	4	41	of	of	ADP
iajs-2011	4	42	education	education	NOUN
iajs-2011	4	43	for	for	ADP
iajs-2011	4	44	pure	pure	ADJ
iajs-2011	4	45	science	science	NOUN
iajs-2011	4	46	ibn	ibn	PROPN
iajs-2011	4	47	al	al	PROPN
iajs-2011	4	48	-	-	PUNCT
iajs-2011	4	49	haitham	haitham	PROPN
iajs-2011	4	50	,	,	PUNCT
iajs-2011	4	51	university	university	PROPN
iajs-2011	4	52	of	of	ADP
iajs-2011	4	53	baghdad	baghdad	PROPN
iajs-2011	4	54	,	,	PUNCT
iajs-2011	4	55	baghdad	baghdad	PROPN
iajs-2011	4	56	,	,	PUNCT
iajs-2011	4	57	iraq	iraq	PROPN
iajs-2011	4	58	zainabmh1977@gmail.com	zainabmh1977@gmail.com	NOUN
iajs-2011	4	59	article	article	PROPN
iajs-2011	4	60	history	history	NOUN
iajs-2011	4	61	:	:	PUNCT
iajs-2011	4	62	received	receive	VERB
iajs-2011	4	63	26	26	NUM
iajs-2011	4	64	june	june	PROPN
iajs-2011	4	65	2018	2018	NUM
iajs-2011	4	66	,	,	PUNCT
iajs-2011	4	67	accepted	accept	VERB
iajs-2011	4	68	18	18	NUM
iajs-2011	4	69	july	july	PROPN
iajs-2011	4	70	2018	2018	NUM
iajs-2011	4	71	,	,	PUNCT
iajs-2011	4	72	published	publish	VERB
iajs-2011	4	73	december	december	PROPN
iajs-2011	4	74	2018	2018	NUM
iajs-2011	4	75	.	.	PUNCT
iajs-2011	5	1	abstract	abstract	ADJ
iajs-2011	5	2	diabetes	diabetes	NOUN
iajs-2011	5	3	mellitus	mellitus	NOUN
iajs-2011	5	4	can	can	AUX
iajs-2011	5	5	be	be	AUX
iajs-2011	5	6	defined	define	VERB
iajs-2011	5	7	as	as	ADP
iajs-2011	5	8	a	a	DET
iajs-2011	5	9	metabolic	metabolic	NOUN
iajs-2011	5	10	disorder	disorder	NOUN
iajs-2011	5	11	disease	disease	NOUN
iajs-2011	5	12	.	.	PUNCT
iajs-2011	6	1	complication	complication	NOUN
iajs-2011	6	2	of	of	ADP
iajs-2011	6	3	diabetes	diabetes	NOUN
iajs-2011	6	4	are	be	AUX
iajs-2011	6	5	due	due	ADJ
iajs-2011	6	6	to	to	ADP
iajs-2011	6	7	diabetic	diabetic	ADJ
iajs-2011	6	8	nephropathy	nephropathy	NOUN
iajs-2011	6	9	.	.	PUNCT
iajs-2011	7	1	this	this	DET
iajs-2011	7	2	study	study	NOUN
iajs-2011	7	3	was	be	AUX
iajs-2011	7	4	done	do	VERB
iajs-2011	7	5	in	in	ADP
iajs-2011	7	6	vitro	vitro	X
iajs-2011	7	7	to	to	PART
iajs-2011	7	8	study	study	VERB
iajs-2011	7	9	the	the	DET
iajs-2011	7	10	effect	effect	NOUN
iajs-2011	7	11	of	of	ADP
iajs-2011	7	12	different	different	ADJ
iajs-2011	7	13	concentrations	concentration	NOUN
iajs-2011	7	14	of	of	ADP
iajs-2011	7	15	erlotinib	erlotinib	ADJ
iajs-2011	7	16	inhibitor	inhibitor	NOUN
iajs-2011	7	17	(	(	PUNCT
iajs-2011	7	18	tyrosine	tyrosine	NOUN
iajs-2011	7	19	kinase	kinase	PROPN
iajs-2011	7	20	inhibitor	inhibitor	PROPN
iajs-2011	7	21	)	)	PUNCT
iajs-2011	7	22	on	on	ADP
iajs-2011	7	23	electrolyte	electrolyte	ADJ
iajs-2011	7	24	levels	level	NOUN
iajs-2011	7	25	(	(	PUNCT
iajs-2011	7	26	mg⁺²	mg⁺²	NOUN
iajs-2011	7	27	,	,	PUNCT
iajs-2011	7	28	ca⁺²	ca⁺²	NOUN
iajs-2011	7	29	,	,	PUNCT
iajs-2011	7	30	na⁺	na⁺	NOUN
iajs-2011	7	31	)	)	PUNCT
iajs-2011	7	32	in	in	ADP
iajs-2011	7	33	sera	sera	NOUN
iajs-2011	7	34	of	of	ADP
iajs-2011	7	35	iraqi	iraqi	ADJ
iajs-2011	7	36	patients	patient	NOUN
iajs-2011	7	37	with	with	ADP
iajs-2011	7	38	newly	newly	ADJ
iajs-2011	7	39	diagnosis	diagnosis	NOUN
iajs-2011	7	40	type2	type2	NOUN
iajs-2011	7	41	diabetes	diabetes	NOUN
iajs-2011	7	42	and	and	CCONJ
iajs-2011	7	43	diabetic	diabetic	ADJ
iajs-2011	7	44	nephropathy	nephropathy	NOUN
iajs-2011	7	45	in	in	ADP
iajs-2011	7	46	addition	addition	NOUN
iajs-2011	7	47	to	to	PART
iajs-2011	7	48	find	find	VERB
iajs-2011	7	49	the	the	DET
iajs-2011	7	50	best	good	ADJ
iajs-2011	7	51	percentage	percentage	NOUN
iajs-2011	7	52	inhibition	inhibition	NOUN
iajs-2011	7	53	for	for	ADP
iajs-2011	7	54	utilizing	utilize	VERB
iajs-2011	7	55	different	different	ADJ
iajs-2011	7	56	concentrations	concentration	NOUN
iajs-2011	7	57	from	from	ADP
iajs-2011	7	58	erlotinib	erlotinib	NOUN
iajs-2011	7	59	(	(	PUNCT
iajs-2011	7	60	6.97x10⁻⁷	6.97x10⁻⁷	ADP
iajs-2011	7	61	,	,	PUNCT
iajs-2011	7	62	9.30x10⁻⁷	9.30x10⁻⁷	NUM
iajs-2011	7	63	,	,	PUNCT
iajs-2011	7	64	1.16x10⁻⁶,1.39x10⁻⁶	1.16x10⁻⁶,1.39x10⁻⁶	NUM
iajs-2011	7	65	,	,	PUNCT
iajs-2011	7	66	1.62x10⁻⁵	1.62x10⁻⁵	X
iajs-2011	7	67	)	)	PUNCT
iajs-2011	7	68	molar	molar	NOUN
iajs-2011	7	69	on	on	ADP
iajs-2011	7	70	electrolyte	electrolyte	ADJ
iajs-2011	7	71	levels	level	NOUN
iajs-2011	7	72	.	.	PUNCT
iajs-2011	8	1	this	this	DET
iajs-2011	8	2	study	study	NOUN
iajs-2011	8	3	was	be	AUX
iajs-2011	8	4	conducted	conduct	VERB
iajs-2011	8	5	in	in	ADP
iajs-2011	8	6	the	the	DET
iajs-2011	8	7	national	national	ADJ
iajs-2011	8	8	diabetes	diabetes	NOUN
iajs-2011	8	9	center	center	NOUN
iajs-2011	8	10	,	,	PUNCT
iajs-2011	8	11	almustansiriya	almustansiriya	PROPN
iajs-2011	8	12	university	university	PROPN
iajs-2011	8	13	baghdad	baghdad	PROPN
iajs-2011	8	14	and	and	CCONJ
iajs-2011	8	15	included	include	VERB
iajs-2011	8	16	150	150	NUM
iajs-2011	8	17	patients	patient	NOUN
iajs-2011	8	18	divided	divide	VERB
iajs-2011	8	19	into50	into50	NOUN
iajs-2011	8	20	patients	patient	NOUN
iajs-2011	8	21	type	type	VERB
iajs-2011	8	22	2	2	NUM
iajs-2011	8	23	diabetic	diabetic	NOUN
iajs-2011	8	24	as	as	ADP
iajs-2011	8	25	group	group	NOUN
iajs-2011	8	26	(	(	PUNCT
iajs-2011	8	27	g2	g2	PROPN
iajs-2011	8	28	)	)	PUNCT
iajs-2011	8	29	,	,	PUNCT
iajs-2011	8	30	50patients	50patients	NUM
iajs-2011	8	31	diabetic	diabetic	ADJ
iajs-2011	8	32	nephropathy	nephropathy	NOUN
iajs-2011	8	33	as	as	ADP
iajs-2011	8	34	group(g3	group(g3	NOUN
iajs-2011	8	35	)	)	PUNCT
iajs-2011	8	36	and	and	CCONJ
iajs-2011	8	37	also	also	ADV
iajs-2011	8	38	50	50	NUM
iajs-2011	8	39	healthy	healthy	ADJ
iajs-2011	8	40	as	as	ADP
iajs-2011	8	41	control	control	NOUN
iajs-2011	8	42	group(g1	group(g1	NOUN
iajs-2011	8	43	)	)	PUNCT
iajs-2011	8	44	.	.	PUNCT
iajs-2011	9	1	the	the	DET
iajs-2011	9	2	period	period	NOUN
iajs-2011	9	3	time	time	NOUN
iajs-2011	9	4	for	for	ADP
iajs-2011	9	5	aggregation	aggregation	NOUN
iajs-2011	9	6	the	the	DET
iajs-2011	9	7	blood	blood	NOUN
iajs-2011	9	8	sampling	sampling	NOUN
iajs-2011	9	9	was	be	AUX
iajs-2011	9	10	from	from	ADP
iajs-2011	9	11	july	july	PROPN
iajs-2011	9	12	to	to	ADP
iajs-2011	9	13	october	october	PROPN
iajs-2011	9	14	2017	2017	NUM
iajs-2011	9	15	.	.	PUNCT
iajs-2011	10	1	all	all	DET
iajs-2011	10	2	patients	patient	NOUN
iajs-2011	10	3	were	be	AUX
iajs-2011	10	4	within	within	ADP
iajs-2011	10	5	(	(	PUNCT
iajs-2011	10	6	18	18	NUM
iajs-2011	10	7	to	to	PART
iajs-2011	10	8	60	60	NUM
iajs-2011	10	9	)	)	PUNCT
iajs-2011	10	10	year	year	NOUN
iajs-2011	10	11	's	's	PART
iajs-2011	10	12	age	age	NOUN
iajs-2011	10	13	.	.	PUNCT
iajs-2011	11	1	erlotinib	erlotinib	PROPN
iajs-2011	11	2	(	(	PUNCT
iajs-2011	11	3	tyrosine	tyrosine	NOUN
iajs-2011	11	4	kinase	kinase	PROPN
iajs-2011	11	5	inhibitor	inhibitor	PROPN
iajs-2011	11	6	)	)	PUNCT
iajs-2011	11	7	affected	affect	VERB
iajs-2011	11	8	on	on	ADP
iajs-2011	11	9	serum	serum	NOUN
iajs-2011	11	10	mg	mg	PROPN
iajs-2011	11	11	⁺²levels	⁺²levels	PROPN
iajs-2011	11	12	in	in	ADP
iajs-2011	11	13	human	human	NOUN
iajs-2011	11	14	as	as	ADP
iajs-2011	11	15	a	a	DET
iajs-2011	11	16	mild	mild	ADJ
iajs-2011	11	17	effect	effect	NOUN
iajs-2011	11	18	and	and	CCONJ
iajs-2011	11	19	a	a	DET
iajs-2011	11	20	slight	slight	ADJ
iajs-2011	11	21	effect	effect	NOUN
iajs-2011	11	22	on	on	ADP
iajs-2011	11	23	serum	serum	NOUN
iajs-2011	11	24	na⁺	na⁺	PROPN
iajs-2011	11	25	and	and	CCONJ
iajs-2011	11	26	ca⁺².the	ca⁺².the	PRON
iajs-2011	11	27	best	good	ADJ
iajs-2011	11	28	inhibition	inhibition	NOUN
iajs-2011	11	29	of	of	ADP
iajs-2011	11	30	erlotinib	erlotinib	NOUN
iajs-2011	11	31	in	in	ADP
iajs-2011	11	32	concentration	concentration	NOUN
iajs-2011	11	33	(	(	PUNCT
iajs-2011	11	34	1.62x10⁻5	1.62x10⁻5	X
iajs-2011	11	35	)	)	PUNCT
iajs-2011	11	36	m	m	VERB
iajs-2011	11	37	for	for	ADP
iajs-2011	11	38	both	both	PRON
iajs-2011	11	39	serum	serum	NOUN
iajs-2011	11	40	na⁺	na⁺	NOUN
iajs-2011	11	41	and	and	CCONJ
iajs-2011	11	42	ca⁺²	ca⁺²	NOUN
iajs-2011	11	43	in	in	ADP
iajs-2011	11	44	newly	newly	ADJ
iajs-2011	11	45	diagnosis	diagnosis	NOUN
iajs-2011	11	46	diabetes	diabetes	NOUN
iajs-2011	11	47	type	type	NOUN
iajs-2011	11	48	2	2	NUM
iajs-2011	11	49	and	and	CCONJ
iajs-2011	11	50	diabetic	diabetic	ADJ
iajs-2011	11	51	nephropathy	nephropathy	NOUN
iajs-2011	11	52	.	.	PUNCT
iajs-2011	12	1	serum	serum	NOUN
iajs-2011	12	2	mg	mg	PROPN
iajs-2011	12	3	⁺²levels	⁺²levels	PROPN
iajs-2011	12	4	showed	show	VERB
iajs-2011	12	5	best	good	ADJ
iajs-2011	12	6	inhibition	inhibition	NOUN
iajs-2011	12	7	in	in	ADP
iajs-2011	12	8	concentration	concentration	NOUN
iajs-2011	12	9	(	(	PUNCT
iajs-2011	12	10	9.30x10⁻7	9.30x10⁻7	NUM
iajs-2011	12	11	)	)	PUNCT
iajs-2011	12	12	m.	m.	NOUN
iajs-2011	12	13	keywords	keyword	NOUN
iajs-2011	12	14	:	:	PUNCT
iajs-2011	12	15	diabetes	diabetes	NOUN
iajs-2011	12	16	mellitus	mellitus	NOUN
iajs-2011	12	17	type	type	VERB
iajs-2011	12	18	2	2	NUM
iajs-2011	12	19	,	,	PUNCT
iajs-2011	12	20	diabetic	diabetic	ADJ
iajs-2011	12	21	nephropathy	nephropathy	NOUN
iajs-2011	12	22	,	,	PUNCT
iajs-2011	12	23	electrolyte	electrolyte	NOUN
iajs-2011	12	24	(	(	PUNCT
iajs-2011	12	25	mg⁺²	mg⁺²	PROPN
iajs-2011	12	26	,	,	PUNCT
iajs-2011	12	27	ca⁺²	ca⁺²	NOUN
iajs-2011	12	28	,	,	PUNCT
iajs-2011	12	29	na⁺	na⁺	PROPN
iajs-2011	12	30	)	)	PUNCT
iajs-2011	12	31	,	,	PUNCT
iajs-2011	12	32	erlotinib	erlotinib	VERB
iajs-2011	12	33	inhibitor	inhibitor	NOUN
iajs-2011	12	34	.	.	PUNCT
iajs-2011	13	1	1	1	X
iajs-2011	13	2	.	.	X
iajs-2011	13	3	introduction	introduction	NOUN
iajs-2011	13	4	diabetes	diabetes	NOUN
iajs-2011	13	5	mellitus	mellitus	NOUN
iajs-2011	13	6	can	can	AUX
iajs-2011	13	7	be	be	AUX
iajs-2011	13	8	defined	define	VERB
iajs-2011	13	9	as	as	ADP
iajs-2011	13	10	a	a	DET
iajs-2011	13	11	metabolic	metabolic	NOUN
iajs-2011	13	12	disorder	disorder	NOUN
iajs-2011	13	13	disease	disease	NOUN
iajs-2011	13	14	categorized	categorize	VERB
iajs-2011	13	15	by	by	ADP
iajs-2011	13	16	hyperglycemia	hyperglycemia	NOUN
iajs-2011	13	17	resulting	result	VERB
iajs-2011	13	18	from	from	ADP
iajs-2011	13	19	defects	defect	NOUN
iajs-2011	13	20	in	in	ADP
iajs-2011	13	21	insulin	insulin	NOUN
iajs-2011	13	22	secretion	secretion	NOUN
iajs-2011	13	23	,	,	PUNCT
iajs-2011	13	24	insulin	insulin	NOUN
iajs-2011	13	25	action	action	NOUN
iajs-2011	13	26	or	or	CCONJ
iajs-2011	13	27	both	both	PRON
iajs-2011	14	1	[	[	X
iajs-2011	14	2	1	1	NUM
iajs-2011	14	3	]	]	PUNCT
iajs-2011	14	4	.	.	PUNCT
iajs-2011	15	1	signs	sign	NOUN
iajs-2011	15	2	of	of	ADP
iajs-2011	15	3	hyperglycemia	hyperglycemia	NOUN
iajs-2011	15	4	often	often	ADV
iajs-2011	15	5	contain	contain	VERB
iajs-2011	15	6	polyuria	polyuria	NOUN
iajs-2011	15	7	,	,	PUNCT
iajs-2011	15	8	polydipsia	polydipsia	NOUN
iajs-2011	15	9	,	,	PUNCT
iajs-2011	15	10	weight	weight	NOUN
iajs-2011	15	11	loss	loss	NOUN
iajs-2011	15	12	,	,	PUNCT
iajs-2011	15	13	polyphagia	polyphagia	NOUN
iajs-2011	15	14	,	,	PUNCT
iajs-2011	15	15	and	and	CCONJ
iajs-2011	15	16	unclear	unclear	ADJ
iajs-2011	15	17	vision	vision	NOUN
iajs-2011	15	18	[	[	X
iajs-2011	15	19	2	2	NUM
iajs-2011	15	20	]	]	PUNCT
iajs-2011	15	21	.	.	PUNCT
iajs-2011	16	1	chronic	chronic	ADJ
iajs-2011	16	2	symptoms	symptom	NOUN
iajs-2011	16	3	of	of	ADP
iajs-2011	16	4	diabetes	diabetes	NOUN
iajs-2011	16	5	include	include	VERB
iajs-2011	16	6	micro	micro	ADJ
iajs-2011	16	7	vascular	vascular	NOUN
iajs-2011	16	8	and	and	CCONJ
iajs-2011	16	9	macro	macro	ADJ
iajs-2011	16	10	vascular	vascular	ADJ
iajs-2011	16	11	complications	complication	NOUN
iajs-2011	16	12	that	that	PRON
iajs-2011	16	13	lead	lead	VERB
iajs-2011	16	14	to	to	ADP
iajs-2011	16	15	visual	visual	ADJ
iajs-2011	16	16	damage	damage	NOUN
iajs-2011	16	17	,	,	PUNCT
iajs-2011	16	18	blindness	blindness	NOUN
iajs-2011	16	19	,	,	PUNCT
iajs-2011	16	20	kidney	kidney	NOUN
iajs-2011	16	21	bug	bug	NOUN
iajs-2011	16	22	,	,	PUNCT
iajs-2011	16	23	nerve	nerve	NOUN
iajs-2011	16	24	loss	loss	NOUN
iajs-2011	16	25	,	,	PUNCT
iajs-2011	16	26	amputation	amputation	NOUN
iajs-2011	16	27	,	,	PUNCT
iajs-2011	16	28	heart	heart	NOUN
iajs-2011	16	29	illness	illness	NOUN
iajs-2011	16	30	,	,	PUNCT
iajs-2011	16	31	and	and	CCONJ
iajs-2011	16	32	stroke	stroke	NOUN
iajs-2011	17	1	[	[	X
iajs-2011	17	2	3	3	NUM
iajs-2011	17	3	]	]	PUNCT
iajs-2011	17	4	,	,	PUNCT
iajs-2011	17	5	and	and	CCONJ
iajs-2011	17	6	this	this	DET
iajs-2011	17	7	disease	disease	NOUN
iajs-2011	17	8	affect	affect	VERB
iajs-2011	17	9	a	a	DET
iajs-2011	17	10	wide	wide	ADJ
iajs-2011	17	11	spread	spread	NOUN
iajs-2011	17	12	countries	country	NOUN
iajs-2011	17	13	and	and	CCONJ
iajs-2011	17	14	in	in	ADP
iajs-2011	17	15	the	the	DET
iajs-2011	17	16	third	third	ADJ
iajs-2011	17	17	world	world	NOUN
iajs-2011	17	18	,	,	PUNCT
iajs-2011	17	19	about	about	ADP
iajs-2011	17	20	of	of	ADP
iajs-2011	17	21	382	382	NUM
iajs-2011	17	22	million	million	NUM
iajs-2011	17	23	people	people	NOUN
iajs-2011	17	24	with	with	ADP
iajs-2011	17	25	diabetes	diabetes	NOUN
iajs-2011	17	26	in	in	ADP
iajs-2011	17	27	2013	2013	NUM
iajs-2011	17	28	,	,	PUNCT
iajs-2011	17	29	expected	expect	VERB
iajs-2011	17	30	to	to	PART
iajs-2011	17	31	rise	rise	VERB
iajs-2011	17	32	to	to	ADP
iajs-2011	17	33	592	592	NUM
iajs-2011	17	34	million	million	NUM
iajs-2011	17	35	by	by	ADP
iajs-2011	17	36	2035(4	2035(4	NOUN
iajs-2011	17	37	)	)	PUNCT
iajs-2011	17	38	the	the	DET
iajs-2011	17	39	classification	classification	NOUN
iajs-2011	17	40	and	and	CCONJ
iajs-2011	17	41	diagnosis	diagnosis	NOUN
iajs-2011	17	42	of	of	ADP
iajs-2011	17	43	diabetes	diabete	NOUN
iajs-2011	17	44	established	establish	VERB
iajs-2011	17	45	by	by	ADP
iajs-2011	17	46	the	the	DET
iajs-2011	17	47	national	national	ADJ
iajs-2011	17	48	diabetes	diabetes	NOUN
iajs-2011	17	49	data	datum	NOUN
iajs-2011	17	50	group	group	NOUN
iajs-2011	17	51	(	(	PUNCT
iajs-2011	17	52	nddg)were	nddg)were	X
iajs-2011	17	53	published	publish	VERB
iajs-2011	17	54	in	in	ADP
iajs-2011	17	55	1979	1979	NUM
iajs-2011	17	56	[	[	X
iajs-2011	17	57	5	5	NUM
iajs-2011	17	58	]	]	PUNCT
iajs-2011	17	59	.	.	PUNCT
iajs-2011	18	1	diabetes	diabetes	NOUN
iajs-2011	18	2	complication	complication	NOUN
iajs-2011	18	3	diabetic	diabetic	ADJ
iajs-2011	18	4	nephropathy	nephropathy	NOUN
iajs-2011	18	5	(	(	PUNCT
iajs-2011	18	6	dn	dn	NOUN
iajs-2011	18	7	)	)	PUNCT
iajs-2011	18	8	is	be	AUX
iajs-2011	18	9	one	one	NUM
iajs-2011	18	10	of	of	ADP
iajs-2011	18	11	the	the	DET
iajs-2011	18	12	most	most	ADV
iajs-2011	18	13	important	important	ADJ
iajs-2011	18	14	long	long	ADJ
iajs-2011	18	15	-	-	PUNCT
iajs-2011	18	16	term	term	NOUN
iajs-2011	18	17	complication	complication	NOUN
iajs-2011	18	18	regarding	regard	VERB
iajs-2011	18	19	morbidity	morbidity	NOUN
iajs-2011	18	20	and	and	CCONJ
iajs-2011	18	21	mortality	mortality	NOUN
iajs-2011	18	22	in	in	ADP
iajs-2011	18	23	diabetics	diabetic	NOUN
iajs-2011	18	24	.	.	PUNCT
iajs-2011	19	1	the	the	DET
iajs-2011	19	2	clinical	clinical	ADJ
iajs-2011	19	3	syndrome	syndrome	NOUN
iajs-2011	19	4	of	of	ADP
iajs-2011	19	5	this	this	DET
iajs-2011	19	6	disease	disease	NOUN
iajs-2011	19	7	is	be	AUX
iajs-2011	19	8	recognized	recognize	VERB
iajs-2011	19	9	by	by	ADP
iajs-2011	19	10	continual	continual	ADJ
iajs-2011	19	11	albuminuria	albuminuria	NOUN
iajs-2011	19	12	,	,	PUNCT
iajs-2011	19	13	developmental	developmental	NOUN
iajs-2011	19	14	decreased	decrease	VERB
iajs-2011	19	15	in	in	ADP
iajs-2011	19	16	the	the	DET
iajs-2011	19	17	glomerular	glomerular	ADJ
iajs-2011	19	18	filtration	filtration	NOUN
iajs-2011	19	19	rate	rate	NOUN
iajs-2011	19	20	and	and	CCONJ
iajs-2011	19	21	increased	increase	VERB
iajs-2011	19	22	arterial	arterial	ADJ
iajs-2011	19	23	blood	blood	NOUN
iajs-2011	19	24	pressure	pressure	NOUN
iajs-2011	19	25	[	[	X
iajs-2011	19	26	6	6	NUM
iajs-2011	19	27	]	]	PUNCT
iajs-2011	19	28	.	.	PUNCT
iajs-2011	20	1	erlotinib	erlotinib	PROPN
iajs-2011	20	2	hydrochloride	hydrochloride	NOUN
iajs-2011	20	3	is	be	AUX
iajs-2011	20	4	an	an	DET
iajs-2011	20	5	orally	orally	ADV
iajs-2011	20	6	administered	administer	VERB
iajs-2011	20	7	small	small	ADJ
iajs-2011	20	8	molecule	molecule	NOUN
iajs-2011	20	9	inhibitor	inhibitor	NOUN
iajs-2011	20	10	of	of	ADP
iajs-2011	20	11	epidermal	epidermal	ADJ
iajs-2011	20	12	chemistry	chemistry	NOUN
iajs-2011	20	13	|	|	ADP
iajs-2011	20	14	64	64	NUM
iajs-2011	20	15	ibn	ibn	PROPN
iajs-2011	20	16	al	al	PROPN
iajs-2011	20	17	-	-	PUNCT
iajs-2011	20	18	haitham	haitham	PROPN
iajs-2011	20	19	jour	jour	X
iajs-2011	20	20	.	.	PROPN
iajs-2011	21	1	for	for	ADP
iajs-2011	21	2	pure	pure	ADJ
iajs-2011	21	3	&	&	CCONJ
iajs-2011	21	4	appl	appl	PROPN
iajs-2011	21	5	.	.	PUNCT
iajs-2011	22	1	sci	sci	PROPN
iajs-2011	22	2	.	.	PROPN
iajs-2011	22	3	ihjpas	ihjpa	VERB
iajs-2011	22	4	https://doi.org/10.30526/31.3.2011	https://doi.org/10.30526/31.3.2011	X
iajs-2011	22	5	vol	vol	NOUN
iajs-2011	22	6	.	.	PROPN
iajs-2011	23	1	31	31	NUM
iajs-2011	23	2	(	(	PUNCT
iajs-2011	23	3	3	3	NUM
iajs-2011	23	4	)	)	SYM
iajs-2011	23	5	2018	2018	NUM
iajs-2011	23	6	growth	growth	NOUN
iajs-2011	23	7	factor	factor	NOUN
iajs-2011	23	8	receptor	receptor	NOUN
iajs-2011	23	9	(	(	PUNCT
iajs-2011	23	10	egfr	egfr	X
iajs-2011	23	11	)	)	PUNCT
iajs-2011	23	12	tyrosine	tyrosine	NOUN
iajs-2011	23	13	kinase	kinase	NOUN
iajs-2011	24	1	[	[	X
iajs-2011	24	2	7	7	X
iajs-2011	24	3	]	]	PUNCT
iajs-2011	24	4	and	and	CCONJ
iajs-2011	24	5	this	this	DET
iajs-2011	24	6	drug	drug	NOUN
iajs-2011	24	7	a	a	PRON
iajs-2011	24	8	is	be	AUX
iajs-2011	24	9	quinazolinamine	quinazolinamine	NOUN
iajs-2011	24	10	with	with	ADP
iajs-2011	24	11	the	the	DET
iajs-2011	24	12	chemical	chemical	NOUN
iajs-2011	24	13	name	name	PROPN
iajs-2011	24	14	n(3ethynylphenyl)6	n(3ethynylphenyl)6	ADP
iajs-2011	24	15	,	,	PUNCT
iajs-2011	24	16	7	7	NUM
iajs-2011	24	17	-	-	PUNCT
iajs-2011	24	18	bis	bis	X
iajs-2011	24	19	(	(	PUNCT
iajs-2011	25	1	2methoxyethoxy)4	2methoxyethoxy)4	NUM
iajs-2011	25	2	quinazolinamine	quinazolinamine	NOUN
iajs-2011	25	3	[	[	X
iajs-2011	25	4	8	8	NUM
iajs-2011	25	5	]	]	PUNCT
iajs-2011	25	6	.	.	PUNCT
iajs-2011	26	1	electrolytes	electrolyte	NOUN
iajs-2011	26	2	are	be	AUX
iajs-2011	26	3	the	the	DET
iajs-2011	26	4	chemical	chemical	NOUN
iajs-2011	26	5	compounds	compound	NOUN
iajs-2011	26	6	present	present	ADJ
iajs-2011	26	7	in	in	ADP
iajs-2011	26	8	body	body	NOUN
iajs-2011	26	9	fluid	fluid	NOUN
iajs-2011	26	10	and	and	CCONJ
iajs-2011	26	11	take	take	VERB
iajs-2011	26	12	part	part	NOUN
iajs-2011	26	13	in	in	ADP
iajs-2011	26	14	some	some	PRON
iajs-2011	26	15	of	of	ADP
iajs-2011	26	16	the	the	DET
iajs-2011	26	17	important	important	ADJ
iajs-2011	26	18	body	body	NOUN
iajs-2011	26	19	processes	process	NOUN
iajs-2011	26	20	[	[	X
iajs-2011	26	21	9	9	NUM
iajs-2011	26	22	]	]	PUNCT
iajs-2011	26	23	.	.	PUNCT
iajs-2011	27	1	disturbances	disturbance	NOUN
iajs-2011	27	2	in	in	ADP
iajs-2011	27	3	serum	serum	NOUN
iajs-2011	27	4	electrolyte	electrolyte	PROPN
iajs-2011	27	5	levels	level	NOUN
iajs-2011	27	6	are	be	AUX
iajs-2011	27	7	found	find	VERB
iajs-2011	27	8	to	to	PART
iajs-2011	27	9	be	be	AUX
iajs-2011	27	10	associated	associate	VERB
iajs-2011	27	11	with	with	ADP
iajs-2011	27	12	diabetes	diabetes	NOUN
iajs-2011	27	13	mellitus	mellitus	NOUN
iajs-2011	28	1	[	[	X
iajs-2011	28	2	10	10	NUM
iajs-2011	28	3	]	]	SYM
iajs-2011	28	4	electrolyte	electrolyte	NOUN
iajs-2011	28	5	derangement	derangement	NOUN
iajs-2011	28	6	resulting	result	VERB
iajs-2011	28	7	from	from	ADP
iajs-2011	28	8	acute	acute	ADJ
iajs-2011	28	9	or	or	CCONJ
iajs-2011	28	10	chronic	chronic	ADJ
iajs-2011	28	11	complications	complication	NOUN
iajs-2011	28	12	of	of	ADP
iajs-2011	28	13	diabetes	diabetes	NOUN
iajs-2011	28	14	[	[	X
iajs-2011	28	15	11	11	NUM
iajs-2011	28	16	]	]	SYM
iajs-2011	28	17	.	.	PUNCT
iajs-2011	29	1	2	2	X
iajs-2011	29	2	.	.	X
iajs-2011	29	3	material	material	NOUN
iajs-2011	29	4	and	and	CCONJ
iajs-2011	29	5	method	method	VERB
iajs-2011	29	6	this	this	DET
iajs-2011	29	7	study	study	NOUN
iajs-2011	29	8	was	be	AUX
iajs-2011	29	9	conducted	conduct	VERB
iajs-2011	29	10	in	in	ADP
iajs-2011	29	11	the	the	DET
iajs-2011	29	12	national	national	ADJ
iajs-2011	29	13	diabetes	diabetes	NOUN
iajs-2011	29	14	center	center	NOUN
iajs-2011	29	15	,	,	PUNCT
iajs-2011	29	16	al	al	PROPN
iajs-2011	29	17	-	-	PUNCT
iajs-2011	29	18	mustansiriya	mustansiriya	PROPN
iajs-2011	29	19	university	university	PROPN
iajs-2011	29	20	–	–	PUNCT
iajs-2011	29	21	baghdad	baghdad	PROPN
iajs-2011	29	22	.	.	PUNCT
iajs-2011	30	1	the	the	DET
iajs-2011	30	2	results	result	NOUN
iajs-2011	30	3	included	include	VERB
iajs-2011	30	4	150	150	NUM
iajs-2011	30	5	patients	patient	NOUN
iajs-2011	30	6	divided	divide	VERB
iajs-2011	30	7	into50	into50	NOUN
iajs-2011	30	8	patients	patient	NOUN
iajs-2011	30	9	with	with	ADP
iajs-2011	30	10	type	type	NOUN
iajs-2011	30	11	2	2	NUM
iajs-2011	30	12	diabetic	diabetic	NOUN
iajs-2011	30	13	as	as	ADP
iajs-2011	30	14	(	(	PUNCT
iajs-2011	30	15	g2	g2	PROPN
iajs-2011	30	16	)	)	PUNCT
iajs-2011	30	17	,	,	PUNCT
iajs-2011	30	18	50	50	NUM
iajs-2011	30	19	patients	patient	NOUN
iajs-2011	30	20	with	with	ADP
iajs-2011	30	21	diabetic	diabetic	ADJ
iajs-2011	30	22	nephropathy	nephropathy	NOUN
iajs-2011	30	23	as	as	ADP
iajs-2011	30	24	(	(	PUNCT
iajs-2011	30	25	g3	g3	NOUN
iajs-2011	30	26	)	)	PUNCT
iajs-2011	30	27	and	and	CCONJ
iajs-2011	30	28	50	50	NUM
iajs-2011	30	29	healthy	healthy	ADJ
iajs-2011	30	30	as	as	ADP
iajs-2011	30	31	control	control	NOUN
iajs-2011	30	32	(	(	PUNCT
iajs-2011	30	33	g1	g1	PROPN
iajs-2011	30	34	)	)	PUNCT
iajs-2011	30	35	,	,	PUNCT
iajs-2011	30	36	the	the	DET
iajs-2011	30	37	period	period	NOUN
iajs-2011	30	38	time	time	NOUN
iajs-2011	30	39	for	for	ADP
iajs-2011	30	40	aggregation	aggregation	NOUN
iajs-2011	30	41	the	the	DET
iajs-2011	30	42	blood	blood	NOUN
iajs-2011	30	43	sampling	sample	VERB
iajs-2011	30	44	july	july	PROPN
iajs-2011	30	45	to	to	ADP
iajs-2011	30	46	october	october	PROPN
iajs-2011	30	47	2017	2017	NUM
iajs-2011	30	48	.	.	PUNCT
iajs-2011	31	1	all	all	DET
iajs-2011	31	2	subjects	subject	NOUN
iajs-2011	31	3	were	be	AUX
iajs-2011	31	4	within	within	ADP
iajs-2011	31	5	(	(	PUNCT
iajs-2011	31	6	18	18	NUM
iajs-2011	31	7	to	to	PART
iajs-2011	31	8	60	60	NUM
iajs-2011	31	9	)	)	PUNCT
iajs-2011	31	10	years	year	NOUN
iajs-2011	31	11	age	age	NOUN
iajs-2011	31	12	.	.	PUNCT
iajs-2011	32	1	approximately	approximately	ADV
iajs-2011	32	2	(	(	PUNCT
iajs-2011	32	3	3	3	X
iajs-2011	32	4	)	)	PUNCT
iajs-2011	32	5	ml	ml	NOUN
iajs-2011	32	6	of	of	ADP
iajs-2011	32	7	venous	venous	ADJ
iajs-2011	32	8	blood	blood	NOUN
iajs-2011	32	9	was	be	AUX
iajs-2011	32	10	put	put	VERB
iajs-2011	32	11	in	in	ADP
iajs-2011	32	12	plan	plan	NOUN
iajs-2011	32	13	tube	tube	NOUN
iajs-2011	32	14	to	to	PART
iajs-2011	32	15	evaluate	evaluate	VERB
iajs-2011	32	16	serum	serum	NOUN
iajs-2011	32	17	mg	mg	PROPN
iajs-2011	32	18	,	,	PUNCT
iajs-2011	32	19	ca	ca	NOUN
iajs-2011	32	20	and	and	CCONJ
iajs-2011	32	21	na	na	INTJ
iajs-2011	32	22	and	and	CCONJ
iajs-2011	32	23	by	by	ADP
iajs-2011	32	24	centrifugation	centrifugation	NOUN
iajs-2011	32	25	at	at	ADP
iajs-2011	32	26	3500	3500	NUM
iajs-2011	32	27	rpm	rpm	NOUN
iajs-2011	32	28	for	for	ADP
iajs-2011	32	29	5	5	NUM
iajs-2011	32	30	minutes	minute	NOUN
iajs-2011	32	31	.	.	PUNCT
iajs-2011	33	1	then	then	ADV
iajs-2011	33	2	storage	storage	VERB
iajs-2011	33	3	the	the	DET
iajs-2011	33	4	serum	serum	NOUN
iajs-2011	33	5	in	in	ADP
iajs-2011	33	6	the	the	DET
iajs-2011	33	7	freezing	freezing	ADJ
iajs-2011	33	8	-20c	-20c	NOUN
iajs-2011	33	9	°	°	NOUN
iajs-2011	33	10	to	to	ADP
iajs-2011	33	11	the	the	DET
iajs-2011	33	12	measured	measure	VERB
iajs-2011	33	13	serum	serum	NOUN
iajs-2011	33	14	electrolyte	electrolyte	NOUN
iajs-2011	33	15	before	before	ADV
iajs-2011	33	16	and	and	CCONJ
iajs-2011	33	17	after	after	ADP
iajs-2011	33	18	addition	addition	NOUN
iajs-2011	33	19	of	of	ADP
iajs-2011	33	20	erlotinib	erlotinib	NOUN
iajs-2011	33	21	inhibitor	inhibitor	NOUN
iajs-2011	33	22	.	.	PUNCT
iajs-2011	34	1	serum	serum	PROPN
iajs-2011	34	2	magnesium	magnesium	NOUN
iajs-2011	34	3	was	be	AUX
iajs-2011	34	4	determined	determine	VERB
iajs-2011	34	5	according	accord	VERB
iajs-2011	34	6	to	to	ADP
iajs-2011	34	7	the	the	DET
iajs-2011	34	8	manufacturer	manufacturer	NOUN
iajs-2011	34	9	instruction	instruction	NOUN
iajs-2011	34	10	as	as	SCONJ
iajs-2011	34	11	supplied	supply	VERB
iajs-2011	34	12	with	with	ADP
iajs-2011	34	13	kit	kit	NOUN
iajs-2011	34	14	from	from	ADP
iajs-2011	34	15	human	human	PROPN
iajs-2011	34	16	germany	germany	PROPN
iajs-2011	34	17	,	,	PUNCT
iajs-2011	34	18	serum	serum	NOUN
iajs-2011	34	19	calcium	calcium	NOUN
iajs-2011	34	20	was	be	AUX
iajs-2011	34	21	determined	determine	VERB
iajs-2011	34	22	according	accord	VERB
iajs-2011	34	23	to	to	ADP
iajs-2011	34	24	the	the	DET
iajs-2011	34	25	manufacturer	manufacturer	NOUN
iajs-2011	34	26	instruction	instruction	NOUN
iajs-2011	34	27	as	as	SCONJ
iajs-2011	34	28	supplied	supply	VERB
iajs-2011	34	29	with	with	ADP
iajs-2011	34	30	kit	kit	NOUN
iajs-2011	34	31	from	from	ADP
iajs-2011	34	32	switzerland	switzerland	PROPN
iajs-2011	34	33	and	and	CCONJ
iajs-2011	34	34	serum	serum	PROPN
iajs-2011	34	35	sodium	sodium	NOUN
iajs-2011	34	36	was	be	AUX
iajs-2011	34	37	determined	determine	VERB
iajs-2011	34	38	according	accord	VERB
iajs-2011	34	39	to	to	ADP
iajs-2011	34	40	the	the	DET
iajs-2011	34	41	manufacturer	manufacturer	NOUN
iajs-2011	34	42	instruction	instruction	NOUN
iajs-2011	34	43	as	as	SCONJ
iajs-2011	34	44	supplied	supply	VERB
iajs-2011	34	45	with	with	ADP
iajs-2011	34	46	kit	kit	NOUN
iajs-2011	34	47	from	from	ADP
iajs-2011	34	48	human	human	PROPN
iajs-2011	34	49	germany	germany	PROPN
iajs-2011	34	50	.	.	PUNCT
iajs-2011	35	1	last	last	ADJ
iajs-2011	35	2	different	different	ADJ
iajs-2011	35	3	concentration	concentration	NOUN
iajs-2011	35	4	was	be	AUX
iajs-2011	35	5	prepared	prepare	VERB
iajs-2011	35	6	from	from	ADP
iajs-2011	35	7	erlotinib	erlotinib	ADJ
iajs-2011	35	8	inhibitor	inhibitor	NOUN
iajs-2011	35	9	via	via	ADP
iajs-2011	35	10	weight	weight	NOUN
iajs-2011	35	11	(	(	PUNCT
iajs-2011	35	12	0.0075	0.0075	NUM
iajs-2011	35	13	,	,	PUNCT
iajs-2011	35	14	0.01	0.01	NUM
iajs-2011	35	15	,	,	PUNCT
iajs-2011	35	16	0.0125	0.0125	NUM
iajs-2011	35	17	,	,	PUNCT
iajs-2011	35	18	0.015	0.015	NUM
iajs-2011	35	19	,	,	PUNCT
iajs-2011	35	20	0.0175	0.0175	NUM
iajs-2011	35	21	)	)	PUNCT
iajs-2011	35	22	mg	mg	PROPN
iajs-2011	35	23	and	and	CCONJ
iajs-2011	35	24	dissolved	dissolve	VERB
iajs-2011	35	25	in	in	ADP
iajs-2011	35	26	distilled	distil	VERB
iajs-2011	35	27	water	water	NOUN
iajs-2011	35	28	and	and	CCONJ
iajs-2011	35	29	conversion	conversion	NOUN
iajs-2011	35	30	to	to	ADP
iajs-2011	35	31	five	five	NUM
iajs-2011	35	32	concentration	concentration	NOUN
iajs-2011	35	33	from	from	ADP
iajs-2011	35	34	erlotinib	erlotinib	NOUN
iajs-2011	35	35	hydrochloride	hydrochloride	NOUN
iajs-2011	35	36	(	(	PUNCT
iajs-2011	35	37	6.97x10⁻⁷	6.97x10⁻⁷	ADP
iajs-2011	35	38	,	,	PUNCT
iajs-2011	35	39	9.30x10⁻⁷	9.30x10⁻⁷	NUM
iajs-2011	35	40	,	,	PUNCT
iajs-2011	35	41	1.16x10⁻⁶	1.16x10⁻⁶	NUM
iajs-2011	35	42	,	,	PUNCT
iajs-2011	35	43	1.39x10⁻⁶	1.39x10⁻⁶	NUM
iajs-2011	35	44	,	,	PUNCT
iajs-2011	35	45	1.62x10⁻⁵	1.62x10⁻⁵	NUM
iajs-2011	35	46	)	)	PUNCT
iajs-2011	35	47	molar	molar	ADJ
iajs-2011	35	48	,	,	PUNCT
iajs-2011	35	49	respectively	respectively	ADV
iajs-2011	35	50	[	[	X
iajs-2011	35	51	12	12	NUM
iajs-2011	35	52	]	]	PUNCT
iajs-2011	35	53	.	.	PUNCT
iajs-2011	36	1	2.1	2.1	NUM
iajs-2011	36	2	statistical	statistical	ADJ
iajs-2011	36	3	analysis	analysis	NOUN
iajs-2011	36	4	results	result	NOUN
iajs-2011	36	5	were	be	AUX
iajs-2011	36	6	expressed	express	VERB
iajs-2011	36	7	as	as	ADP
iajs-2011	36	8	mean±	mean±	PROPN
iajs-2011	36	9	sd	sd	PROPN
iajs-2011	36	10	.	.	PUNCT
iajs-2011	37	1	statistical	statistical	ADJ
iajs-2011	37	2	analysis	analysis	NOUN
iajs-2011	37	3	was	be	AUX
iajs-2011	37	4	done	do	VERB
iajs-2011	37	5	by	by	ADP
iajs-2011	37	6	anova	anova	PROPN
iajs-2011	37	7	to	to	PART
iajs-2011	37	8	compare	compare	VERB
iajs-2011	37	9	between	between	ADP
iajs-2011	37	10	three	three	NUM
iajs-2011	37	11	studied	study	VERB
iajs-2011	37	12	groups	group	NOUN
iajs-2011	37	13	and	and	CCONJ
iajs-2011	37	14	unpaired	unpaired	ADJ
iajs-2011	37	15	student	student	NOUN
iajs-2011	37	16	t	t	PROPN
iajs-2011	37	17	-	-	PUNCT
iajs-2011	37	18	test	test	NOUN
iajs-2011	37	19	to	to	PART
iajs-2011	37	20	compare	compare	VERB
iajs-2011	37	21	between	between	ADP
iajs-2011	37	22	two	two	NUM
iajs-2011	37	23	groups	group	NOUN
iajs-2011	37	24	variation	variation	NOUN
iajs-2011	37	25	which	which	PRON
iajs-2011	37	26	are	be	AUX
iajs-2011	37	27	considered	consider	VERB
iajs-2011	37	28	significant	significant	ADJ
iajs-2011	37	29	when	when	SCONJ
iajs-2011	37	30	pvalues	pvalue	NOUN
iajs-2011	37	31	are	be	AUX
iajs-2011	37	32	≤	≤	NOUN
iajs-2011	37	33	0.05	0.05	NUM
iajs-2011	37	34	.	.	PUNCT
iajs-2011	38	1	3	3	NUM
iajs-2011	38	2	.	.	NOUN
iajs-2011	38	3	result	result	NOUN
iajs-2011	38	4	and	and	CCONJ
iajs-2011	38	5	discussion	discussion	NOUN
iajs-2011	38	6	3.1	3.1	NUM
iajs-2011	38	7	.	.	PUNCT
iajs-2011	39	1	a	a	X
iajs-2011	39	2	-	-	PUNCT
iajs-2011	39	3	before	before	NOUN
iajs-2011	39	4	addition	addition	NOUN
iajs-2011	39	5	inhibitor	inhibitor	NOUN
iajs-2011	39	6	:	:	PUNCT
iajs-2011	39	7	anova	anova	PROPN
iajs-2011	39	8	test	test	NOUN
iajs-2011	39	9	showed	show	VERB
iajs-2011	39	10	a	a	DET
iajs-2011	39	11	highly	highly	ADV
iajs-2011	39	12	significant	significant	ADJ
iajs-2011	39	13	difference	difference	NOUN
iajs-2011	39	14	for	for	ADP
iajs-2011	39	15	levels	level	NOUN
iajs-2011	39	16	of	of	ADP
iajs-2011	39	17	serum	serum	NOUN
iajs-2011	39	18	(	(	PUNCT
iajs-2011	39	19	mg⁺²,ca⁺²and	mg⁺²,ca⁺²and	PROPN
iajs-2011	39	20	na⁺)when	na⁺)when	NOUN
iajs-2011	39	21	compared	compare	VERB
iajs-2011	39	22	between	between	ADP
iajs-2011	39	23	three	three	NUM
iajs-2011	39	24	studied	study	VERB
iajs-2011	39	25	groups	group	NOUN
iajs-2011	39	26	as	as	SCONJ
iajs-2011	39	27	shown	show	VERB
iajs-2011	39	28	in	in	ADP
iajs-2011	39	29	table	table	NOUN
iajs-2011	39	30	1	1	NUM
iajs-2011	39	31	.	.	PUNCT
iajs-2011	39	32	also	also	ADV
iajs-2011	39	33	in	in	ADP
iajs-2011	39	34	table	table	NOUN
iajs-2011	39	35	1	1	NUM
iajs-2011	39	36	.	.	PUNCT
iajs-2011	39	37	explained	explain	VERB
iajs-2011	39	38	the	the	DET
iajs-2011	39	39	levels	level	NOUN
iajs-2011	39	40	of	of	ADP
iajs-2011	39	41	serummg⁺²in	serummg⁺²in	NOUN
iajs-2011	39	42	g1	g1	NOUN
iajs-2011	39	43	and	and	CCONJ
iajs-2011	39	44	g2	g2	PROPN
iajs-2011	39	45	were	be	AUX
iajs-2011	39	46	(	(	PUNCT
iajs-2011	39	47	2.84±	2.84±	NOUN
iajs-2011	39	48	0.34	0.34	NUM
iajs-2011	39	49	and	and	CCONJ
iajs-2011	39	50	2.87±0.24	2.87±0.24	NUM
iajs-2011	39	51	)	)	PUNCT
iajs-2011	39	52	mg	mg	PROPN
iajs-2011	39	53	/	/	SYM
iajs-2011	39	54	dl	dl	PROPN
iajs-2011	39	55	respectively	respectively	ADV
iajs-2011	39	56	,	,	PUNCT
iajs-2011	39	57	and	and	CCONJ
iajs-2011	39	58	there	there	PRON
iajs-2011	39	59	was	be	VERB
iajs-2011	39	60	non	non	ADJ
iajs-2011	39	61	-	-	ADJ
iajs-2011	39	62	significant	significant	ADJ
iajs-2011	39	63	difference	difference	NOUN
iajs-2011	39	64	between	between	ADP
iajs-2011	39	65	two	two	NUM
iajs-2011	39	66	groups	group	NOUN
iajs-2011	39	67	.	.	PUNCT
iajs-2011	40	1	these	these	DET
iajs-2011	40	2	results	result	NOUN
iajs-2011	40	3	are	be	AUX
iajs-2011	40	4	  	  	SPACE
iajs-2011	40	5	in	in	ADP
iajs-2011	40	6	agreement	agreement	NOUN
iajs-2011	40	7	with	with	ADP
iajs-2011	40	8	previous	previous	ADJ
iajs-2011	40	9	studies	study	NOUN
iajs-2011	40	10	[	[	X
iajs-2011	40	11	13	13	NUM
iajs-2011	40	12	-	-	SYM
iajs-2011	40	13	15	15	NUM
iajs-2011	40	14	]	]	PUNCT
iajs-2011	40	15	due	due	ADP
iajs-2011	40	16	to	to	ADP
iajs-2011	40	17	its	its	PRON
iajs-2011	40	18	diet	diet	NOUN
iajs-2011	40	19	low	low	ADJ
iajs-2011	40	20	in	in	ADP
iajs-2011	40	21	magnesium	magnesium	NOUN
iajs-2011	40	22	,	,	PUNCT
iajs-2011	40	23	osmotic	osmotic	ADJ
iajs-2011	40	24	diuresis	diuresis	NOUN
iajs-2011	40	25	causing	cause	VERB
iajs-2011	40	26	high	high	ADJ
iajs-2011	40	27	renal	renal	ADJ
iajs-2011	40	28	excretion	excretion	NOUN
iajs-2011	40	29	of	of	ADP
iajs-2011	40	30	magnesium	magnesium	NOUN
iajs-2011	40	31	[	[	X
iajs-2011	40	32	16].while	16].while	PROPN
iajs-2011	40	33	the	the	DET
iajs-2011	40	34	levels	level	NOUN
iajs-2011	40	35	of	of	ADP
iajs-2011	40	36	serum	serum	NOUN
iajs-2011	40	37	mg⁺²in	mg⁺²in	PROPN
iajs-2011	40	38	g3	g3	PROPN
iajs-2011	40	39	and	and	CCONJ
iajs-2011	40	40	g1	g1	PROPN
iajs-2011	40	41	were	be	AUX
iajs-2011	40	42	(	(	PUNCT
iajs-2011	40	43	2.38±0.08	2.38±0.08	NUM
iajs-2011	40	44	and	and	CCONJ
iajs-2011	40	45	2.87±0.24	2.87±0.24	NUM
iajs-2011	40	46	)	)	PUNCT
iajs-2011	40	47	mg	mg	PROPN
iajs-2011	40	48	/	/	SYM
iajs-2011	40	49	dl	dl	PROPN
iajs-2011	40	50	respectively	respectively	ADV
iajs-2011	40	51	,	,	PUNCT
iajs-2011	40	52	there	there	PRON
iajs-2011	40	53	was	be	VERB
iajs-2011	40	54	significant	significant	ADJ
iajs-2011	40	55	difference	difference	NOUN
iajs-2011	40	56	between	between	ADP
iajs-2011	40	57	two	two	NUM
iajs-2011	40	58	groups	group	NOUN
iajs-2011	40	59	,	,	PUNCT
iajs-2011	40	60	due	due	ADJ
iajs-2011	40	61	to	to	ADP
iajs-2011	40	62	poor	poor	ADJ
iajs-2011	40	63	dietary	dietary	ADJ
iajs-2011	40	64	intake	intake	NOUN
iajs-2011	40	65	,	,	PUNCT
iajs-2011	40	66	impaired	impaired	ADJ
iajs-2011	40	67	absorption	absorption	NOUN
iajs-2011	40	68	of	of	ADP
iajs-2011	40	69	magnesium	magnesium	NOUN
iajs-2011	40	70	,	,	PUNCT
iajs-2011	40	71	increased	increase	VERB
iajs-2011	40	72	urinary	urinary	ADJ
iajs-2011	40	73	loss	loss	NOUN
iajs-2011	40	74	because	because	SCONJ
iajs-2011	40	75	hyperglycemia	hyperglycemia	NOUN
iajs-2011	40	76	,	,	PUNCT
iajs-2011	40	77	osmotic	osmotic	ADJ
iajs-2011	40	78	diuresis	diuresis	NOUN
iajs-2011	40	79	,	,	PUNCT
iajs-2011	40	80	defective	defective	ADJ
iajs-2011	40	81	mg	mg	PROPN
iajs-2011	40	82	reabsorption	reabsorption	NOUN
iajs-2011	40	83	from	from	ADP
iajs-2011	40	84	renal	renal	ADJ
iajs-2011	40	85	tubules	tubule	NOUN
iajs-2011	40	86	and	and	CCONJ
iajs-2011	40	87	loss	loss	NOUN
iajs-2011	40	88	of	of	ADP
iajs-2011	40	89	plasma	plasma	NOUN
iajs-2011	40	90	protein	protein	NOUN
iajs-2011	40	91	bound	bind	VERB
iajs-2011	40	92	mg	mg	NOUN
iajs-2011	41	1	[	[	X
iajs-2011	41	2	17	17	NUM
iajs-2011	41	3	]	]	PUNCT
iajs-2011	41	4	.	.	PUNCT
iajs-2011	42	1	these	these	DET
iajs-2011	42	2	results	result	NOUN
iajs-2011	42	3	are	be	AUX
iajs-2011	42	4	in	in	ADP
iajs-2011	42	5	agreement	agreement	NOUN
iajs-2011	42	6	with	with	ADP
iajs-2011	42	7	previous	previous	ADJ
iajs-2011	42	8	study	study	NOUN
iajs-2011	42	9	[	[	X
iajs-2011	42	10	15	15	NUM
iajs-2011	42	11	]	]	PUNCT
iajs-2011	42	12	.	.	PUNCT
iajs-2011	43	1	also	also	ADV
iajs-2011	43	2	the	the	DET
iajs-2011	43	3	levels	level	NOUN
iajs-2011	43	4	of	of	ADP
iajs-2011	43	5	serum	serum	NOUN
iajs-2011	43	6	mg⁺²	mg⁺²	NOUN
iajs-2011	43	7	in	in	ADP
iajs-2011	43	8	g3	g3	PROPN
iajs-2011	43	9	and	and	CCONJ
iajs-2011	43	10	g2	g2	PROPN
iajs-2011	43	11	there	there	PRON
iajs-2011	43	12	were	be	VERB
iajs-2011	43	13	(	(	PUNCT
iajs-2011	43	14	2.38±0.08	2.38±0.08	NUM
iajs-2011	43	15	and	and	CCONJ
iajs-2011	43	16	2.84±	2.84±	NUM
iajs-2011	43	17	0.34	0.34	NUM
iajs-2011	43	18	)	)	PUNCT
iajs-2011	43	19	mg	mg	PROPN
iajs-2011	43	20	/	/	SYM
iajs-2011	43	21	dl	dl	PROPN
iajs-2011	43	22	respectively	respectively	ADV
iajs-2011	43	23	,	,	PUNCT
iajs-2011	43	24	there	there	PRON
iajs-2011	43	25	was	be	VERB
iajs-2011	43	26	significant	significant	ADJ
iajs-2011	43	27	difference	difference	NOUN
iajs-2011	43	28	between	between	ADP
iajs-2011	43	29	two	two	NUM
iajs-2011	43	30	groups	group	NOUN
iajs-2011	43	31	.	.	PUNCT
iajs-2011	44	1	table	table	NOUN
iajs-2011	44	2	1	1	NUM
iajs-2011	44	3	.	.	PUNCT
iajs-2011	44	4	explained	explain	VERB
iajs-2011	44	5	the	the	DET
iajs-2011	44	6	levels	level	NOUN
iajs-2011	44	7	of	of	ADP
iajs-2011	44	8	serum	serum	NOUN
iajs-2011	44	9	ca⁺²	ca⁺²	NOUN
iajs-2011	44	10	in	in	ADP
iajs-2011	44	11	g2	g2	PROPN
iajs-2011	44	12	and	and	CCONJ
iajs-2011	44	13	g1	g1	PROPN
iajs-2011	44	14	there	there	PRON
iajs-2011	44	15	were	be	VERB
iajs-2011	44	16	(	(	PUNCT
iajs-2011	44	17	8.8±0.37	8.8±0.37	NUM
iajs-2011	44	18	and	and	CCONJ
iajs-2011	44	19	8.81±0.34	8.81±0.34	NUM
iajs-2011	44	20	)	)	PUNCT
iajs-2011	44	21	mg	mg	PROPN
iajs-2011	44	22	/	/	SYM
iajs-2011	44	23	dl	dl	PROPN
iajs-2011	44	24	respectively	respectively	ADV
iajs-2011	44	25	,	,	PUNCT
iajs-2011	44	26	there	there	PRON
iajs-2011	44	27	was	be	VERB
iajs-2011	44	28	nonsignificant	nonsignificant	ADJ
iajs-2011	44	29	difference	difference	NOUN
iajs-2011	44	30	between	between	ADP
iajs-2011	44	31	two	two	NUM
iajs-2011	44	32	groups	group	NOUN
iajs-2011	44	33	.	.	PUNCT
iajs-2011	45	1	these	these	DET
iajs-2011	45	2	result	result	NOUN
iajs-2011	45	3	sare	sare	PROPN
iajs-2011	45	4	in	in	ADP
iajs-2011	45	5	agreement	agreement	NOUN
iajs-2011	45	6	with	with	ADP
iajs-2011	45	7	previous	previous	ADJ
iajs-2011	45	8	study	study	NOUN
iajs-2011	45	9	(	(	PUNCT
iajs-2011	45	10	18	18	NUM
iajs-2011	45	11	)	)	PUNCT
iajs-2011	45	12	due	due	ADP
iajs-2011	45	13	to	to	ADP
iajs-2011	45	14	the	the	DET
iajs-2011	45	15	patients	patient	NOUN
iajs-2011	45	16	in	in	ADP
iajs-2011	45	17	g2	g2	PROPN
iajs-2011	45	18	were	be	AUX
iajs-2011	45	19	newly	newly	ADV
iajs-2011	45	20	diagnosed	diagnose	VERB
iajs-2011	45	21	so	so	SCONJ
iajs-2011	45	22	that	that	SCONJ
iajs-2011	45	23	chemistry	chemistry	NOUN
iajs-2011	45	24	|	|	ADV
iajs-2011	45	25	65	65	NUM
iajs-2011	45	26	ibn	ibn	PROPN
iajs-2011	45	27	al	al	PROPN
iajs-2011	45	28	-	-	PUNCT
iajs-2011	45	29	haitham	haitham	PROPN
iajs-2011	45	30	jour	jour	X
iajs-2011	45	31	.	.	PROPN
iajs-2011	46	1	for	for	ADP
iajs-2011	46	2	pure	pure	ADJ
iajs-2011	46	3	&	&	CCONJ
iajs-2011	46	4	appl	appl	PROPN
iajs-2011	46	5	.	.	PUNCT
iajs-2011	47	1	sci	sci	PROPN
iajs-2011	47	2	.	.	PROPN
iajs-2011	47	3	ihjpas	ihjpa	VERB
iajs-2011	47	4	https://doi.org/10.30526/31.3.2011	https://doi.org/10.30526/31.3.2011	X
iajs-2011	47	5	vol	vol	NOUN
iajs-2011	47	6	.	.	PROPN
iajs-2011	48	1	31	31	NUM
iajs-2011	48	2	(	(	PUNCT
iajs-2011	48	3	3	3	NUM
iajs-2011	48	4	)	)	PUNCT
iajs-2011	48	5	2018	2018	NUM
iajs-2011	48	6	the	the	DET
iajs-2011	48	7	disorder	disorder	NOUN
iajs-2011	48	8	in	in	ADP
iajs-2011	48	9	electrolyte	electrolyte	NOUN
iajs-2011	48	10	did	do	AUX
iajs-2011	48	11	not	not	PART
iajs-2011	48	12	begin	begin	VERB
iajs-2011	48	13	yet	yet	ADV
iajs-2011	48	14	,	,	PUNCT
iajs-2011	48	15	while	while	SCONJ
iajs-2011	48	16	the	the	DET
iajs-2011	48	17	levels	level	NOUN
iajs-2011	48	18	of	of	ADP
iajs-2011	48	19	serum	serum	NOUN
iajs-2011	48	20	ca⁺²	ca⁺²	PROPN
iajs-2011	48	21	in	in	ADP
iajs-2011	48	22	g3	g3	PROPN
iajs-2011	48	23	and	and	CCONJ
iajs-2011	48	24	g1there	g1there	PROPN
iajs-2011	48	25	were	be	AUX
iajs-2011	48	26	(	(	PUNCT
iajs-2011	48	27	9.01±0.5	9.01±0.5	NUM
iajs-2011	48	28	and	and	CCONJ
iajs-2011	48	29	8.81±0.34	8.81±0.34	NUM
iajs-2011	48	30	)	)	PUNCT
iajs-2011	48	31	mg	mg	PROPN
iajs-2011	48	32	/	/	SYM
iajs-2011	48	33	dl	dl	PROPN
iajs-2011	48	34	respectively	respectively	ADV
iajs-2011	48	35	,	,	PUNCT
iajs-2011	48	36	there	there	PRON
iajs-2011	48	37	was	be	VERB
iajs-2011	48	38	significant	significant	ADJ
iajs-2011	48	39	difference	difference	NOUN
iajs-2011	48	40	between	between	ADP
iajs-2011	48	41	two	two	NUM
iajs-2011	48	42	groups	group	NOUN
iajs-2011	48	43	,	,	PUNCT
iajs-2011	48	44	but	but	CCONJ
iajs-2011	48	45	the	the	DET
iajs-2011	48	46	levels	level	NOUN
iajs-2011	48	47	of	of	ADP
iajs-2011	48	48	serum	serum	NOUN
iajs-2011	48	49	ca⁺²	ca⁺²	PROPN
iajs-2011	48	50	in	in	ADP
iajs-2011	48	51	g3	g3	PROPN
iajs-2011	48	52	and	and	CCONJ
iajs-2011	48	53	g2	g2	PROPN
iajs-2011	48	54	were	be	AUX
iajs-2011	48	55	(	(	PUNCT
iajs-2011	48	56	9.01±0.5vs.8.8±0.37	9.01±0.5vs.8.8±0.37	NUM
iajs-2011	48	57	)	)	PUNCT
iajs-2011	48	58	mg	mg	PROPN
iajs-2011	48	59	/	/	SYM
iajs-2011	48	60	dl	dl	PROPN
iajs-2011	48	61	respectively	respectively	ADV
iajs-2011	48	62	,	,	PUNCT
iajs-2011	48	63	there	there	PRON
iajs-2011	48	64	was	be	VERB
iajs-2011	48	65	significant	significant	ADJ
iajs-2011	48	66	difference	difference	NOUN
iajs-2011	48	67	between	between	ADP
iajs-2011	48	68	two	two	NUM
iajs-2011	48	69	groups	group	NOUN
iajs-2011	48	70	.	.	PUNCT
iajs-2011	49	1	the	the	DET
iajs-2011	49	2	reason	reason	NOUN
iajs-2011	49	3	for	for	ADP
iajs-2011	49	4	elevated	elevated	ADJ
iajs-2011	49	5	serum	serum	NOUN
iajs-2011	49	6	ca⁺²	ca⁺²	NOUN
iajs-2011	49	7	levels	level	NOUN
iajs-2011	49	8	was	be	AUX
iajs-2011	49	9	explained	explain	VERB
iajs-2011	49	10	ca2	ca2	PROPN
iajs-2011	49	11	+	+	PROPN
iajs-2011	50	1	reabsorption	reabsorption	NOUN
iajs-2011	50	2	in	in	ADP
iajs-2011	50	3	proximal	proximal	ADJ
iajs-2011	50	4	tubule	tubule	NOUN
iajs-2011	50	5	was	be	AUX
iajs-2011	50	6	related	relate	VERB
iajs-2011	50	7	with	with	ADP
iajs-2011	50	8	na+	na+	NOUN
iajs-2011	50	9	re	re	NOUN
iajs-2011	50	10	absorption	absorption	NOUN
iajs-2011	50	11	as	as	ADV
iajs-2011	50	12	well	well	ADV
iajs-2011	50	13	as	as	ADP
iajs-2011	50	14	ca2	ca2	PROPN
iajs-2011	50	15	+	+	PROPN
iajs-2011	50	16	competes	compete	NOUN
iajs-2011	50	17	with	with	ADP
iajs-2011	50	18	mg2	mg2	PROPN
iajs-2011	50	19	+	+	PROPN
iajs-2011	50	20	that	that	SCONJ
iajs-2011	50	21	transport	transport	NOUN
iajs-2011	50	22	in	in	ADP
iajs-2011	50	23	the	the	DET
iajs-2011	50	24	loop	loop	NOUN
iajs-2011	50	25	of	of	ADP
iajs-2011	50	26	henley	henley	NOUN
iajs-2011	50	27	[	[	X
iajs-2011	50	28	18	18	NUM
iajs-2011	50	29	]	]	PUNCT
iajs-2011	50	30	.	.	PUNCT
iajs-2011	51	1	depend	depend	VERB
iajs-2011	51	2	on	on	ADP
iajs-2011	51	3	the	the	DET
iajs-2011	51	4	resnick	resnick	PROPN
iajs-2011	51	5	ionic	ionic	ADJ
iajs-2011	51	6	study	study	NOUN
iajs-2011	51	7	suggested	suggest	VERB
iajs-2011	51	8	disorders	disorder	NOUN
iajs-2011	51	9	like	like	ADP
iajs-2011	51	10	metabolic	metabolic	NOUN
iajs-2011	51	11	syndrome	syndrome	NOUN
iajs-2011	51	12	,	,	PUNCT
iajs-2011	51	13	hypertension	hypertension	NOUN
iajs-2011	51	14	and	and	CCONJ
iajs-2011	51	15	diabetes	diabetes	NOUN
iajs-2011	51	16	contribute	contribute	VERB
iajs-2011	51	17	to	to	ADP
iajs-2011	51	18	common	common	ADJ
iajs-2011	51	19	intracellular	intracellular	ADJ
iajs-2011	51	20	condition	condition	NOUN
iajs-2011	51	21	in	in	ADP
iajs-2011	51	22	which	which	PRON
iajs-2011	51	23	decreased	decrease	VERB
iajs-2011	51	24	level	level	NOUN
iajs-2011	51	25	of	of	ADP
iajs-2011	51	26	mg2	mg2	PROPN
iajs-2011	51	27	+	+	PROPN
iajs-2011	51	28	is	be	AUX
iajs-2011	51	29	associated	associate	VERB
iajs-2011	51	30	with	with	ADP
iajs-2011	51	31	elevated	elevated	ADJ
iajs-2011	51	32	free	free	ADJ
iajs-2011	51	33	intracellular	intracellular	ADJ
iajs-2011	51	34	ca2	ca2	PROPN
iajs-2011	51	35	+	+	NOUN
iajs-2011	51	36	level	level	NOUN
iajs-2011	52	1	[	[	X
iajs-2011	52	2	11	11	NUM
iajs-2011	52	3	]	]	PUNCT
iajs-2011	52	4	.	.	PUNCT
iajs-2011	53	1	table	table	NOUN
iajs-2011	53	2	1	1	NUM
iajs-2011	53	3	.	.	PUNCT
iajs-2011	53	4	showed	showed	AUX
iajs-2011	53	5	decrease	decrease	VERB
iajs-2011	53	6	significant	significant	ADJ
iajs-2011	53	7	difference	difference	NOUN
iajs-2011	53	8	in	in	ADP
iajs-2011	53	9	serum	serum	NOUN
iajs-2011	53	10	na⁺	na⁺	PROPN
iajs-2011	53	11	levels	level	NOUN
iajs-2011	53	12	between	between	ADP
iajs-2011	53	13	g2vs.g1	g2vs.g1	PUNCT
iajs-2011	53	14	(	(	PUNCT
iajs-2011	53	15	135.02±	135.02±	NUM
iajs-2011	53	16	1.99vs.138.68	1.99vs.138.68	NUM
iajs-2011	53	17	±1.35	±1.35	NOUN
iajs-2011	53	18	)	)	PUNCT
iajs-2011	53	19	mmo	mmo	ADJ
iajs-2011	53	20	l	l	PROPN
iajs-2011	53	21	/	/	SYM
iajs-2011	53	22	l	l	NOUN
iajs-2011	53	23	respectively	respectively	ADV
iajs-2011	53	24	,	,	PUNCT
iajs-2011	53	25	due	due	ADP
iajs-2011	53	26	to	to	ADP
iajs-2011	53	27	hyperglycemia	hyperglycemia	NOUN
iajs-2011	53	28	in	in	ADP
iajs-2011	53	29	diabetes	diabetes	NOUN
iajs-2011	53	30	lead	lead	VERB
iajs-2011	53	31	to	to	ADP
iajs-2011	53	32	shifting	shift	VERB
iajs-2011	53	33	water	water	NOUN
iajs-2011	53	34	from	from	ADP
iajs-2011	53	35	intracellular	intracellular	ADJ
iajs-2011	53	36	space	space	NOUN
iajs-2011	53	37	to	to	ADP
iajs-2011	53	38	extracellular	extracellular	ADJ
iajs-2011	53	39	space	space	NOUN
iajs-2011	53	40	diluting	dilute	VERB
iajs-2011	53	41	the	the	DET
iajs-2011	53	42	extracellular	extracellular	ADJ
iajs-2011	53	43	na+	na+	NOUN
iajs-2011	53	44	leading	lead	VERB
iajs-2011	53	45	to	to	ADP
iajs-2011	53	46	lower	low	ADJ
iajs-2011	53	47	serum	serum	NOUN
iajs-2011	53	48	na+	na+	NOUN
iajs-2011	53	49	level	level	NOUN
iajs-2011	54	1	[	[	X
iajs-2011	54	2	19	19	NUM
iajs-2011	54	3	]	]	PUNCT
iajs-2011	54	4	.	.	PUNCT
iajs-2011	55	1	alteration	alteration	NOUN
iajs-2011	55	2	in	in	ADP
iajs-2011	55	3	rennin	rennin	NOUN
iajs-2011	55	4	angiotensin	angiotensin	NOUN
iajs-2011	55	5	system	system	NOUN
iajs-2011	55	6	in	in	ADP
iajs-2011	55	7	diabetes	diabetes	NOUN
iajs-2011	55	8	leads	lead	VERB
iajs-2011	55	9	to	to	PART
iajs-2011	55	10	change	change	VERB
iajs-2011	55	11	in	in	ADP
iajs-2011	55	12	serum	serum	NOUN
iajs-2011	55	13	sodium	sodium	NOUN
iajs-2011	55	14	concentration	concentration	NOUN
iajs-2011	55	15	[	[	X
iajs-2011	55	16	20	20	NUM
iajs-2011	55	17	]	]	PUNCT
iajs-2011	55	18	.	.	PUNCT
iajs-2011	56	1	in	in	ADP
iajs-2011	56	2	the	the	DET
iajs-2011	56	3	current	current	ADJ
iajs-2011	56	4	study	study	NOUN
iajs-2011	56	5	,	,	PUNCT
iajs-2011	56	6	the	the	DET
iajs-2011	56	7	levels	level	NOUN
iajs-2011	56	8	of	of	ADP
iajs-2011	56	9	na+	na+	NOUN
iajs-2011	56	10	in	in	ADP
iajs-2011	56	11	g1	g1	PROPN
iajs-2011	56	12	,	,	PUNCT
iajs-2011	56	13	g2	g2	PROPN
iajs-2011	56	14	and	and	CCONJ
iajs-2011	56	15	g3	g3	PROPN
iajs-2011	56	16	were	be	AUX
iajs-2011	56	17	(	(	PUNCT
iajs-2011	56	18	138.68±	138.68±	NUM
iajs-2011	56	19	1.35	1.35	NUM
iajs-2011	56	20	,	,	PUNCT
iajs-2011	56	21	135.02	135.02	NUM
iajs-2011	56	22	±1.99	±1.99	PROPN
iajs-2011	56	23	and146.22±29.26	and146.22±29.26	PROPN
iajs-2011	56	24	mmol	mmol	NOUN
iajs-2011	56	25	/l	/l	PUNCT
iajs-2011	56	26	respectively	respectively	ADV
iajs-2011	56	27	,	,	PUNCT
iajs-2011	56	28	also	also	ADV
iajs-2011	56	29	there	there	PRON
iajs-2011	56	30	was	be	VERB
iajs-2011	56	31	a	a	DET
iajs-2011	56	32	highly	highly	ADV
iajs-2011	56	33	significant	significant	ADJ
iajs-2011	56	34	difference	difference	NOUN
iajs-2011	56	35	when	when	SCONJ
iajs-2011	56	36	compared	compare	VERB
iajs-2011	56	37	between	between	ADP
iajs-2011	56	38	g3	g3	PROPN
iajs-2011	56	39	with	with	ADP
iajs-2011	56	40	g1	g1	NOUN
iajs-2011	56	41	.	.	PUNCT
iajs-2011	57	1	these	these	DET
iajs-2011	57	2	findings	finding	NOUN
iajs-2011	57	3	suggest	suggest	VERB
iajs-2011	57	4	kidney	kidney	NOUN
iajs-2011	57	5	damage	damage	NOUN
iajs-2011	57	6	in	in	ADP
iajs-2011	57	7	individuals	individual	NOUN
iajs-2011	57	8	and	and	CCONJ
iajs-2011	57	9	this	this	PRON
iajs-2011	57	10	is	be	AUX
iajs-2011	57	11	in	in	ADP
iajs-2011	57	12	agreement	agreement	NOUN
iajs-2011	57	13	with	with	ADP
iajs-2011	57	14	study	study	NOUN
iajs-2011	57	15	[	[	X
iajs-2011	57	16	21	21	NUM
iajs-2011	57	17	]	]	PUNCT
iajs-2011	57	18	.	.	PUNCT
iajs-2011	58	1	3.2	3.2	NUM
iajs-2011	58	2	.	.	X
iajs-2011	59	1	b	b	X
iajs-2011	59	2	-	-	PUNCT
iajs-2011	59	3	after	after	ADP
iajs-2011	59	4	addition	addition	NOUN
iajs-2011	59	5	inhibitor	inhibitor	NOUN
iajs-2011	59	6	the	the	DET
iajs-2011	59	7	recent	recent	ADJ
iajs-2011	59	8	study	study	NOUN
iajs-2011	59	9	is	be	AUX
iajs-2011	59	10	considered	consider	VERB
iajs-2011	59	11	as	as	ADP
iajs-2011	59	12	a	a	DET
iajs-2011	59	13	first	first	ADJ
iajs-2011	59	14	study	study	NOUN
iajs-2011	59	15	in	in	ADP
iajs-2011	59	16	vitro	vitro	X
iajs-2011	59	17	for	for	ADP
iajs-2011	59	18	human	human	NOUN
iajs-2011	59	19	that	that	SCONJ
iajs-2011	59	20	deals	deal	VERB
iajs-2011	59	21	with	with	ADP
iajs-2011	59	22	the	the	DET
iajs-2011	59	23	effect	effect	NOUN
iajs-2011	59	24	of	of	ADP
iajs-2011	59	25	different	different	ADJ
iajs-2011	59	26	concentrations	concentration	NOUN
iajs-2011	59	27	of	of	ADP
iajs-2011	59	28	erlotinib	erlotinib	ADJ
iajs-2011	59	29	inhibitor	inhibitor	NOUN
iajs-2011	59	30	on	on	ADP
iajs-2011	59	31	mg⁺²	mg⁺²	NOUN
iajs-2011	59	32	levels	level	NOUN
iajs-2011	59	33	in	in	ADP
iajs-2011	59	34	diabetes	diabetes	NOUN
iajs-2011	59	35	type2	type2	PROPN
iajs-2011	59	36	and	and	CCONJ
iajs-2011	59	37	diabetic	diabetic	ADJ
iajs-2011	59	38	nephropathy	nephropathy	NOUN
iajs-2011	59	39	,	,	PUNCT
iajs-2011	59	40	so	so	SCONJ
iajs-2011	59	41	no	no	DET
iajs-2011	59	42	clinical	clinical	ADJ
iajs-2011	59	43	reports	report	NOUN
iajs-2011	59	44	on	on	ADP
iajs-2011	59	45	the	the	DET
iajs-2011	59	46	mg2	mg2	PROPN
iajs-2011	59	47	+	+	PROPN
iajs-2011	59	48	status	status	NOUN
iajs-2011	59	49	after	after	ADP
iajs-2011	59	50	addition	addition	NOUN
iajs-2011	59	51	erlotinib	erlotinib	NOUN
iajs-2011	59	52	inhibitor	inhibitor	NOUN
iajs-2011	59	53	was	be	AUX
iajs-2011	59	54	available	available	ADJ
iajs-2011	59	55	(	(	PUNCT
iajs-2011	59	56	22	22	NUM
iajs-2011	59	57	)	)	PUNCT
iajs-2011	59	58	.	.	PUNCT
iajs-2011	60	1	the	the	DET
iajs-2011	60	2	results	result	NOUN
iajs-2011	60	3	in	in	ADP
iajs-2011	60	4	tables	table	NOUN
iajs-2011	60	5	(	(	PUNCT
iajs-2011	60	6	2	2	NUM
iajs-2011	60	7	-	-	SYM
iajs-2011	60	8	6	6	NUM
iajs-2011	60	9	)	)	PUNCT
iajs-2011	60	10	explain	explain	VERB
iajs-2011	60	11	mg⁺²	mg⁺²	NOUN
iajs-2011	60	12	levels	level	NOUN
iajs-2011	60	13	which	which	PRON
iajs-2011	60	14	show	show	VERB
iajs-2011	60	15	decrease	decrease	NOUN
iajs-2011	60	16	of	of	ADP
iajs-2011	60	17	significant	significant	ADJ
iajs-2011	60	18	g2	g2	PROPN
iajs-2011	60	19	when	when	SCONJ
iajs-2011	60	20	compared	compare	VERB
iajs-2011	60	21	between	between	ADP
iajs-2011	60	22	before	before	ADP
iajs-2011	60	23	and	and	CCONJ
iajs-2011	60	24	after	after	ADP
iajs-2011	60	25	addition	addition	NOUN
iajs-2011	60	26	of	of	ADP
iajs-2011	60	27	five	five	NUM
iajs-2011	60	28	concentrations	concentration	NOUN
iajs-2011	60	29	of	of	ADP
iajs-2011	60	30	erlotinib	erlotinib	NOUN
iajs-2011	60	31	.	.	PUNCT
iajs-2011	61	1	the	the	DET
iajs-2011	61	2	previous	previous	ADJ
iajs-2011	61	3	studies	study	NOUN
iajs-2011	61	4	explain	explain	VERB
iajs-2011	61	5	in	in	ADP
iajs-2011	61	6	mice	mouse	NOUN
iajs-2011	61	7	that	that	SCONJ
iajs-2011	61	8	only	only	ADV
iajs-2011	61	9	a	a	DET
iajs-2011	61	10	mild	mild	ADJ
iajs-2011	61	11	decrease	decrease	NOUN
iajs-2011	61	12	in	in	ADP
iajs-2011	61	13	mg2	mg2	PROPN
iajs-2011	61	14	+	+	CCONJ
iajs-2011	61	15	level	level	NOUN
iajs-2011	61	16	was	be	AUX
iajs-2011	61	17	observed	observe	VERB
iajs-2011	61	18	after	after	ADP
iajs-2011	61	19	addition	addition	NOUN
iajs-2011	61	20	of	of	ADP
iajs-2011	61	21	erlotinib	erlotinib	NOUN
iajs-2011	61	22	,	,	PUNCT
iajs-2011	61	23	while	while	SCONJ
iajs-2011	61	24	the	the	DET
iajs-2011	61	25	fractional	fractional	ADJ
iajs-2011	61	26	excretion	excretion	NOUN
iajs-2011	61	27	of	of	ADP
iajs-2011	61	28	mg2	mg2	PROPN
iajs-2011	61	29	+	+	CCONJ
iajs-2011	61	30	remained	remain	VERB
iajs-2011	61	31	unchanged	unchanged	ADJ
iajs-2011	61	32	(	(	PUNCT
iajs-2011	61	33	13	13	NUM
iajs-2011	61	34	)	)	PUNCT
iajs-2011	61	35	.	.	PUNCT
iajs-2011	62	1	in	in	ADP
iajs-2011	62	2	g3	g3	PROPN
iajs-2011	62	3	,	,	PUNCT
iajs-2011	62	4	the	the	DET
iajs-2011	62	5	mg⁺²levels	mg⁺²level	NOUN
iajs-2011	62	6	show	show	VERB
iajs-2011	62	7	non	non	ADJ
iajs-2011	62	8	-	-	ADJ
iajs-2011	62	9	significant	significant	ADJ
iajs-2011	62	10	difference	difference	NOUN
iajs-2011	62	11	in	in	ADP
iajs-2011	62	12	concentration	concentration	NOUN
iajs-2011	62	13	(	(	PUNCT
iajs-2011	62	14	6.97x10⁻⁷	6.97x10⁻⁷	NUM
iajs-2011	62	15	and	and	CCONJ
iajs-2011	62	16	9.30x10⁻⁷	9.30x10⁻⁷	NUM
iajs-2011	62	17	)	)	PUNCT
iajs-2011	62	18	m	m	NOUN
iajs-2011	62	19	,	,	PUNCT
iajs-2011	62	20	while	while	SCONJ
iajs-2011	62	21	they	they	PRON
iajs-2011	62	22	show	show	VERB
iajs-2011	62	23	significant	significant	ADJ
iajs-2011	62	24	difference	difference	NOUN
iajs-2011	62	25	in	in	ADP
iajs-2011	62	26	concentration	concentration	NOUN
iajs-2011	62	27	(	(	PUNCT
iajs-2011	62	28	1.16x10⁻⁶,1.39x10⁻⁶	1.16x10⁻⁶,1.39x10⁻⁶	NUM
iajs-2011	62	29	and	and	CCONJ
iajs-2011	62	30	1.62x10⁻⁵	1.62x10⁻⁵	NUM
iajs-2011	62	31	)	)	PUNCT
iajs-2011	62	32	m	m	PROPN
iajs-2011	62	33	,	,	PUNCT
iajs-2011	62	34	because	because	SCONJ
iajs-2011	62	35	the	the	DET
iajs-2011	62	36	egfr	egfr	NOUN
iajs-2011	62	37	play	play	VERB
iajs-2011	62	38	a	a	DET
iajs-2011	62	39	minimal	minimal	ADJ
iajs-2011	62	40	biolovital	biolovital	ADJ
iajs-2011	62	41	role	role	NOUN
iajs-2011	62	42	in	in	ADP
iajs-2011	62	43	control	control	PROPN
iajs-2011	62	44	mg2	mg2	PROPN
iajs-2011	62	45	+	+	PROPN
iajs-2011	62	46	level	level	NOUN
iajs-2011	62	47	at	at	ADP
iajs-2011	62	48	the	the	DET
iajs-2011	62	49	nephron	nephron	NOUN
iajs-2011	62	50	,	,	PUNCT
iajs-2011	62	51	so	so	SCONJ
iajs-2011	62	52	that	that	SCONJ
iajs-2011	62	53	the	the	DET
iajs-2011	62	54	high	high	ADJ
iajs-2011	62	55	dose	dose	NOUN
iajs-2011	62	56	from	from	ADP
iajs-2011	62	57	inhibitor	inhibitor	NOUN
iajs-2011	62	58	leads	lead	VERB
iajs-2011	62	59	to	to	ADP
iajs-2011	62	60	nephrons	nephron	NOUN
iajs-2011	62	61	to	to	PART
iajs-2011	62	62	preserve	preserve	VERB
iajs-2011	62	63	mg2	mg2	PROPN
iajs-2011	62	64	+	+	PROPN
iajs-2011	62	65	and	and	CCONJ
iajs-2011	62	66	causes	cause	VERB
iajs-2011	62	67	moderate	moderate	ADJ
iajs-2011	62	68	increase	increase	NOUN
iajs-2011	62	69	from	from	ADP
iajs-2011	62	70	mg2+level	mg2+level	PROPN
iajs-2011	62	71	(	(	PUNCT
iajs-2011	62	72	12	12	NUM
iajs-2011	62	73	)	)	PUNCT
iajs-2011	62	74	.	.	PUNCT
iajs-2011	63	1	the	the	DET
iajs-2011	63	2	current	current	ADJ
iajs-2011	63	3	study	study	NOUN
iajs-2011	63	4	shows	show	VERB
iajs-2011	63	5	that	that	SCONJ
iajs-2011	63	6	the	the	DET
iajs-2011	63	7	best	good	ADJ
iajs-2011	63	8	inhibition	inhibition	NOUN
iajs-2011	63	9	in	in	ADP
iajs-2011	63	10	mg2+level	mg2+level	NOUN
iajs-2011	63	11	in	in	ADP
iajs-2011	63	12	g2	g2	PROPN
iajs-2011	63	13	at	at	ADP
iajs-2011	63	14	erlotinib	erlotinib	NOUN
iajs-2011	63	15	concentration	concentration	NOUN
iajs-2011	63	16	(	(	PUNCT
iajs-2011	63	17	9.30x10⁻⁷	9.30x10⁻⁷	NUM
iajs-2011	63	18	)	)	PUNCT
iajs-2011	63	19	m	m	NOUN
iajs-2011	63	20	,	,	PUNCT
iajs-2011	63	21	while	while	SCONJ
iajs-2011	63	22	in	in	ADP
iajs-2011	63	23	g3	g3	NOUN
iajs-2011	63	24	best	good	ADJ
iajs-2011	63	25	inhibition	inhibition	NOUN
iajs-2011	63	26	in	in	ADP
iajs-2011	63	27	mg2+level	mg2+level	NOUN
iajs-2011	63	28	appeared	appear	VERB
iajs-2011	63	29	at	at	ADP
iajs-2011	63	30	concentration	concentration	NOUN
iajs-2011	63	31	(	(	PUNCT
iajs-2011	63	32	1.62x10⁻⁵	1.62x10⁻⁵	NUM
iajs-2011	63	33	)	)	PUNCT
iajs-2011	63	34	m.	m.	NOUN
iajs-2011	63	35	the	the	DET
iajs-2011	63	36	results	result	NOUN
iajs-2011	63	37	of	of	ADP
iajs-2011	63	38	ca⁺²levels	ca⁺²level	NOUN
iajs-2011	63	39	showed	show	VERB
iajs-2011	63	40	non	non	ADJ
iajs-2011	63	41	-	-	ADJ
iajs-2011	63	42	significant	significant	ADJ
iajs-2011	63	43	inhibition	inhibition	NOUN
iajs-2011	63	44	in	in	ADP
iajs-2011	63	45	ca⁺²levels	ca⁺²level	NOUN
iajs-2011	63	46	in	in	ADP
iajs-2011	63	47	g2at	g2at	NOUN
iajs-2011	63	48	concentration	concentration	NOUN
iajs-2011	63	49	(	(	PUNCT
iajs-2011	63	50	6.97x10⁻⁷	6.97x10⁻⁷	ADP
iajs-2011	63	51	,	,	PUNCT
iajs-2011	63	52	9.30x10⁻⁷	9.30x10⁻⁷	NOUN
iajs-2011	63	53	,	,	PUNCT
iajs-2011	63	54	1.39x10⁻⁶	1.39x10⁻⁶	NUM
iajs-2011	63	55	,	,	PUNCT
iajs-2011	63	56	1.62x10⁻⁵m	1.62x10⁻⁵m	NUM
iajs-2011	63	57	)	)	PUNCT
iajs-2011	63	58	,	,	PUNCT
iajs-2011	63	59	while	while	SCONJ
iajs-2011	63	60	in	in	ADP
iajs-2011	63	61	concentration	concentration	NOUN
iajs-2011	63	62	(	(	PUNCT
iajs-2011	63	63	1.16x10⁻⁶m	1.16x10⁻⁶m	PROPN
iajs-2011	63	64	)	)	PUNCT
iajs-2011	63	65	appeared	appear	VERB
iajs-2011	63	66	decrease	decrease	NOUN
iajs-2011	63	67	significant	significant	ADV
iajs-2011	63	68	suggested	suggest	VERB
iajs-2011	63	69	the	the	DET
iajs-2011	63	70	patients	patient	NOUN
iajs-2011	63	71	in	in	ADP
iajs-2011	63	72	g2	g2	PROPN
iajs-2011	63	73	were	be	AUX
iajs-2011	63	74	newly	newly	ADV
iajs-2011	63	75	diagnoses	diagnosis	NOUN
iajs-2011	63	76	with	with	ADP
iajs-2011	63	77	diabetes	diabetes	NOUN
iajs-2011	63	78	mellitus	mellitus	NOUN
iajs-2011	63	79	and	and	CCONJ
iajs-2011	63	80	the	the	DET
iajs-2011	63	81	disorder	disorder	NOUN
iajs-2011	63	82	on	on	ADP
iajs-2011	63	83	calcium	calcium	NOUN
iajs-2011	63	84	concentration	concentration	NOUN
iajs-2011	63	85	did	do	AUX
iajs-2011	63	86	not	not	PART
iajs-2011	63	87	start	start	VERB
iajs-2011	63	88	.	.	PUNCT
iajs-2011	64	1	there	there	PRON
iajs-2011	64	2	is	be	VERB
iajs-2011	64	3	no	no	DET
iajs-2011	64	4	clinical	clinical	ADJ
iajs-2011	64	5	study	study	NOUN
iajs-2011	64	6	demonstrated	demonstrate	VERB
iajs-2011	64	7	the	the	DET
iajs-2011	64	8	effect	effect	NOUN
iajs-2011	64	9	of	of	ADP
iajs-2011	64	10	erlotinib	erlotinib	NOUN
iajs-2011	64	11	on	on	ADP
iajs-2011	64	12	calcium	calcium	NOUN
iajs-2011	64	13	levels	level	NOUN
iajs-2011	64	14	and	and	CCONJ
iajs-2011	64	15	this	this	DET
iajs-2011	64	16	study	study	NOUN
iajs-2011	64	17	is	be	AUX
iajs-2011	64	18	considered	consider	VERB
iajs-2011	64	19	the	the	DET
iajs-2011	64	20	first	first	ADJ
iajs-2011	64	21	in	in	ADP
iajs-2011	64	22	human	human	NOUN
iajs-2011	64	23	.	.	PUNCT
iajs-2011	65	1	in	in	ADP
iajs-2011	65	2	group	group	PROPN
iajs-2011	65	3	g3	g3	NOUN
iajs-2011	65	4	the	the	DET
iajs-2011	65	5	ca⁺²levels	ca⁺²level	NOUN
iajs-2011	65	6	show	show	VERB
iajs-2011	65	7	decrease	decrease	NOUN
iajs-2011	65	8	of	of	ADP
iajs-2011	65	9	significant	significant	ADJ
iajs-2011	65	10	difference	difference	NOUN
iajs-2011	65	11	for	for	ADP
iajs-2011	65	12	all	all	DET
iajs-2011	65	13	five	five	NUM
iajs-2011	65	14	concentrations	concentration	NOUN
iajs-2011	65	15	of	of	ADP
iajs-2011	65	16	inhibitor	inhibitor	NOUN
iajs-2011	65	17	.	.	PUNCT
iajs-2011	66	1	demik	demik	ADJ
iajs-2011	66	2	in	in	ADP
iajs-2011	66	3	his	his	PRON
iajs-2011	66	4	study	study	NOUN
iajs-2011	66	5	about	about	ADP
iajs-2011	66	6	mice	mouse	NOUN
iajs-2011	66	7	is	be	AUX
iajs-2011	66	8	in	in	ADP
iajs-2011	66	9	agreement	agreement	NOUN
iajs-2011	66	10	with	with	ADP
iajs-2011	66	11	the	the	DET
iajs-2011	66	12	recent	recent	ADJ
iajs-2011	66	13	study	study	NOUN
iajs-2011	66	14	that	that	PRON
iajs-2011	66	15	he	he	PRON
iajs-2011	66	16	observed	observe	VERB
iajs-2011	66	17	about	about	ADP
iajs-2011	66	18	the	the	DET
iajs-2011	66	19	systematic	systematic	ADJ
iajs-2011	66	20	and	and	CCONJ
iajs-2011	66	21	renal	renal	ADJ
iajs-2011	66	22	ca⁺²	ca⁺²	NOUN
iajs-2011	66	23	homeostasis	homeostasis	NOUN
iajs-2011	66	24	that	that	PRON
iajs-2011	66	25	still	still	ADV
iajs-2011	66	26	unaffected	unaffected	ADJ
iajs-2011	66	27	during	during	ADP
iajs-2011	66	28	adsorption	adsorption	NOUN
iajs-2011	66	29	of	of	ADP
iajs-2011	66	30	erlotinib	erlotinib	NOUN
iajs-2011	66	31	because	because	SCONJ
iajs-2011	66	32	egf	egf	PROPN
iajs-2011	66	33	does	do	AUX
iajs-2011	66	34	n’t	not	PART
iajs-2011	66	35	directly	directly	ADV
iajs-2011	66	36	influence	influence	VERB
iajs-2011	66	37	ca2	ca2	PROPN
iajs-2011	66	38	+	+	NOUN
iajs-2011	66	39	handling	handling	NOUN
iajs-2011	66	40	so	so	SCONJ
iajs-2011	66	41	that	that	SCONJ
iajs-2011	66	42	the	the	DET
iajs-2011	66	43	changes	change	NOUN
iajs-2011	66	44	in	in	ADP
iajs-2011	66	45	renal	renal	ADJ
iajs-2011	66	46	mg2	mg2	PROPN
iajs-2011	66	47	+	+	CCONJ
iajs-2011	66	48	concentration	concentration	NOUN
iajs-2011	66	49	lead	lead	NOUN
iajs-2011	66	50	to	to	PART
iajs-2011	66	51	subsequently	subsequently	ADV
iajs-2011	66	52	correlate	correlate	VERB
iajs-2011	66	53	well	well	ADV
iajs-2011	66	54	with	with	ADP
iajs-2011	66	55	decrease	decrease	NOUN
iajs-2011	66	56	fraction	fraction	NOUN
iajs-2011	66	57	of	of	ADP
iajs-2011	66	58	distal	distal	ADJ
iajs-2011	66	59	tubular	tubular	ADJ
iajs-2011	66	60	transport	transport	NOUN
iajs-2011	66	61	where	where	SCONJ
iajs-2011	66	62	mg2	mg2	NOUN
iajs-2011	66	63	+	+	NOUN
iajs-2011	66	64	transport	transport	NOUN
iajs-2011	66	65	is	be	AUX
iajs-2011	66	66	mechanistically	mechanistically	ADV
iajs-2011	66	67	separated	separate	VERB
iajs-2011	66	68	from	from	ADP
iajs-2011	66	69	that	that	PRON
iajs-2011	66	70	of	of	ADP
iajs-2011	66	71	ca2+(12	ca2+(12	PROPN
iajs-2011	66	72	)	)	PUNCT
iajs-2011	66	73	.	.	PUNCT
iajs-2011	67	1	in	in	ADP
iajs-2011	67	2	table	table	NOUN
iajs-2011	67	3	(	(	PUNCT
iajs-2011	67	4	7	7	NUM
iajs-2011	67	5	)	)	PUNCT
iajs-2011	67	6	the	the	DET
iajs-2011	67	7	best	good	ADJ
iajs-2011	67	8	inhibition	inhibition	NOUN
iajs-2011	67	9	appeared	appear	VERB
iajs-2011	67	10	in	in	ADP
iajs-2011	67	11	concentration	concentration	NOUN
iajs-2011	67	12	(	(	PUNCT
iajs-2011	67	13	1.62×10⁻⁵	1.62×10⁻⁵	NUM
iajs-2011	67	14	)	)	PUNCT
iajs-2011	67	15	m	m	PROPN
iajs-2011	67	16	for	for	ADP
iajs-2011	67	17	g2	g2	PROPN
iajs-2011	67	18	and	and	CCONJ
iajs-2011	67	19	chemistry	chemistry	NOUN
iajs-2011	67	20	|	|	ADV
iajs-2011	67	21	66	66	NUM
iajs-2011	67	22	ibn	ibn	PROPN
iajs-2011	67	23	al	al	PROPN
iajs-2011	67	24	-	-	PUNCT
iajs-2011	67	25	haitham	haitham	PROPN
iajs-2011	67	26	jour	jour	X
iajs-2011	67	27	.	.	PROPN
iajs-2011	68	1	for	for	ADP
iajs-2011	68	2	pure	pure	ADJ
iajs-2011	68	3	&	&	CCONJ
iajs-2011	68	4	appl	appl	PROPN
iajs-2011	68	5	.	.	PUNCT
iajs-2011	69	1	sci	sci	PROPN
iajs-2011	69	2	.	.	PROPN
iajs-2011	69	3	ihjpas	ihjpa	VERB
iajs-2011	69	4	https://doi.org/10.30526/31.3.2011	https://doi.org/10.30526/31.3.2011	X
iajs-2011	69	5	vol	vol	NOUN
iajs-2011	69	6	.	.	PROPN
iajs-2011	70	1	31	31	NUM
iajs-2011	70	2	(	(	PUNCT
iajs-2011	70	3	3	3	NUM
iajs-2011	70	4	)	)	SYM
iajs-2011	70	5	2018	2018	NUM
iajs-2011	70	6	g3	g3	NOUN
iajs-2011	70	7	.	.	PUNCT
iajs-2011	71	1	at	at	ADP
iajs-2011	71	2	last	last	ADJ
iajs-2011	71	3	the	the	DET
iajs-2011	71	4	na⁺	na⁺	PROPN
iajs-2011	71	5	levels	level	NOUN
iajs-2011	71	6	show	show	VERB
iajs-2011	71	7	in	in	ADP
iajs-2011	71	8	tables	table	NOUN
iajs-2011	71	9	(	(	PUNCT
iajs-2011	71	10	2	2	NUM
iajs-2011	71	11	-	-	SYM
iajs-2011	71	12	6	6	NUM
iajs-2011	71	13	)	)	PUNCT
iajs-2011	71	14	the	the	DET
iajs-2011	71	15	decrease	decrease	NOUN
iajs-2011	71	16	of	of	ADP
iajs-2011	71	17	significant	significant	ADJ
iajs-2011	71	18	difference	difference	NOUN
iajs-2011	71	19	in	in	ADP
iajs-2011	71	20	concentration	concentration	NOUN
iajs-2011	71	21	(	(	PUNCT
iajs-2011	71	22	6.97x10⁻⁷	6.97x10⁻⁷	ADP
iajs-2011	71	23	,	,	PUNCT
iajs-2011	71	24	1.16x10⁻⁶	1.16x10⁻⁶	NUM
iajs-2011	71	25	,	,	PUNCT
iajs-2011	71	26	1.39x10⁻⁶	1.39x10⁻⁶	NUM
iajs-2011	71	27	,	,	PUNCT
iajs-2011	71	28	1.62x10⁻⁵	1.62x10⁻⁵	X
iajs-2011	71	29	)	)	PUNCT
iajs-2011	71	30	m	m	NOUN
iajs-2011	71	31	,	,	PUNCT
iajs-2011	71	32	while	while	SCONJ
iajs-2011	71	33	in	in	ADP
iajs-2011	71	34	concentration	concentration	NOUN
iajs-2011	71	35	(	(	PUNCT
iajs-2011	71	36	9.30x10⁻⁷	9.30x10⁻⁷	X
iajs-2011	71	37	)	)	PUNCT
iajs-2011	71	38	m	m	VERB
iajs-2011	71	39	appeared	appear	VERB
iajs-2011	71	40	non	non	ADJ
iajs-2011	71	41	-	-	ADJ
iajs-2011	71	42	significant	significant	ADJ
iajs-2011	71	43	in	in	ADP
iajs-2011	71	44	g2	g2	PROPN
iajs-2011	71	45	.	.	PUNCT
iajs-2011	72	1	in	in	ADP
iajs-2011	72	2	group	group	NOUN
iajs-2011	72	3	g3the	g3the	DET
iajs-2011	72	4	na⁺	na⁺	PROPN
iajs-2011	72	5	levels	level	NOUN
iajs-2011	72	6	showed	show	VERB
iajs-2011	72	7	significant	significant	ADJ
iajs-2011	72	8	difference	difference	NOUN
iajs-2011	72	9	for	for	ADP
iajs-2011	72	10	five	five	NUM
iajs-2011	72	11	concentrations	concentration	NOUN
iajs-2011	72	12	of	of	ADP
iajs-2011	72	13	erlotinib	erlotinib	NOUN
iajs-2011	72	14	.	.	PUNCT
iajs-2011	73	1	these	these	DET
iajs-2011	73	2	results	result	NOUN
iajs-2011	73	3	are	be	AUX
iajs-2011	73	4	in	in	ADP
iajs-2011	73	5	agreement	agreement	NOUN
iajs-2011	73	6	with	with	ADP
iajs-2011	73	7	study	study	NOUN
iajs-2011	73	8	for	for	ADP
iajs-2011	73	9	another	another	DET
iajs-2011	73	10	inhibitor	inhibitor	NOUN
iajs-2011	73	11	gefitinib	gefitinib	NOUN
iajs-2011	73	12	(	(	PUNCT
iajs-2011	73	13	23	23	NUM
iajs-2011	73	14	)	)	PUNCT
iajs-2011	73	15	,	,	PUNCT
iajs-2011	73	16	(	(	PUNCT
iajs-2011	73	17	24	24	NUM
iajs-2011	73	18	)	)	PUNCT
iajs-2011	73	19	,	,	PUNCT
iajs-2011	73	20	and	and	CCONJ
iajs-2011	73	21	in	in	ADP
iajs-2011	73	22	agreement	agreement	NOUN
iajs-2011	73	23	with	with	ADP
iajs-2011	73	24	the	the	DET
iajs-2011	73	25	pervious	pervious	ADJ
iajs-2011	73	26	study	study	NOUN
iajs-2011	73	27	(	(	PUNCT
iajs-2011	73	28	25	25	NUM
iajs-2011	73	29	)	)	PUNCT
iajs-2011	73	30	that	that	PRON
iajs-2011	73	31	suggest	suggest	VERB
iajs-2011	73	32	in	in	ADP
iajs-2011	73	33	patients	patient	NOUN
iajs-2011	73	34	with	with	ADP
iajs-2011	73	35	t2	t2	PROPN
iajs-2011	73	36	dm	dm	PROPN
iajs-2011	73	37	,	,	PUNCT
iajs-2011	73	38	canagliflozin	canagliflozin	PROPN
iajs-2011	73	39	was	be	AUX
iajs-2011	73	40	generally	generally	ADV
iajs-2011	73	41	associated	associate	VERB
iajs-2011	73	42	with	with	ADP
iajs-2011	73	43	small	small	ADJ
iajs-2011	73	44	mean	mean	ADJ
iajs-2011	73	45	percent	percent	NOUN
iajs-2011	73	46	changes	change	NOUN
iajs-2011	73	47	in	in	ADP
iajs-2011	73	48	serum	serum	NOUN
iajs-2011	73	49	electrolytes	electrolyte	NOUN
iajs-2011	73	50	(	(	PUNCT
iajs-2011	73	51	for	for	ADP
iajs-2011	73	52	both	both	PRON
iajs-2011	73	53	sodium	sodium	NOUN
iajs-2011	73	54	and	and	CCONJ
iajs-2011	73	55	calcium	calcium	NOUN
iajs-2011	73	56	concentration	concentration	NOUN
iajs-2011	73	57	)	)	PUNCT
iajs-2011	73	58	.	.	PUNCT
iajs-2011	74	1	in	in	ADP
iajs-2011	74	2	table	table	NOUN
iajs-2011	74	3	7	7	NUM
iajs-2011	74	4	.	.	PUNCT
iajs-2011	75	1	the	the	DET
iajs-2011	75	2	best	good	ADJ
iajs-2011	75	3	inhibition	inhibition	NOUN
iajs-2011	75	4	in	in	ADP
iajs-2011	75	5	na⁺	na⁺	ADJ
iajs-2011	75	6	levels	level	NOUN
iajs-2011	75	7	in	in	ADP
iajs-2011	75	8	erlotinib	erlotinib	NOUN
iajs-2011	75	9	concentration	concentration	NOUN
iajs-2011	75	10	(	(	PUNCT
iajs-2011	75	11	1.62x10⁻⁵	1.62x10⁻⁵	X
iajs-2011	75	12	)	)	PUNCT
iajs-2011	75	13	m	m	PROPN
iajs-2011	75	14	for	for	ADP
iajs-2011	75	15	g2	g2	PROPN
iajs-2011	75	16	and	and	CCONJ
iajs-2011	75	17	g3	g3	PROPN
iajs-2011	75	18	.	.	PUNCT
iajs-2011	75	19	table	table	NOUN
iajs-2011	75	20	1	1	NUM
iajs-2011	75	21	.	.	PUNCT
iajs-2011	75	22	levels	level	NOUN
iajs-2011	75	23	of	of	ADP
iajs-2011	75	24	s.	s.	PROPN
iajs-2011	75	25	(	(	PUNCT
iajs-2011	75	26	mg⁺²	mg⁺²	PROPN
iajs-2011	75	27	,	,	PUNCT
iajs-2011	75	28	ca⁺²	ca⁺²	NOUN
iajs-2011	75	29	,	,	PUNCT
iajs-2011	75	30	na⁺	na⁺	PROPN
iajs-2011	75	31	)	)	PUNCT
iajs-2011	75	32	of	of	ADP
iajs-2011	75	33	the	the	DET
iajs-2011	75	34	studied	study	VERB
iajs-2011	75	35	groups	group	NOUN
iajs-2011	75	36	before	before	ADP
iajs-2011	75	37	addition	addition	NOUN
iajs-2011	75	38	of	of	ADP
iajs-2011	75	39	inhibitor	inhibitor	NOUN
iajs-2011	75	40	.	.	PUNCT
iajs-2011	76	1	parameters	parameter	NOUN
iajs-2011	76	2	g1(n	g1(n	X
iajs-2011	77	1	=	=	NOUN
iajs-2011	77	2	50	50	NUM
iajs-2011	77	3	)	)	PUNCT
iajs-2011	77	4	mean	mean	VERB
iajs-2011	77	5	±sd	±sd	PROPN
iajs-2011	77	6	g2(n=50	g2(n=50	ADJ
iajs-2011	77	7	)	)	PUNCT
iajs-2011	78	1	mean	mean	VERB
iajs-2011	78	2	±sd	±sd	PROPN
iajs-2011	78	3	g3(n=50	g3(n=50	NOUN
iajs-2011	78	4	)	)	PUNCT
iajs-2011	79	1	mean	mean	VERB
iajs-2011	79	2	±sd	±sd	PROPN
iajs-2011	79	3	p	p	PROPN
iajs-2011	79	4	value	value	NOUN
iajs-2011	79	5	g2vs.g1	g2vs.g1	PUNCT
iajs-2011	79	6	g3vs.g1	g3vs.g1	PROPN
iajs-2011	79	7	g3vs	g3vs	PUNCT
iajs-2011	79	8	.	.	PUNCT
iajs-2011	80	1	g2	g2	PROPN
iajs-2011	80	2	mg⁺	mg⁺	PROPN
iajs-2011	80	3	 	 	SPACE
iajs-2011	81	1	²(mg	²(mg	PROPN
iajs-2011	81	2	/	/	SYM
iajs-2011	81	3	dl	dl	NOUN
iajs-2011	81	4	)	)	PUNCT
iajs-2011	81	5	2.87±0.24	2.87±0.24	NUM
iajs-2011	81	6	2.84±0.34	2.84±0.34	PROPN
iajs-2011	82	1	2.38±0.08	2.38±0.08	NUM
iajs-2011	82	2	hs	hs	INTJ
iajs-2011	82	3	ns	ns	PROPN
iajs-2011	82	4	s	s	PROPN
iajs-2011	82	5	s↓	s↓	NOUN
iajs-2011	82	6	ca⁺	ca⁺	NOUN
iajs-2011	82	7	 	 	SPACE
iajs-2011	82	8	²(mg	²(mg	PROPN
iajs-2011	82	9	/	/	SYM
iajs-2011	82	10	dl	dl	NOUN
iajs-2011	82	11	)	)	PUNCT
iajs-2011	82	12	8.81±0.34	8.81±0.34	PROPN
iajs-2011	82	13	8.8±0.37	8.8±0.37	NUM
iajs-2011	82	14	9.01±0.5	9.01±0.5	NUM
iajs-2011	82	15	hs	hs	PROPN
iajs-2011	82	16	ns	ns	PROPN
iajs-2011	82	17	s↑	s↑	PROPN
iajs-2011	82	18	s↑	s↑	PROPN
iajs-2011	82	19	na⁺	na⁺	NOUN
iajs-2011	82	20	 	 	SPACE
iajs-2011	82	21	(	(	PUNCT
iajs-2011	82	22	mmol	mmol	NOUN
iajs-2011	82	23	/	/	SYM
iajs-2011	82	24	l	l	NOUN
iajs-2011	82	25	)	)	PUNCT
iajs-2011	82	26	138.68±1.35	138.68±1.35	NOUN
iajs-2011	82	27	135.02	135.02	NUM
iajs-2011	82	28	±1.99	±1.99	PROPN
iajs-2011	82	29	146.22±29.26	146.22±29.26	NUM
iajs-2011	82	30	hs	hs	PROPN
iajs-2011	82	31	s↓	s↓	NOUN
iajs-2011	82	32	hs↑	hs↑	PROPN
iajs-2011	82	33	hs↑	hs↑	PROPN
iajs-2011	82	34	table	table	NOUN
iajs-2011	82	35	2	2	NUM
iajs-2011	82	36	.	.	PUNCT
iajs-2011	82	37	levels	level	NOUN
iajs-2011	82	38	of	of	ADP
iajs-2011	82	39	s.	s.	PROPN
iajs-2011	82	40	(	(	PUNCT
iajs-2011	82	41	mg⁺²	mg⁺²	PROPN
iajs-2011	82	42	,	,	PUNCT
iajs-2011	82	43	ca⁺²	ca⁺²	NOUN
iajs-2011	82	44	,	,	PUNCT
iajs-2011	82	45	na⁺	na⁺	PROPN
iajs-2011	82	46	)	)	PUNCT
iajs-2011	82	47	in	in	ADP
iajs-2011	82	48	concentration(6.97x10⁻7	concentration(6.97x10⁻7	NOUN
iajs-2011	82	49	)	)	PUNCT
iajs-2011	82	50	m	m	VERB
iajs-2011	82	51	erlotinib	erlotinib	NOUN
iajs-2011	82	52	.	.	PUNCT
iajs-2011	83	1	parameters	parameter	NOUN
iajs-2011	83	2	g2	g2	PROPN
iajs-2011	83	3	no	no	INTJ
iajs-2011	83	4	.	.	PUNCT
iajs-2011	84	1	(	(	PUNCT
iajs-2011	84	2	50	50	NUM
iajs-2011	84	3	)	)	PUNCT
iajs-2011	84	4	before	before	ADP
iajs-2011	84	5	g2	g2	PROPN
iajs-2011	84	6	no	no	INTJ
iajs-2011	84	7	.	.	PUNCT
iajs-2011	85	1	(	(	PUNCT
iajs-2011	85	2	50	50	NUM
iajs-2011	85	3	)	)	PUNCT
iajs-2011	85	4	after	after	ADP
iajs-2011	85	5	p	p	NOUN
iajs-2011	85	6	value	value	NOUN
iajs-2011	85	7	g3	g3	NOUN
iajs-2011	85	8	no	no	INTJ
iajs-2011	85	9	.	.	PUNCT
iajs-2011	86	1	(	(	PUNCT
iajs-2011	86	2	50	50	NUM
iajs-2011	86	3	)	)	PUNCT
iajs-2011	86	4	before	before	ADP
iajs-2011	86	5	g3	g3	PROPN
iajs-2011	86	6	no	no	INTJ
iajs-2011	86	7	.	.	PUNCT
iajs-2011	87	1	(	(	PUNCT
iajs-2011	87	2	50	50	NUM
iajs-2011	87	3	)	)	PUNCT
iajs-2011	87	4	after	after	ADP
iajs-2011	87	5	p	p	NOUN
iajs-2011	87	6	value	value	NOUN
iajs-2011	88	1	mg+2	mg+2	NOUN
iajs-2011	88	2	2.84±0.34	2.84±0.34	VERB
iajs-2011	88	3	2.59±0.51	2.59±0.51	NOUN
iajs-2011	88	4	s↓	s↓	PUNCT
iajs-2011	89	1	2.38±0.08	2.38±0.08	NUM
iajs-2011	89	2	2.35±0.04	2.35±0.04	NUM
iajs-2011	89	3	ns	ns	NUM
iajs-2011	89	4	ca+2	ca+2	PROPN
iajs-2011	89	5	8.8±0.37	8.8±0.37	PROPN
iajs-2011	89	6	8.65±0.1	8.65±0.1	NUM
iajs-2011	89	7	ns	ns	NUM
iajs-2011	89	8	9.01±0.5	9.01±0.5	NUM
iajs-2011	89	9	8.85±0.03	8.85±0.03	PROPN
iajs-2011	89	10	s	s	PART
iajs-2011	89	11	na+	na+	NOUN
iajs-2011	89	12	135.02±1.99	135.02±1.99	NOUN
iajs-2011	89	13	135.87±4.45	135.87±4.45	NUM
iajs-2011	89	14	s↑	s↑	NOUN
iajs-2011	89	15	146.22±29.26	146.22±29.26	NUM
iajs-2011	89	16	156.73±1.17	156.73±1.17	PRON
iajs-2011	89	17	s↑	s↑	PROPN
iajs-2011	89	18	table	table	NOUN
iajs-2011	89	19	3	3	NUM
iajs-2011	89	20	.	.	PUNCT
iajs-2011	89	21	levels	level	NOUN
iajs-2011	89	22	of	of	ADP
iajs-2011	89	23	s.	s.	PROPN
iajs-2011	89	24	(	(	PUNCT
iajs-2011	89	25	mg⁺²	mg⁺²	PROPN
iajs-2011	89	26	,	,	PUNCT
iajs-2011	89	27	ca⁺²	ca⁺²	NOUN
iajs-2011	89	28	,	,	PUNCT
iajs-2011	89	29	na⁺	na⁺	NOUN
iajs-2011	89	30	)	)	PUNCT
iajs-2011	89	31	in	in	ADP
iajs-2011	89	32	concentration	concentration	NOUN
iajs-2011	89	33	(	(	PUNCT
iajs-2011	89	34	9.30	9.30	NUM
iajs-2011	89	35	x10⁻7	x10⁻7	PROPN
iajs-2011	89	36	m	m	NOUN
iajs-2011	89	37	)	)	PUNCT
iajs-2011	89	38	erlotinib	erlotinib	NOUN
iajs-2011	89	39	.	.	PUNCT
iajs-2011	90	1	parameters	parameter	NOUN
iajs-2011	90	2	g2	g2	PROPN
iajs-2011	90	3	no	no	INTJ
iajs-2011	90	4	.	.	PUNCT
iajs-2011	91	1	(	(	PUNCT
iajs-2011	91	2	50	50	NUM
iajs-2011	91	3	)	)	PUNCT
iajs-2011	91	4	before	before	ADP
iajs-2011	91	5	g2	g2	PROPN
iajs-2011	91	6	no	no	INTJ
iajs-2011	91	7	.	.	PUNCT
iajs-2011	92	1	(	(	PUNCT
iajs-2011	92	2	50	50	NUM
iajs-2011	92	3	)	)	PUNCT
iajs-2011	92	4	after	after	ADP
iajs-2011	92	5	p	p	NOUN
iajs-2011	92	6	value	value	NOUN
iajs-2011	92	7	g3	g3	NOUN
iajs-2011	92	8	no	no	INTJ
iajs-2011	92	9	.	.	PUNCT
iajs-2011	93	1	(	(	PUNCT
iajs-2011	93	2	50	50	NUM
iajs-2011	93	3	)	)	PUNCT
iajs-2011	93	4	before	before	ADP
iajs-2011	93	5	g3	g3	PROPN
iajs-2011	93	6	no	no	INTJ
iajs-2011	93	7	.	.	PUNCT
iajs-2011	94	1	(	(	PUNCT
iajs-2011	94	2	50	50	NUM
iajs-2011	94	3	)	)	PUNCT
iajs-2011	94	4	after	after	ADP
iajs-2011	94	5	p	p	NOUN
iajs-2011	94	6	value	value	NOUN
iajs-2011	95	1	mg+2	mg+2	NOUN
iajs-2011	95	2	2.84±0.34	2.84±0.34	NOUN
iajs-2011	95	3	2	2	NUM
iajs-2011	95	4	±0.14	±0.14	NOUN
iajs-2011	95	5	s↓	s↓	PROPN
iajs-2011	96	1	2.38±0.08	2.38±0.08	NUM
iajs-2011	96	2	2.25±0.03	2.25±0.03	NUM
iajs-2011	96	3	ns	ns	NUM
iajs-2011	96	4	ca+2	ca+2	PROPN
iajs-2011	96	5	8.8±0.37	8.8±0.37	NUM
iajs-2011	96	6	8.69±0.09	8.69±0.09	NUM
iajs-2011	96	7	ns	ns	NUM
iajs-2011	96	8	9.01±0.5	9.01±0.5	NUM
iajs-2011	96	9	8.68±0.04	8.68±0.04	NOUN
iajs-2011	96	10	s	s	PART
iajs-2011	96	11	na+	na+	NOUN
iajs-2011	96	12	135.02±1.99	135.02±1.99	NOUN
iajs-2011	96	13	135.28±0.3	135.28±0.3	NUM
iajs-2011	96	14	ns	ns	NUM
iajs-2011	96	15	146.22±29.26	146.22±29.26	NUM
iajs-2011	96	16	145.62	145.62	NUM
iajs-2011	96	17	±0.68	±0.68	PROPN
iajs-2011	96	18	s↑	s↑	PROPN
iajs-2011	96	19	table	table	NOUN
iajs-2011	96	20	4	4	NUM
iajs-2011	96	21	.	.	PUNCT
iajs-2011	96	22	levels	level	NOUN
iajs-2011	96	23	of	of	ADP
iajs-2011	96	24	s.	s.	PROPN
iajs-2011	96	25	(	(	PUNCT
iajs-2011	96	26	mg⁺²	mg⁺²	PROPN
iajs-2011	96	27	,	,	PUNCT
iajs-2011	96	28	ca⁺²	ca⁺²	NOUN
iajs-2011	96	29	,	,	PUNCT
iajs-2011	96	30	na⁺	na⁺	NOUN
iajs-2011	96	31	)	)	PUNCT
iajs-2011	96	32	in	in	ADP
iajs-2011	96	33	concentration	concentration	NOUN
iajs-2011	96	34	(	(	PUNCT
iajs-2011	96	35	1.16	1.16	NUM
iajs-2011	96	36	x10⁻6	x10⁻6	NOUN
iajs-2011	96	37	m	m	NOUN
iajs-2011	96	38	)	)	PUNCT
iajs-2011	96	39	erlotinib	erlotinib	NOUN
iajs-2011	96	40	.	.	PUNCT
iajs-2011	97	1	parameters	parameter	NOUN
iajs-2011	97	2	g2	g2	PROPN
iajs-2011	97	3	no	no	INTJ
iajs-2011	97	4	.	.	PUNCT
iajs-2011	98	1	(	(	PUNCT
iajs-2011	98	2	50	50	NUM
iajs-2011	98	3	)	)	PUNCT
iajs-2011	98	4	before	before	ADP
iajs-2011	98	5	g2	g2	PROPN
iajs-2011	98	6	no	no	INTJ
iajs-2011	98	7	.	.	PUNCT
iajs-2011	99	1	(	(	PUNCT
iajs-2011	99	2	50	50	NUM
iajs-2011	99	3	)	)	PUNCT
iajs-2011	99	4	after	after	ADP
iajs-2011	99	5	p	p	NOUN
iajs-2011	99	6	value	value	NOUN
iajs-2011	99	7	g3	g3	NOUN
iajs-2011	99	8	no	no	INTJ
iajs-2011	99	9	.	.	PUNCT
iajs-2011	100	1	(	(	PUNCT
iajs-2011	100	2	50	50	NUM
iajs-2011	100	3	)	)	PUNCT
iajs-2011	100	4	before	before	ADP
iajs-2011	100	5	g3	g3	PROPN
iajs-2011	100	6	no	no	INTJ
iajs-2011	100	7	.	.	PUNCT
iajs-2011	101	1	(	(	PUNCT
iajs-2011	101	2	50	50	NUM
iajs-2011	101	3	)	)	PUNCT
iajs-2011	101	4	after	after	ADP
iajs-2011	101	5	p	p	NOUN
iajs-2011	101	6	value	value	NOUN
iajs-2011	102	1	mg+2	mg+2	NOUN
iajs-2011	102	2	2.84±0.34	2.84±0.34	NOUN
iajs-2011	102	3	2.24±0.09	2.24±0.09	NUM
iajs-2011	102	4	s↓	s↓	PUNCT
iajs-2011	103	1	2.38±0.08	2.38±0.08	NUM
iajs-2011	103	2	2.14±0.03	2.14±0.03	NOUN
iajs-2011	103	3	s	s	PART
iajs-2011	103	4	ca+2	ca+2	PROPN
iajs-2011	103	5	8.8±0.37	8.8±0.37	NUM
iajs-2011	103	6	8.55±0.11	8.55±0.11	NOUN
iajs-2011	103	7	s↓	s↓	PUNCT
iajs-2011	104	1	9.01±0.5	9.01±0.5	NUM
iajs-2011	104	2	8.55±0.03	8.55±0.03	NUM
iajs-2011	104	3	s	s	PART
iajs-2011	104	4	na+	na+	NOUN
iajs-2011	104	5	135.02±1.99	135.02±1.99	NOUN
iajs-2011	104	6	134.79±1.66	134.79±1.66	NUM
iajs-2011	104	7	s	s	NOUN
iajs-2011	104	8	146.22±29.26	146.22±29.26	NUM
iajs-2011	104	9	144.62±0.29	144.62±0.29	NUM
iajs-2011	104	10	s↑	s↑	PROPN
iajs-2011	104	11	chemistry	chemistry	NOUN
iajs-2011	104	12	|	|	ADV
iajs-2011	104	13	67	67	NUM
iajs-2011	104	14	ibn	ibn	PROPN
iajs-2011	104	15	al	al	PROPN
iajs-2011	104	16	-	-	PUNCT
iajs-2011	104	17	haitham	haitham	PROPN
iajs-2011	104	18	jour	jour	X
iajs-2011	104	19	.	.	PROPN
iajs-2011	104	20	for	for	ADP
iajs-2011	104	21	pure	pure	ADJ
iajs-2011	104	22	&	&	CCONJ
iajs-2011	104	23	appl	appl	PROPN
iajs-2011	104	24	.	.	PUNCT
iajs-2011	105	1	sci	sci	PROPN
iajs-2011	105	2	.	.	PROPN
iajs-2011	105	3	ihjpas	ihjpa	VERB
iajs-2011	105	4	https://doi.org/10.30526/31.3.2011	https://doi.org/10.30526/31.3.2011	X
iajs-2011	105	5	vol	vol	NOUN
iajs-2011	105	6	.	.	PROPN
iajs-2011	106	1	31	31	NUM
iajs-2011	106	2	(	(	PUNCT
iajs-2011	106	3	3	3	NUM
iajs-2011	106	4	)	)	SYM
iajs-2011	106	5	2018	2018	NUM
iajs-2011	106	6	table	table	NOUN
iajs-2011	106	7	5	5	NUM
iajs-2011	106	8	.	.	PUNCT
iajs-2011	106	9	levels	level	NOUN
iajs-2011	106	10	of	of	ADP
iajs-2011	106	11	s.	s.	PROPN
iajs-2011	106	12	(	(	PUNCT
iajs-2011	106	13	mg⁺²	mg⁺²	PROPN
iajs-2011	106	14	,	,	PUNCT
iajs-2011	106	15	ca⁺²	ca⁺²	NOUN
iajs-2011	106	16	,	,	PUNCT
iajs-2011	106	17	na⁺	na⁺	NOUN
iajs-2011	106	18	)	)	PUNCT
iajs-2011	106	19	in	in	ADP
iajs-2011	106	20	concentration	concentration	NOUN
iajs-2011	106	21	(	(	PUNCT
iajs-2011	106	22	1.39	1.39	NUM
iajs-2011	106	23	x10⁻6	x10⁻6	NOUN
iajs-2011	106	24	m	m	NOUN
iajs-2011	106	25	)	)	PUNCT
iajs-2011	106	26	erlotinib	erlotinib	NOUN
iajs-2011	106	27	.	.	PUNCT
iajs-2011	107	1	parameters	parameter	NOUN
iajs-2011	107	2	g2	g2	PROPN
iajs-2011	107	3	no	no	INTJ
iajs-2011	107	4	.	.	PUNCT
iajs-2011	108	1	(	(	PUNCT
iajs-2011	108	2	50	50	NUM
iajs-2011	108	3	)	)	PUNCT
iajs-2011	108	4	before	before	ADP
iajs-2011	108	5	g2	g2	PROPN
iajs-2011	108	6	no	no	INTJ
iajs-2011	108	7	.	.	PUNCT
iajs-2011	109	1	(	(	PUNCT
iajs-2011	109	2	50	50	NUM
iajs-2011	109	3	)	)	PUNCT
iajs-2011	109	4	after	after	ADP
iajs-2011	109	5	p	p	NOUN
iajs-2011	109	6	value	value	NOUN
iajs-2011	109	7	g3	g3	NOUN
iajs-2011	109	8	no	no	INTJ
iajs-2011	109	9	.	.	PUNCT
iajs-2011	110	1	(	(	PUNCT
iajs-2011	110	2	50	50	NUM
iajs-2011	110	3	)	)	PUNCT
iajs-2011	110	4	before	before	ADP
iajs-2011	110	5	g3	g3	PROPN
iajs-2011	110	6	no	no	INTJ
iajs-2011	110	7	.	.	PUNCT
iajs-2011	111	1	(	(	PUNCT
iajs-2011	111	2	50	50	NUM
iajs-2011	111	3	)	)	PUNCT
iajs-2011	111	4	after	after	ADP
iajs-2011	111	5	p	p	NOUN
iajs-2011	111	6	value	value	NOUN
iajs-2011	112	1	mg+2	mg+2	NOUN
iajs-2011	112	2	2.84±0.34	2.84±0.34	NOUN
iajs-2011	112	3	2.26±0.23	2.26±0.23	NUM
iajs-2011	112	4	s↓	s↓	PUNCT
iajs-2011	112	5	2.38±0.08	2.38±0.08	NUM
iajs-2011	112	6	1.95±0.04	1.95±0.04	NUM
iajs-2011	112	7	s	s	PART
iajs-2011	112	8	ca+2	ca+2	PROPN
iajs-2011	112	9	8.8±0.37	8.8±0.37	NUM
iajs-2011	112	10	8.6±0.2	8.6±0.2	NUM
iajs-2011	112	11	ns	ns	NUM
iajs-2011	112	12	9.01±0.5	9.01±0.5	NUM
iajs-2011	112	13	8.45±0.03	8.45±0.03	NOUN
iajs-2011	112	14	s	s	PART
iajs-2011	112	15	na+	na+	NOUN
iajs-2011	112	16	135.02±1.99	135.02±1.99	NOUN
iajs-2011	112	17	133.67±0.69	133.67±0.69	NOUN
iajs-2011	112	18	s	s	PART
iajs-2011	112	19	146.22±29.26	146.22±29.26	NUM
iajs-2011	112	20	143.04±0.34	143.04±0.34	NUM
iajs-2011	112	21	s↑	s↑	PROPN
iajs-2011	112	22	table	table	NOUN
iajs-2011	112	23	6	6	NUM
iajs-2011	112	24	.	.	PUNCT
iajs-2011	113	1	levels	level	NOUN
iajs-2011	113	2	of	of	ADP
iajs-2011	113	3	s.	s.	PROPN
iajs-2011	113	4	(	(	PUNCT
iajs-2011	113	5	mg⁺²	mg⁺²	PROPN
iajs-2011	113	6	,	,	PUNCT
iajs-2011	113	7	ca⁺²	ca⁺²	NOUN
iajs-2011	113	8	,	,	PUNCT
iajs-2011	113	9	na⁺	na⁺	NOUN
iajs-2011	113	10	)	)	PUNCT
iajs-2011	113	11	in	in	ADP
iajs-2011	113	12	concentration	concentration	NOUN
iajs-2011	113	13	(	(	PUNCT
iajs-2011	113	14	1.62	1.62	NUM
iajs-2011	113	15	x10⁻5	x10⁻5	PROPN
iajs-2011	113	16	m	m	NOUN
iajs-2011	113	17	)	)	PUNCT
iajs-2011	113	18	erlotinib	erlotinib	NOUN
iajs-2011	113	19	.	.	PUNCT
iajs-2011	114	1	parameters	parameter	NOUN
iajs-2011	114	2	g2	g2	PROPN
iajs-2011	114	3	no	no	INTJ
iajs-2011	114	4	.	.	PUNCT
iajs-2011	115	1	(	(	PUNCT
iajs-2011	115	2	50	50	NUM
iajs-2011	115	3	)	)	PUNCT
iajs-2011	115	4	before	before	ADP
iajs-2011	115	5	g2	g2	PROPN
iajs-2011	115	6	no	no	INTJ
iajs-2011	115	7	.	.	PUNCT
iajs-2011	116	1	(	(	PUNCT
iajs-2011	116	2	50	50	NUM
iajs-2011	116	3	)	)	PUNCT
iajs-2011	116	4	after	after	ADP
iajs-2011	116	5	p	p	NOUN
iajs-2011	116	6	value	value	NOUN
iajs-2011	116	7	g3	g3	NOUN
iajs-2011	116	8	no	no	INTJ
iajs-2011	116	9	.	.	PUNCT
iajs-2011	117	1	(	(	PUNCT
iajs-2011	117	2	50	50	NUM
iajs-2011	117	3	)	)	PUNCT
iajs-2011	117	4	before	before	ADP
iajs-2011	117	5	g3	g3	PROPN
iajs-2011	117	6	no	no	INTJ
iajs-2011	117	7	.	.	PUNCT
iajs-2011	118	1	(	(	PUNCT
iajs-2011	118	2	50	50	NUM
iajs-2011	118	3	)	)	PUNCT
iajs-2011	118	4	after	after	ADP
iajs-2011	118	5	p	p	NOUN
iajs-2011	118	6	value	value	NOUN
iajs-2011	118	7	mg+2	mg+2	PROPN
iajs-2011	118	8	2.84±0.34	2.84±0.34	NOUN
iajs-2011	118	9	2.08±0.13	2.08±0.13	NUM
iajs-2011	118	10	s↓	s↓	PUNCT
iajs-2011	119	1	2.38±0.08	2.38±0.08	NUM
iajs-2011	119	2	1.91	1.91	NUM
iajs-2011	119	3	±0.03	±0.03	PROPN
iajs-2011	119	4	s	s	PART
iajs-2011	119	5	ca+2	ca+2	PROPN
iajs-2011	119	6	8.8±0.37	8.8±0.37	NUM
iajs-2011	119	7	8.51±0.25	8.51±0.25	NUM
iajs-2011	119	8	ns	ns	NUM
iajs-2011	119	9	9.01±0.5	9.01±0.5	NUM
iajs-2011	119	10	8.34±0.03	8.34±0.03	NUM
iajs-2011	119	11	s	s	PART
iajs-2011	119	12	na+	na+	NOUN
iajs-2011	119	13	135.02±1.99	135.02±1.99	NOUN
iajs-2011	119	14	133.04±1.2	133.04±1.2	NUM
iajs-2011	119	15	s	s	PART
iajs-2011	119	16	146.22±29.26	146.22±29.26	NUM
iajs-2011	119	17	140.92±0.77	140.92±0.77	NUM
iajs-2011	119	18	s↑	s↑	NOUN
iajs-2011	119	19	table	table	NOUN
iajs-2011	119	20	7	7	NUM
iajs-2011	119	21	.	.	PUNCT
iajs-2011	120	1	the	the	DET
iajs-2011	120	2	percentage	percentage	NOUN
iajs-2011	120	3	inhibition	inhibition	NOUN
iajs-2011	120	4	of	of	ADP
iajs-2011	120	5	s.	s.	PROPN
iajs-2011	120	6	(	(	PUNCT
iajs-2011	120	7	mg⁺²	mg⁺²	PROPN
iajs-2011	120	8	,	,	PUNCT
iajs-2011	120	9	ca⁺²	ca⁺²	NOUN
iajs-2011	120	10	,	,	PUNCT
iajs-2011	120	11	na⁺	na⁺	PROPN
iajs-2011	120	12	)	)	PUNCT
iajs-2011	120	13	in	in	ADP
iajs-2011	120	14	g2	g2	PROPN
iajs-2011	120	15	and	and	CCONJ
iajs-2011	120	16	g3	g3	PROPN
iajs-2011	120	17	4	4	NUM
iajs-2011	120	18	.	.	PUNCT
iajs-2011	120	19	conclusion	conclusion	NOUN
iajs-2011	120	20	this	this	DET
iajs-2011	120	21	study	study	NOUN
iajs-2011	120	22	is	be	AUX
iajs-2011	120	23	considered	consider	VERB
iajs-2011	120	24	the	the	DET
iajs-2011	120	25	first	first	ADJ
iajs-2011	120	26	study	study	NOUN
iajs-2011	120	27	in	in	ADP
iajs-2011	120	28	iraq	iraq	PROPN
iajs-2011	120	29	that	that	PRON
iajs-2011	120	30	concluded	conclude	VERB
iajs-2011	120	31	the	the	DET
iajs-2011	120	32	best	good	ADJ
iajs-2011	120	33	percentage	percentage	NOUN
iajs-2011	120	34	inhibition	inhibition	NOUN
iajs-2011	120	35	from	from	ADP
iajs-2011	120	36	utilizing	utilize	VERB
iajs-2011	120	37	different	different	ADJ
iajs-2011	120	38	concentrations	concentration	NOUN
iajs-2011	120	39	of	of	ADP
iajs-2011	120	40	erlotinib	erlotinib	NOUN
iajs-2011	120	41	drug	drug	NOUN
iajs-2011	120	42	on	on	ADP
iajs-2011	120	43	electrolyte	electrolyte	ADJ
iajs-2011	120	44	levels	level	NOUN
iajs-2011	120	45	in	in	ADP
iajs-2011	120	46	type	type	NOUN
iajs-2011	120	47	2	2	NUM
iajs-2011	120	48	diabetic	diabetic	ADJ
iajs-2011	120	49	and	and	CCONJ
iajs-2011	120	50	diabetic	diabetic	ADJ
iajs-2011	120	51	nephropathy	nephropathy	NOUN
iajs-2011	120	52	.	.	PUNCT
iajs-2011	121	1	therefore	therefore	ADV
iajs-2011	121	2	,	,	PUNCT
iajs-2011	121	3	a	a	DET
iajs-2011	121	4	mild	mild	ADJ
iajs-2011	121	5	effect	effect	NOUN
iajs-2011	121	6	of	of	ADP
iajs-2011	121	7	erlotinib	erlotinib	ADJ
iajs-2011	121	8	inhibitor	inhibitor	NOUN
iajs-2011	121	9	on	on	ADP
iajs-2011	121	10	serum	serum	NOUN
iajs-2011	121	11	mg	mg	PROPN
iajs-2011	121	12	⁺²levels	⁺²levels	PROPN
iajs-2011	121	13	in	in	ADP
iajs-2011	121	14	human	human	NOUN
iajs-2011	121	15	and	and	CCONJ
iajs-2011	121	16	a	a	DET
iajs-2011	121	17	slight	slight	ADJ
iajs-2011	121	18	effect	effect	NOUN
iajs-2011	121	19	of	of	ADP
iajs-2011	121	20	erlotinib	erlotinib	ADJ
iajs-2011	121	21	inhibitor	inhibitor	NOUN
iajs-2011	121	22	on	on	ADP
iajs-2011	121	23	serum	serum	PROPN
iajs-2011	121	24	na⁺	na⁺	PROPN
iajs-2011	121	25	and	and	CCONJ
iajs-2011	121	26	ca⁺².the	ca⁺².the	PRON
iajs-2011	121	27	best	good	ADJ
iajs-2011	121	28	inhibition	inhibition	NOUN
iajs-2011	121	29	of	of	ADP
iajs-2011	121	30	erlotinib	erlotinib	NOUN
iajs-2011	121	31	in	in	ADP
iajs-2011	121	32	concentration	concentration	NOUN
iajs-2011	121	33	(	(	PUNCT
iajs-2011	121	34	1.62x10⁻5	1.62x10⁻5	NUM
iajs-2011	121	35	m	m	NOUN
iajs-2011	121	36	)	)	PUNCT
iajs-2011	121	37	for	for	ADP
iajs-2011	121	38	both	both	PRON
iajs-2011	121	39	serum	serum	NOUN
iajs-2011	121	40	na⁺	na⁺	PROPN
iajs-2011	121	41	and	and	CCONJ
iajs-2011	121	42	ca⁺²	ca⁺²	PROPN
iajs-2011	121	43	,	,	PUNCT
iajs-2011	121	44	except	except	SCONJ
iajs-2011	121	45	mg	mg	PROPN
iajs-2011	121	46	⁺²levels	⁺²levels	PROPN
iajs-2011	121	47	showed	show	VERB
iajs-2011	121	48	best	good	ADJ
iajs-2011	121	49	inhibition	inhibition	NOUN
iajs-2011	121	50	in	in	ADP
iajs-2011	121	51	(	(	PUNCT
iajs-2011	121	52	9.30x10⁻7	9.30x10⁻7	NUM
iajs-2011	121	53	m	m	NOUN
iajs-2011	121	54	)	)	PUNCT
iajs-2011	121	55	.	.	PUNCT
iajs-2011	122	1	references	reference	NOUN
iajs-2011	122	2	1	1	NUM
iajs-2011	122	3	.	.	PUNCT
iajs-2011	122	4	american	american	ADJ
iajs-2011	122	5	diabetes	diabetes	PROPN
iajs-2011	122	6	association	association	PROPN
iajs-2011	122	7	.	.	PUNCT
iajs-2011	123	1	diagnosis	diagnosis	NOUN
iajs-2011	123	2	and	and	CCONJ
iajs-2011	123	3	classification	classification	NOUN
iajs-2011	123	4	of	of	ADP
iajs-2011	123	5	diabetes	diabetes	NOUN
iajs-2011	123	6	mellitus	mellitus	NOUN
iajs-2011	123	7	.	.	PUNCT
iajs-2011	124	1	diabetes	diabetes	NOUN
iajs-2011	124	2	care	care	NOUN
iajs-2011	124	3	.	.	PUNCT
iajs-2011	125	1	2014	2014	NUM
iajs-2011	125	2	,	,	PUNCT
iajs-2011	125	3	37	37	NUM
iajs-2011	125	4	,	,	PUNCT
iajs-2011	125	5	1	1	NUM
iajs-2011	125	6	,	,	PUNCT
iajs-2011	125	7	s81	s81	NOUN
iajs-2011	125	8	-	-	PUNCT
iajs-2011	125	9	s90	s90	NOUN
iajs-2011	125	10	.	.	PUNCT
iajs-2011	126	1	2	2	NUM
iajs-2011	126	2	.	.	X
iajs-2011	126	3	american	american	ADJ
iajs-2011	126	4	diabetes	diabetes	PROPN
iajs-2011	126	5	association	association	PROPN
iajs-2011	126	6	.	.	PUNCT
iajs-2011	127	1	;	;	PUNCT
iajs-2011	127	2	diagnosis	diagnosis	NOUN
iajs-2011	127	3	and	and	CCONJ
iajs-2011	127	4	classification	classification	NOUN
iajs-2011	127	5	of	of	ADP
iajs-2011	127	6	diabetes	diabetes	NOUN
iajs-2011	127	7	mellitus	mellitus	NOUN
iajs-2011	127	8	.	.	PUNCT
iajs-2011	128	1	3	3	X
iajs-2011	128	2	.	.	X
iajs-2011	128	3	diabetes	diabetes	NOUN
iajs-2011	128	4	care	care	NOUN
iajs-2011	128	5	.	.	PUNCT
iajs-2011	129	1	2013	2013	NUM
iajs-2011	129	2	,	,	PUNCT
iajs-2011	129	3	36	36	NUM
iajs-2011	129	4	,	,	PUNCT
iajs-2011	129	5	1	1	NUM
iajs-2011	129	6	,	,	PUNCT
iajs-2011	129	7	67–74	67–74	NUM
iajs-2011	129	8	.	.	PUNCT
iajs-2011	130	1	4	4	NUM
iajs-2011	130	2	.	.	X
iajs-2011	130	3	nathan	nathan	PROPN
iajs-2011	130	4	,	,	PUNCT
iajs-2011	130	5	d.m	d.m	PROPN
iajs-2011	130	6	.	.	PUNCT
iajs-2011	130	7	;	;	PUNCT
iajs-2011	130	8	group	group	NOUN
iajs-2011	130	9	d.e.r	d.e.r	NOUN
iajs-2011	130	10	.	.	PUNCT
iajs-2011	131	1	the	the	DET
iajs-2011	131	2	diabetes	diabetes	NOUN
iajs-2011	131	3	control	control	NOUN
iajs-2011	131	4	and	and	CCONJ
iajs-2011	131	5	complications	complication	NOUN
iajs-2011	131	6	trial	trial	NOUN
iajs-2011	131	7	/	/	SYM
iajs-2011	131	8	epidemiology	epidemiology	NOUN
iajs-2011	131	9	of	of	ADP
iajs-2011	131	10	diabetes	diabetes	NOUN
iajs-2011	131	11	interventions	intervention	NOUN
iajs-2011	131	12	and	and	CCONJ
iajs-2011	131	13	complications	complication	NOUN
iajs-2011	131	14	study	study	NOUN
iajs-2011	131	15	at	at	ADP
iajs-2011	131	16	30	30	NUM
iajs-2011	131	17	years	year	NOUN
iajs-2011	131	18	:	:	PUNCT
iajs-2011	131	19	overview	overview	NOUN
iajs-2011	131	20	.	.	PUNCT
iajs-2011	132	1	diabetes	diabetes	NOUN
iajs-2011	132	2	care	care	NOUN
iajs-2011	132	3	.	.	PUNCT
iajs-2011	133	1	2014	2014	NUM
iajs-2011	133	2	,	,	PUNCT
iajs-2011	133	3	37	37	NUM
iajs-2011	133	4	,	,	PUNCT
iajs-2011	133	5	1	1	NUM
iajs-2011	133	6	,	,	PUNCT
iajs-2011	133	7	9	9	NUM
iajs-2011	133	8	-	-	SYM
iajs-2011	133	9	16	16	NUM
iajs-2011	133	10	.	.	PUNCT
iajs-2011	134	1	5	5	X
iajs-2011	134	2	.	.	X
iajs-2011	134	3	forouhi	forouhi	PROPN
iajs-2011	134	4	,	,	PUNCT
iajs-2011	134	5	n.g	n.g	PROPN
iajs-2011	134	6	.	.	PROPN
iajs-2011	134	7	;	;	PUNCT
iajs-2011	135	1	wareham	wareham	PROPN
iajs-2011	135	2	.	.	PUNCT
iajs-2011	136	1	n.j	n.j	PROPN
iajs-2011	136	2	.	.	PROPN
iajs-2011	136	3	epidemiology	epidemiology	NOUN
iajs-2011	136	4	of	of	ADP
iajs-2011	136	5	diabetes	diabetes	NOUN
iajs-2011	136	6	.	.	PUNCT
iajs-2011	137	1	medicine	medicine	NOUN
iajs-2011	137	2	.	.	PUNCT
iajs-2011	138	1	2010	2010	NUM
iajs-2011	138	2	,	,	PUNCT
iajs-2011	138	3	38,11	38,11	PROPN
iajs-2011	138	4	,	,	PUNCT
iajs-2011	138	5	602606	602606	NUM
iajs-2011	138	6	.	.	PUNCT
iajs-2011	139	1	concentration	concentration	NOUN
iajs-2011	139	2	of	of	ADP
iajs-2011	139	3	erlotinib	erlotinib	NOUN
iajs-2011	139	4	g2	g2	PROPN
iajs-2011	139	5	%	%	NOUN
iajs-2011	139	6	mg⁺²	mg⁺²	PROPN
iajs-2011	139	7	g3	g3	PROPN
iajs-2011	139	8	%	%	PROPN
iajs-2011	139	9	mg⁺²	mg⁺²	NOUN
iajs-2011	139	10	g2	g2	PROPN
iajs-2011	139	11	%	%	NOUN
iajs-2011	139	12	ca⁺²	ca⁺²	NOUN
iajs-2011	139	13	g3	g3	PROPN
iajs-2011	139	14	%	%	NOUN
iajs-2011	139	15	ca⁺²	ca⁺²	NOUN
iajs-2011	139	16	g2	g2	PROPN
iajs-2011	139	17	%	%	VERB
iajs-2011	139	18	na⁺	na⁺	PROPN
iajs-2011	139	19	g3	g3	PROPN
iajs-2011	139	20	%	%	PROPN
iajs-2011	139	21	na⁺	na⁺	PROPN
iajs-2011	139	22	6.96x10⁻7	6.96x10⁻7	NOUN
iajs-2011	139	23	m	m	NOUN
iajs-2011	139	24	8.9	8.9	NUM
iajs-2011	139	25	%	%	NOUN
iajs-2011	139	26	1.3	1.3	NUM
iajs-2011	139	27	%	%	NOUN
iajs-2011	139	28	1.8	1.8	NUM
iajs-2011	139	29	%	%	NOUN
iajs-2011	139	30	1.8	1.8	NUM
iajs-2011	139	31	%	%	NOUN
iajs-2011	139	32	0	0	NUM
iajs-2011	139	33	%	%	NOUN
iajs-2011	139	34	0	0	NUM
iajs-2011	139	35	%	%	NOUN
iajs-2011	140	1	9.30x10⁻7	9.30x10⁻7	NUM
iajs-2011	140	2	m	m	NOUN
iajs-2011	140	3	29.6	29.6	NUM
iajs-2011	140	4	%	%	NOUN
iajs-2011	140	5	5.5	5.5	NUM
iajs-2011	140	6	%	%	NOUN
iajs-2011	140	7	1.3	1.3	NUM
iajs-2011	140	8	%	%	NOUN
iajs-2011	140	9	3.7	3.7	NUM
iajs-2011	140	10	%	%	NOUN
iajs-2011	140	11	0	0	NUM
iajs-2011	140	12	%	%	NOUN
iajs-2011	140	13	0.5	0.5	NUM
iajs-2011	140	14	%	%	NOUN
iajs-2011	140	15	1.16x10⁻6	1.16x10⁻6	NUM
iajs-2011	140	16	m	m	NOUN
iajs-2011	140	17	21.2	21.2	NUM
iajs-2011	140	18	%	%	NOUN
iajs-2011	140	19	10.1	10.1	NUM
iajs-2011	140	20	%	%	NOUN
iajs-2011	140	21	2.9	2.9	NUM
iajs-2011	140	22	%	%	NOUN
iajs-2011	140	23	5.2	5.2	NUM
iajs-2011	140	24	%	%	NOUN
iajs-2011	140	25	0.2	0.2	NUM
iajs-2011	140	26	%	%	NOUN
iajs-2011	140	27	1.1	1.1	NUM
iajs-2011	140	28	%	%	NOUN
iajs-2011	140	29	1.39x10⁻6	1.39x10⁻6	NOUN
iajs-2011	140	30	m	m	NUM
iajs-2011	140	31	26.8	26.8	NUM
iajs-2011	140	32	%	%	NOUN
iajs-2011	140	33	18.1	18.1	NUM
iajs-2011	140	34	%	%	NOUN
iajs-2011	140	35	2.3	2.3	NUM
iajs-2011	140	36	%	%	NOUN
iajs-2011	140	37	6.3	6.3	NUM
iajs-2011	140	38	%	%	NOUN
iajs-2011	140	39	1	1	NUM
iajs-2011	140	40	%	%	NOUN
iajs-2011	140	41	2.2	2.2	NUM
iajs-2011	140	42	%	%	NOUN
iajs-2011	140	43	1.62x10⁻5	1.62x10⁻5	NUM
iajs-2011	140	44	m	m	NOUN
iajs-2011	140	45	26.7	26.7	NUM
iajs-2011	140	46	%	%	NOUN
iajs-2011	140	47	19.8	19.8	NUM
iajs-2011	140	48	%	%	NOUN
iajs-2011	140	49	3.3	3.3	NUM
iajs-2011	140	50	%	%	NOUN
iajs-2011	140	51	7.5	7.5	NUM
iajs-2011	140	52	%	%	NOUN
iajs-2011	140	53	1.5	1.5	NUM
iajs-2011	140	54	%	%	NOUN
iajs-2011	140	55	3.63	3.63	NUM
iajs-2011	140	56	%	%	NOUN
iajs-2011	140	57	chemistry	chemistry	NOUN
iajs-2011	140	58	|	|	ADV
iajs-2011	140	59	68	68	NUM
iajs-2011	140	60	ibn	ibn	PROPN
iajs-2011	140	61	al	al	PROPN
iajs-2011	140	62	-	-	PUNCT
iajs-2011	140	63	haitham	haitham	PROPN
iajs-2011	140	64	jour	jour	X
iajs-2011	140	65	.	.	PROPN
iajs-2011	141	1	for	for	ADP
iajs-2011	141	2	pure	pure	ADJ
iajs-2011	141	3	&	&	CCONJ
iajs-2011	141	4	appl	appl	PROPN
iajs-2011	141	5	.	.	PUNCT
iajs-2011	142	1	sci	sci	PROPN
iajs-2011	142	2	.	.	PROPN
iajs-2011	142	3	ihjpas	ihjpa	VERB
iajs-2011	142	4	https://doi.org/10.30526/31.3.2011	https://doi.org/10.30526/31.3.2011	X
iajs-2011	142	5	vol	vol	NOUN
iajs-2011	142	6	.	.	PROPN
iajs-2011	143	1	31	31	NUM
iajs-2011	143	2	(	(	PUNCT
iajs-2011	143	3	3	3	NUM
iajs-2011	143	4	)	)	PUNCT
iajs-2011	143	5	2018	2018	NUM
iajs-2011	143	6	6	6	NUM
iajs-2011	143	7	.	.	PUNCT
iajs-2011	143	8	batuman	batuman	NOUN
iajs-2011	143	9	,	,	PUNCT
iajs-2011	143	10	v.	v.	PROPN
iajs-2011	143	11	;	;	PUNCT
iajs-2011	143	12	lerma	lerma	PROPN
iajs-2011	143	13	,	,	PUNCT
iajs-2011	143	14	e.	e.	PROPN
iajs-2011	143	15	v.	v.	PROPN
iajs-2011	143	16	chapter	chapter	PROPN
iajs-2011	143	17	2	2	NUM
iajs-2011	143	18	.	.	PUNCT
iajs-2011	143	19	diabetic	diabetic	ADJ
iajs-2011	143	20	nephropathy	nephropathy	NOUN
iajs-2011	143	21	.	.	PUNCT
iajs-2011	144	1	c2014	c2014	NOUN
iajs-2011	144	2	,	,	PUNCT
iajs-2011	144	3	p.9	p.9	PROPN
iajs-2011	144	4	-	-	NOUN
iajs-2011	144	5	14	14	NUM
iajs-2011	144	6	.	.	PUNCT
iajs-2011	145	1	isbn	isbn	ADJ
iajs-2011	145	2	978	978	NUM
iajs-2011	145	3	-	-	SYM
iajs-2011	145	4	1	1	NUM
iajs-2011	145	5	-	-	PUNCT
iajs-2011	145	6	4939	4939	NUM
iajs-2011	145	7	-	-	PUNCT
iajs-2011	145	8	0793	0793	NUM
iajs-2011	145	9	-	-	SYM
iajs-2011	145	10	9	9	NUM
iajs-2011	145	11	.	.	NOUN
iajs-2011	145	12	7	7	NUM
iajs-2011	145	13	.	.	X
iajs-2011	145	14	eizirik	eizirik	PROPN
iajs-2011	145	15	,	,	PUNCT
iajs-2011	145	16	d.l	d.l	PROPN
iajs-2011	145	17	.	.	PROPN
iajs-2011	145	18	;	;	PUNCT
iajs-2011	145	19	colli	colli	PROPN
iajs-2011	145	20	,	,	PUNCT
iajs-2011	145	21	m.l	m.l	PROPN
iajs-2011	145	22	.	.	PROPN
iajs-2011	145	23	;	;	PUNCT
iajs-2011	145	24	ortis	ortis	PROPN
iajs-2011	145	25	,	,	PUNCT
iajs-2011	145	26	f.	f.	NOUN
iajs-2011	145	27	the	the	DET
iajs-2011	145	28	role	role	NOUN
iajs-2011	145	29	of	of	ADP
iajs-2011	145	30	inflammation	inflammation	NOUN
iajs-2011	145	31	in	in	ADP
iajs-2011	145	32	insulitis	insulitis	PROPN
iajs-2011	145	33	and	and	CCONJ
iajs-2011	145	34	β	β	NOUN
iajs-2011	145	35	-	-	NOUN
iajs-2011	145	36	cell	cell	NOUN
iajs-2011	145	37	loss	loss	NOUN
iajs-2011	145	38	in	in	ADP
iajs-2011	145	39	type	type	NOUN
iajs-2011	145	40	1	1	NUM
iajs-2011	145	41	diabetes	diabetes	NOUN
iajs-2011	145	42	.	.	PUNCT
iajs-2011	146	1	nat	nat	PROPN
iajs-2011	146	2	rev	rev	PROPN
iajs-2011	146	3	endocrinol	endocrinol	NOUN
iajs-2011	146	4	.	.	PUNCT
iajs-2011	147	1	2009	2009	NUM
iajs-2011	147	2	,	,	PUNCT
iajs-2011	147	3	5	5	NUM
iajs-2011	147	4	,	,	PUNCT
iajs-2011	147	5	4	4	NUM
iajs-2011	147	6	,	,	PUNCT
iajs-2011	147	7	219	219	NUM
iajs-2011	147	8	-	-	SYM
iajs-2011	147	9	226	226	NUM
iajs-2011	147	10	.	.	NOUN
iajs-2011	148	1	8	8	NUM
iajs-2011	148	2	.	.	PUNCT
iajs-2011	148	3	jawhari	jawhari	PROPN
iajs-2011	148	4	,	,	PUNCT
iajs-2011	148	5	d.	d.	PROPN
iajs-2011	148	6	;	;	PUNCT
iajs-2011	148	7	alswisi	alswisi	VERB
iajs-2011	148	8	.	.	PUNCT
iajs-2011	149	1	m.	m.	NOUN
iajs-2011	149	2	;	;	PUNCT
iajs-2011	149	3	ghannam	ghannam	NOUN
iajs-2011	149	4	,	,	PUNCT
iajs-2011	149	5	m.	m.	NOUN
iajs-2011	149	6	;	;	PUNCT
iajs-2011	149	7	halman	halman	NOUN
iajs-2011	149	8	,	,	PUNCT
iajs-2011	149	9	j.a	j.a	PROPN
iajs-2011	149	10	.	.	PROPN
iajs-2011	149	11	bioequivalence	bioequivalence	NOUN
iajs-2011	149	12	of	of	ADP
iajs-2011	149	13	a	a	DET
iajs-2011	149	14	new	new	ADJ
iajs-2011	149	15	generic	generic	ADJ
iajs-2011	149	16	formulation	formulation	NOUN
iajs-2011	149	17	of	of	ADP
iajs-2011	149	18	erlotinib	erlotinib	NOUN
iajs-2011	149	19	hydrochloride	hydrochloride	NOUN
iajs-2011	149	20	150	150	NUM
iajs-2011	149	21	mg	mg	NOUN
iajs-2011	149	22	tablets	tablet	NOUN
iajs-2011	149	23	versus	versus	ADP
iajs-2011	149	24	tarceva	tarceva	VERB
iajs-2011	149	25	in	in	ADP
iajs-2011	149	26	healthy	healthy	ADJ
iajs-2011	149	27	volunteers	volunteer	NOUN
iajs-2011	149	28	under	under	ADP
iajs-2011	149	29	fasting	fast	VERB
iajs-2011	149	30	conditions	condition	NOUN
iajs-2011	149	31	.	.	PUNCT
iajs-2011	150	1	j	j	PROPN
iajs-2011	150	2	bioequiv	bioequiv	PROPN
iajs-2011	150	3	availab	availab	PROPN
iajs-2011	150	4	.	.	PUNCT
iajs-2011	151	1	2014	2014	NUM
iajs-2011	151	2	,	,	PUNCT
iajs-2011	151	3	6	6	NUM
iajs-2011	151	4	,	,	PUNCT
iajs-2011	151	5	4	4	NUM
iajs-2011	151	6	,	,	PUNCT
iajs-2011	151	7	119123	119123	NUM
iajs-2011	151	8	.	.	PUNCT
iajs-2011	152	1	9	9	X
iajs-2011	152	2	.	.	X
iajs-2011	152	3	piperdi	piperdi	PROPN
iajs-2011	152	4	,	,	PUNCT
iajs-2011	152	5	b.	b.	PROPN
iajs-2011	152	6	;	;	PUNCT
iajs-2011	152	7	perez	perez	PROPN
iajs-2011	152	8	-	-	PUNCT
iajs-2011	152	9	soler	soler	PROPN
iajs-2011	152	10	,	,	PUNCT
iajs-2011	152	11	r.	r.	PROPN
iajs-2011	152	12	role	role	NOUN
iajs-2011	152	13	of	of	ADP
iajs-2011	152	14	erlotinib	erlotinib	NOUN
iajs-2011	152	15	in	in	ADP
iajs-2011	152	16	the	the	DET
iajs-2011	152	17	treatment	treatment	NOUN
iajs-2011	152	18	of	of	ADP
iajs-2011	152	19	non	non	ADJ
iajs-2011	152	20	-	-	ADJ
iajs-2011	152	21	small	small	ADJ
iajs-2011	152	22	cell	cell	NOUN
iajs-2011	152	23	lung	lung	NOUN
iajs-2011	152	24	cancer	cancer	NOUN
iajs-2011	152	25	:	:	PUNCT
iajs-2011	152	26	clinical	clinical	ADJ
iajs-2011	152	27	outcomes	outcome	NOUN
iajs-2011	152	28	in	in	ADP
iajs-2011	152	29	wild	wild	ADJ
iajs-2011	152	30	-	-	PUNCT
iajs-2011	152	31	type	type	NOUN
iajs-2011	152	32	epidermal	epidermal	ADJ
iajs-2011	152	33	growth	growth	NOUN
iajs-2011	152	34	factor	factor	NOUN
iajs-2011	152	35	receptor	receptor	NOUN
iajs-2011	152	36	patients	patient	NOUN
iajs-2011	152	37	.	.	PUNCT
iajs-2011	153	1	drugs	drug	NOUN
iajs-2011	153	2	.	.	PUNCT
iajs-2011	154	1	2012	2012	NUM
iajs-2011	154	2	,	,	PUNCT
iajs-2011	154	3	72	72	NUM
iajs-2011	154	4	,	,	PUNCT
iajs-2011	154	5	1	1	NUM
iajs-2011	154	6	,	,	PUNCT
iajs-2011	154	7	11	11	NUM
iajs-2011	154	8	-	-	SYM
iajs-2011	154	9	9	9	NUM
iajs-2011	154	10	.	.	NOUN
iajs-2011	154	11	10	10	NUM
iajs-2011	154	12	.	.	PUNCT
iajs-2011	155	1	husain	husain	PROPN
iajs-2011	155	2	,	,	PUNCT
iajs-2011	155	3	f.	f.	PROPN
iajs-2011	155	4	;	;	PUNCT
iajs-2011	156	1	arif	arif	PROPN
iajs-2011	156	2	maan	maan	PROPN
iajs-2011	156	3	.	.	PUNCT
iajs-2011	156	4	m.	m.	PROPN
iajs-2011	156	5	;	;	PUNCT
iajs-2011	156	6	sheikh.m.a	sheikh.m.a	X
iajs-2011	156	7	.	.	PROPN
iajs-2011	156	8	;	;	PUNCT
iajs-2011	156	9	nawaz.h	nawaz.h	NUM
iajs-2011	156	10	.	.	PUNCT
iajs-2011	156	11	;	;	PUNCT
iajs-2011	157	1	jamil	jamil	PROPN
iajs-2011	157	2	,	,	PUNCT
iajs-2011	157	3	a.	a.	NOUN
iajs-2011	157	4	trace	trace	NOUN
iajs-2011	157	5	elements	element	NOUN
iajs-2011	157	6	status	status	NOUN
iajs-2011	157	7	in	in	ADP
iajs-2011	157	8	type	type	NOUN
iajs-2011	157	9	2	2	NUM
iajs-2011	157	10	diabetes	diabetes	NOUN
iajs-2011	157	11	.	.	PUNCT
iajs-2011	158	1	asian	asian	PROPN
iajs-2011	158	2	j.med.sci	j.med.sci	PROPN
iajs-2011	158	3	.	.	PUNCT
iajs-2011	159	1	2013	2013	NUM
iajs-2011	159	2	,	,	PUNCT
iajs-2011	159	3	5	5	NUM
iajs-2011	159	4	,	,	PUNCT
iajs-2011	159	5	5	5	NUM
iajs-2011	159	6	,	,	PUNCT
iajs-2011	159	7	108	108	NUM
iajs-2011	159	8	-	-	SYM
iajs-2011	159	9	112	112	NUM
iajs-2011	159	10	.	.	PUNCT
iajs-2011	160	1	11	11	NUM
iajs-2011	160	2	.	.	PUNCT
iajs-2011	161	1	shenqi	shenqi	NOUN
iajs-2011	161	2	,	,	PUNCT
iajs-2011	161	3	w.	w.	PROPN
iajs-2011	161	4	;	;	PUNCT
iajs-2011	161	5	xuhong	xuhong	PROPN
iajs-2011	161	6	h.;yu	h.;yu	PROPN
iajs-2011	161	7	,	,	PUNCT
iajs-2011	161	8	l.	l.	PROPN
iajs-2011	161	9	;	;	PUNCT
iajs-2011	161	10	lu	lu	PROPN
iajs-2011	161	11	,	,	PUNCT
iajs-2011	161	12	h.	h.	PROPN
iajs-2011	161	13	;	;	PUNCT
iajs-2011	161	14	li	li	PROPN
iajs-2011	161	15	,	,	PUNCT
iajs-2011	161	16	w.	w.	PROPN
iajs-2011	161	17	;	;	PUNCT
iajs-2011	161	18	bao	bao	PROPN
iajs-2011	161	19	,	,	PUNCT
iajs-2011	161	20	y.	y.	PROPN
iajs-2011	161	21	;	;	PUNCT
iajs-2011	161	22	jia	jia	PROPN
iajs-2011	161	23	,	,	PUNCT
iajs-2011	161	24	w.	w.	PROPN
iajs-2011	161	25	serum	serum	PROPN
iajs-2011	161	26	electrolyte	electrolyte	PROPN
iajs-2011	161	27	levels	level	NOUN
iajs-2011	161	28	in	in	ADP
iajs-2011	161	29	relation	relation	NOUN
iajs-2011	161	30	to	to	PART
iajs-2011	161	31	macrovascular	macrovascular	VERB
iajs-2011	161	32	complications	complication	NOUN
iajs-2011	161	33	in	in	ADP
iajs-2011	161	34	chinese	chinese	ADJ
iajs-2011	161	35	patients	patient	NOUN
iajs-2011	161	36	with	with	ADP
iajs-2011	161	37	diabetes	diabetes	NOUN
iajs-2011	161	38	mellitus	mellitus	NOUN
iajs-2011	161	39	.	.	PUNCT
iajs-2011	162	1	cardiovasc	cardiovasc	PROPN
iajs-2011	162	2	diabetol	diabetol	VERB
iajs-2011	162	3	.	.	PUNCT
iajs-2011	163	1	2013	2013	NUM
iajs-2011	163	2	,	,	PUNCT
iajs-2011	163	3	12	12	NUM
iajs-2011	163	4	,	,	PUNCT
iajs-2011	163	5	146	146	NUM
iajs-2011	163	6	,	,	PUNCT
iajs-2011	163	7	1	1	NUM
iajs-2011	163	8	-	-	SYM
iajs-2011	163	9	10	10	NUM
iajs-2011	163	10	.	.	PUNCT
iajs-2011	164	1	12	12	NUM
iajs-2011	164	2	.	.	PUNCT
iajs-2011	165	1	adiga	adiga	PROPN
iajs-2011	165	2	,	,	PUNCT
iajs-2011	165	3	u.	u.	PROPN
iajs-2011	165	4	;	;	PUNCT
iajs-2011	165	5	malawadi	malawadi	NOUN
iajs-2011	165	6	;	;	PUNCT
iajs-2011	165	7	b.n	b.n	PROPN
iajs-2011	165	8	.	.	PROPN
iajs-2011	165	9	alterations	alteration	NOUN
iajs-2011	165	10	in	in	ADP
iajs-2011	165	11	serum	serum	NOUN
iajs-2011	165	12	electrolytes	electrolyte	NOUN
iajs-2011	165	13	in	in	ADP
iajs-2011	165	14	type	type	NOUN
iajs-2011	165	15	2	2	NUM
iajs-2011	165	16	diabetes	diabetes	NOUN
iajs-2011	165	17	mellitus	mellitus	NOUN
iajs-2011	165	18	.	.	PUNCT
iajs-2011	166	1	adv	adv	PROPN
iajs-2011	166	2	lab	lab	PROPN
iajs-2011	166	3	med	med	ADJ
iajs-2011	166	4	int	int	NOUN
iajs-2011	166	5	.	.	PUNCT
iajs-2011	167	1	2016	2016	NUM
iajs-2011	167	2	,	,	PUNCT
iajs-2011	167	3	6	6	NUM
iajs-2011	167	4	,	,	PUNCT
iajs-2011	167	5	3	3	NUM
iajs-2011	167	6	,	,	PUNCT
iajs-2011	167	7	58	58	NUM
iajs-2011	167	8	62	62	NUM
iajs-2011	167	9	.	.	PUNCT
iajs-2011	168	1	13	13	NUM
iajs-2011	168	2	.	.	PUNCT
iajs-2011	169	1	dimke	dimke	PROPN
iajs-2011	169	2	,	,	PUNCT
iajs-2011	169	3	h.	h.	PROPN
iajs-2011	169	4	;	;	PUNCT
iajs-2011	169	5	van	van	PROPN
iajs-2011	169	6	der	der	NOUN
iajs-2011	169	7	wijst	wijst	ADJ
iajs-2011	169	8	.	.	PUNCT
iajs-2011	170	1	j.	j.	PROPN
iajs-2011	170	2	;	;	PUNCT
iajs-2011	170	3	alexander	alexander	PROPN
iajs-2011	170	4	,	,	PUNCT
iajs-2011	170	5	t.r	t.r	PROPN
iajs-2011	170	6	.	.	PROPN
iajs-2011	170	7	;	;	PUNCT
iajs-2011	170	8	meijerm	meijerm	PROPN
iajs-2011	170	9	,	,	PUNCT
iajs-2011	170	10	i.m	i.m	PROPN
iajs-2011	170	11	.	.	PROPN
iajs-2011	170	12	;	;	PUNCT
iajs-2011	170	13	mulder	mulder	PROPN
iajs-2011	170	14	,	,	PUNCT
iajs-2011	170	15	g.m	g.m	PROPN
iajs-2011	170	16	.	.	PROPN
iajs-2011	170	17	;	;	PUNCT
iajs-2011	170	18	van	van	PROPN
iajs-2011	170	19	goor	goor	PROPN
iajs-2011	170	20	.	.	PUNCT
iajs-2011	171	1	h.	h.	PROPN
iajs-2011	171	2	;	;	PUNCT
iajs-2011	171	3	tejpar	tejpar	ADV
iajs-2011	171	4	,	,	PUNCT
iajs-2011	171	5	s.	s.	PROPN
iajs-2011	171	6	;	;	PUNCT
iajs-2011	171	7	hoenderop	hoenderop	PROPN
iajs-2011	171	8	,	,	PUNCT
iajs-2011	171	9	j.g	j.g	PROPN
iajs-2011	171	10	.	.	PROPN
iajs-2011	171	11	;	;	PUNCT
iajs-2011	171	12	bindels	bindel	NOUN
iajs-2011	171	13	,	,	PUNCT
iajs-2011	171	14	r.j	r.j	PROPN
iajs-2011	171	15	.	.	PROPN
iajs-2011	171	16	effects	effect	NOUN
iajs-2011	171	17	of	of	ADP
iajs-2011	171	18	the	the	DET
iajs-2011	171	19	egfr	egfr	ADJ
iajs-2011	171	20	inhibitor	inhibitor	NOUN
iajs-2011	171	21	erlotinib	erlotinib	NOUN
iajs-2011	171	22	on	on	ADP
iajs-2011	171	23	magnesium	magnesium	NOUN
iajs-2011	171	24	handling	handling	NOUN
iajs-2011	171	25	.	.	PUNCT
iajs-2011	172	1	j.	j.	PROPN
iajs-2011	172	2	am	am	PROPN
iajs-2011	172	3	.	.	PUNCT
iajs-2011	173	1	soc	soc	PROPN
iajs-2011	173	2	.	.	PUNCT
iajs-2011	174	1	nephrol	nephrol	PROPN
iajs-2011	174	2	.	.	PUNCT
iajs-2011	175	1	2010	2010	NUM
iajs-2011	175	2	,	,	PUNCT
iajs-2011	175	3	21	21	NUM
iajs-2011	175	4	,	,	PUNCT
iajs-2011	175	5	8,1309	8,1309	NUM
iajs-2011	175	6	-	-	SYM
iajs-2011	175	7	1316	1316	NUM
iajs-2011	175	8	.	.	PUNCT
iajs-2011	176	1	14	14	NUM
iajs-2011	176	2	.	.	PUNCT
iajs-2011	177	1	parlapally	parlapally	ADV
iajs-2011	177	2	,	,	PUNCT
iajs-2011	177	3	r.p	r.p	PROPN
iajs-2011	177	4	.	.	PROPN
iajs-2011	177	5	;	;	PUNCT
iajs-2011	177	6	kumari	kumari	PROPN
iajs-2011	177	7	,	,	PUNCT
iajs-2011	177	8	k.r	k.r	PROPN
iajs-2011	177	9	.	.	PROPN
iajs-2011	177	10	;	;	PUNCT
iajs-2011	178	1	jyothi	jyothi	PROPN
iajs-2011	178	2	.	.	PUNCT
iajs-2011	178	3	s.a	s.a	PROPN
iajs-2011	178	4	.	.	PROPN
iajs-2011	178	5	serum	serum	PROPN
iajs-2011	178	6	magnesium	magnesium	NOUN
iajs-2011	178	7	levels	level	NOUN
iajs-2011	178	8	in	in	ADP
iajs-2011	178	9	type	type	NOUN
iajs-2011	178	10	2	2	NUM
iajs-2011	178	11	diabetes	diabetes	NOUN
iajs-2011	178	12	mellitus	mellitus	NOUN
iajs-2011	178	13	.	.	PUNCT
iajs-2011	179	1	int	int	PROPN
iajs-2011	180	1	j	j	PROPN
iajs-2011	180	2	sci	sci	PROPN
iajs-2011	180	3	stud	stud	NOUN
iajs-2011	180	4	.	.	PUNCT
iajs-2011	181	1	2016	2016	NUM
iajs-2011	181	2	,	,	PUNCT
iajs-2011	181	3	4	4	NUM
iajs-2011	181	4	,	,	PUNCT
iajs-2011	181	5	5	5	NUM
iajs-2011	181	6	,	,	PUNCT
iajs-2011	181	7	176	176	NUM
iajs-2011	181	8	-	-	SYM
iajs-2011	181	9	179	179	NUM
iajs-2011	181	10	,	,	PUNCT
iajs-2011	181	11	doi	doi	NOUN
iajs-2011	181	12	:	:	PUNCT
iajs-2011	181	13	10.17354	10.17354	NUM
iajs-2011	181	14	/	/	SYM
iajs-2011	181	15	ijss/2016/455	ijss/2016/455	NOUN
iajs-2011	181	16	.	.	NOUN
iajs-2011	182	1	15	15	NUM
iajs-2011	182	2	.	.	X
iajs-2011	183	1	belhasan	belhasan	PROPN
iajs-2011	183	2	o.	o.	PROPN
iajs-2011	183	3	;	;	PUNCT
iajs-2011	183	4	sheriff	sheriff	NOUN
iajs-2011	183	5	.	.	PUNCT
iajs-2011	184	1	d.	d.	PROPN
iajs-2011	184	2	serum	serum	PROPN
iajs-2011	184	3	magnesium	magnesium	NOUN
iajs-2011	184	4	levels	level	NOUN
iajs-2011	184	5	in	in	ADP
iajs-2011	184	6	type	type	NOUN
iajs-2011	184	7	2	2	NUM
iajs-2011	184	8	diabetic	diabetic	ADJ
iajs-2011	184	9	libyan	libyan	ADJ
iajs-2011	184	10	patients	patient	NOUN
iajs-2011	184	11	.	.	PUNCT
iajs-2011	185	1	jop	jop	PROPN
iajs-2011	185	2	.	.	PUNCT
iajs-2011	186	1	j	j	PROPN
iajs-2011	186	2	pancrea	pancrea	PROPN
iajs-2011	186	3	.	.	PUNCT
iajs-2011	187	1	2017	2017	NUM
iajs-2011	187	2	,	,	PUNCT
iajs-2011	187	3	18	18	NUM
iajs-2011	187	4	,	,	PUNCT
iajs-2011	187	5	2	2	NUM
iajs-2011	187	6	,	,	PUNCT
iajs-2011	187	7	121	121	NUM
iajs-2011	187	8	-	-	SYM
iajs-2011	187	9	124	124	NUM
iajs-2011	187	10	.	.	PUNCT
iajs-2011	188	1	16	16	NUM
iajs-2011	188	2	.	.	PUNCT
iajs-2011	189	1	barbagallo	barbagallo	PROPN
iajs-2011	189	2	,	,	PUNCT
iajs-2011	189	3	m.	m.	NOUN
iajs-2011	189	4	;	;	PUNCT
iajs-2011	189	5	dominguez	dominguez	PROPN
iajs-2011	189	6	,	,	PUNCT
iajs-2011	189	7	l.j	l.j	PROPN
iajs-2011	189	8	.	.	PROPN
iajs-2011	189	9	magnesium	magnesium	NOUN
iajs-2011	189	10	and	and	CCONJ
iajs-2011	189	11	type	type	NOUN
iajs-2011	189	12	2	2	NUM
iajs-2011	189	13	diabetes	diabetes	NOUN
iajs-2011	189	14	.	.	PUNCT
iajs-2011	190	1	world	world	NOUN
iajs-2011	190	2	j	j	PROPN
iajs-2011	190	3	diabetes	diabetes	PROPN
iajs-2011	190	4	.	.	PUNCT
iajs-2011	191	1	2015	2015	NUM
iajs-2011	191	2	,	,	PUNCT
iajs-2011	191	3	6,10	6,10	NUM
iajs-2011	191	4	,	,	PUNCT
iajs-2011	191	5	1152–1157	1152–1157	NUM
iajs-2011	191	6	.	.	PUNCT
iajs-2011	192	1	17	17	NUM
iajs-2011	192	2	.	.	PUNCT
iajs-2011	193	1	najeeb	najeeb	PROPN
iajs-2011	193	2	,	,	PUNCT
iajs-2011	193	3	q.	q.	PROPN
iajs-2011	193	4	;	;	PUNCT
iajs-2011	193	5	aziz	aziz	PROPN
iajs-2011	193	6	,	,	PUNCT
iajs-2011	193	7	r.	r.	PROPN
iajs-2011	193	8	;	;	PUNCT
iajs-2011	193	9	hamid	hamid	PROPN
iajs-2011	193	10	,	,	PUNCT
iajs-2011	193	11	s.	s.	PROPN
iajs-2011	193	12	to	to	PART
iajs-2011	193	13	evaluate	evaluate	VERB
iajs-2011	193	14	the	the	DET
iajs-2011	193	15	levels	level	NOUN
iajs-2011	193	16	of	of	ADP
iajs-2011	193	17	glycated	glycate	VERB
iajs-2011	193	18	hemoglobin	hemoglobin	NOUN
iajs-2011	193	19	,	,	PUNCT
iajs-2011	193	20	serum	serum	NOUN
iajs-2011	193	21	calcium	calcium	NOUN
iajs-2011	193	22	,	,	PUNCT
iajs-2011	193	23	magnesium	magnesium	NOUN
iajs-2011	193	24	,	,	PUNCT
iajs-2011	193	25	phosphate	phosphate	NOUN
iajs-2011	193	26	,	,	PUNCT
iajs-2011	193	27	uric	uric	ADJ
iajs-2011	193	28	acid	acid	NOUN
iajs-2011	193	29	and	and	CCONJ
iajs-2011	193	30	microalbuminuria	microalbuminuria	PROPN
iajs-2011	193	31	in	in	ADP
iajs-2011	193	32	patients	patient	NOUN
iajs-2011	193	33	with	with	ADP
iajs-2011	193	34	newly	newly	ADV
iajs-2011	193	35	diagnosed	diagnose	VERB
iajs-2011	193	36	type	type	NOUN
iajs-2011	193	37	2	2	NUM
iajs-2011	193	38	diabetes	diabetes	NOUN
iajs-2011	193	39	mellitus	mellitus	NOUN
iajs-2011	193	40	.	.	PUNCT
iajs-2011	194	1	int	int	PROPN
iajs-2011	194	2	j	j	PROPN
iajs-2011	194	3	res	res	PROPN
iajs-2011	194	4	med	med	PROPN
iajs-2011	194	5	sci	sci	PROPN
iajs-2011	194	6	.	.	PROPN
iajs-2011	194	7	2014	2014	NUM
iajs-2011	194	8	,	,	PUNCT
iajs-2011	194	9	2	2	NUM
iajs-2011	194	10	,	,	PUNCT
iajs-2011	194	11	4	4	NUM
iajs-2011	194	12	,	,	PUNCT
iajs-2011	194	13	1462	1462	NUM
iajs-2011	194	14	-	-	SYM
iajs-2011	194	15	1465	1465	NUM
iajs-2011	194	16	.	.	PUNCT
iajs-2011	195	1	18	18	NUM
iajs-2011	195	2	.	.	X
iajs-2011	195	3	sajjan	sajjan	PROPN
iajs-2011	195	4	,	,	PUNCT
iajs-2011	195	5	n.b	n.b	PROPN
iajs-2011	195	6	.	.	PROPN
iajs-2011	195	7	;	;	PUNCT
iajs-2011	195	8	choudhari	choudhari	X
iajs-2011	195	9	,	,	PUNCT
iajs-2011	195	10	a.s	a.s	PROPN
iajs-2011	195	11	.	.	PROPN
iajs-2011	195	12	;	;	PUNCT
iajs-2011	195	13	desai	desai	PROPN
iajs-2011	195	14	,	,	PUNCT
iajs-2011	195	15	g.m	g.m	PROPN
iajs-2011	195	16	.	.	PROPN
iajs-2011	195	17	;	;	PUNCT
iajs-2011	195	18	dharapur	dharapur	VERB
iajs-2011	195	19	,	,	PUNCT
iajs-2011	195	20	z.z	z.z	PROPN
iajs-2011	195	21	.	.	PROPN
iajs-2011	195	22	,	,	PUNCT
iajs-2011	195	23	m.s	m.s	PROPN
iajs-2011	195	24	.	.	PROPN
iajs-2011	195	25	;	;	PUNCT
iajs-2011	196	1	wali	wali	PROPN
iajs-2011	196	2	.	.	PROPN
iajs-2011	197	1	v.v	v.v	PROPN
iajs-2011	197	2	.	.	PROPN
iajs-2011	197	3	evaluation	evaluation	NOUN
iajs-2011	197	4	of	of	ADP
iajs-2011	197	5	association	association	NOUN
iajs-2011	197	6	of	of	ADP
iajs-2011	197	7	serum	serum	PROPN
iajs-2011	197	8	magnesium	magnesium	NOUN
iajs-2011	197	9	with	with	ADP
iajs-2011	197	10	dyslipidemia	dyslipidemia	NOUN
iajs-2011	197	11	in	in	ADP
iajs-2011	197	12	diabetic	diabetic	ADJ
iajs-2011	197	13	nephropathy	nephropathy	NOUN
iajs-2011	197	14	a	a	DET
iajs-2011	197	15	case	case	NOUN
iajs-2011	197	16	control	control	NOUN
iajs-2011	197	17	study	study	NOUN
iajs-2011	197	18	.	.	PUNCT
iajs-2011	198	1	nat	nat	PROPN
iajs-2011	198	2	j	j	PROPN
iajs-2011	198	3	med	med	PROPN
iajs-2011	198	4	res	re	NOUN
iajs-2011	198	5	.	.	PUNCT
iajs-2011	198	6	2014	2014	NUM
iajs-2011	198	7	,	,	PUNCT
iajs-2011	198	8	4	4	NUM
iajs-2011	198	9	,	,	PUNCT
iajs-2011	198	10	318	318	NUM
iajs-2011	198	11	-	-	SYM
iajs-2011	198	12	321	321	NUM
iajs-2011	198	13	.	.	NOUN
iajs-2011	198	14	19	19	NUM
iajs-2011	198	15	.	.	X
iajs-2011	198	16	sitholay	sitholay	PROPN
iajs-2011	198	17	,	,	PUNCT
iajs-2011	198	18	p.a	p.a	PROPN
iajs-2011	198	19	.	.	PROPN
iajs-2011	198	20	;	;	PUNCT
iajs-2011	198	21	agnihotri	agnihotri	PROPN
iajs-2011	198	22	.	.	PUNCT
iajs-2011	199	1	m.a	m.a	PROPN
iajs-2011	199	2	.	.	PROPN
iajs-2011	199	3	;	;	PUNCT
iajs-2011	199	4	ambad	ambad	PROPN
iajs-2011	199	5	.	.	PUNCT
iajs-2011	200	1	r.s	r.s	PROPN
iajs-2011	200	2	.	.	PROPN
iajs-2011	200	3	study	study	PROPN
iajs-2011	200	4	of	of	ADP
iajs-2011	200	5	renal	renal	ADJ
iajs-2011	200	6	function	function	NOUN
iajs-2011	200	7	and	and	CCONJ
iajs-2011	200	8	serm	serm	ADJ
iajs-2011	200	9	electrolyte	electrolyte	ADJ
iajs-2011	200	10	type	type	NOUN
iajs-2011	200	11	-2	-2	INTJ
iajs-2011	200	12	dm	dm	PROPN
iajs-2011	200	13	.	.	PUNCT
iajs-2011	200	14	ijirms	ijirm	NOUN
iajs-2011	200	15	.	.	PUNCT
iajs-2011	201	1	2017	2017	NUM
iajs-2011	201	2	,	,	PUNCT
iajs-2011	201	3	2	2	NUM
iajs-2011	201	4	,	,	PUNCT
iajs-2011	201	5	8	8	NUM
iajs-2011	201	6	,	,	PUNCT
iajs-2011	201	7	1149	1149	NUM
iajs-2011	201	8	-	-	SYM
iajs-2011	201	9	1153	1153	NUM
iajs-2011	201	10	.	.	PUNCT
iajs-2011	202	1	20	20	NUM
iajs-2011	202	2	.	.	X
iajs-2011	203	1	palmer	palmer	PROPN
iajs-2011	203	2	,	,	PUNCT
iajs-2011	203	3	b.f	b.f	PROPN
iajs-2011	203	4	.	.	PROPN
iajs-2011	203	5	;	;	PUNCT
iajs-2011	204	1	clegg	clegg	PROPN
iajs-2011	204	2	.	.	PUNCT
iajs-2011	205	1	d.j	d.j	PROPN
iajs-2011	205	2	.	.	PROPN
iajs-2011	205	3	electrolyte	electrolyte	PROPN
iajs-2011	205	4	and	and	CCONJ
iajs-2011	205	5	acid	acid	ADJ
iajs-2011	205	6	–	–	PUNCT
iajs-2011	205	7	base	base	NOUN
iajs-2011	205	8	disturbances	disturbance	NOUN
iajs-2011	205	9	in	in	ADP
iajs-2011	205	10	patients	patient	NOUN
iajs-2011	205	11	with	with	ADP
iajs-2011	205	12	diabetes	diabetes	NOUN
iajs-2011	205	13	mellitus	mellitus	NOUN
iajs-2011	205	14	.	.	PUNCT
iajs-2011	206	1	n	n	PRON
iajs-2011	206	2	engl	engl	PROPN
iajs-2011	206	3	j	j	PROPN
iajs-2011	206	4	med	med	PROPN
iajs-2011	206	5	.	.	PROPN
iajs-2011	207	1	2015	2015	NUM
iajs-2011	207	2	,	,	PUNCT
iajs-2011	207	3	373	373	NUM
iajs-2011	207	4	,	,	PUNCT
iajs-2011	207	5	6	6	NUM
iajs-2011	207	6	,	,	PUNCT
iajs-2011	207	7	548	548	NUM
iajs-2011	207	8	-	-	SYM
iajs-2011	207	9	559	559	NUM
iajs-2011	207	10	.	.	PUNCT
iajs-2011	208	1	21	21	NUM
iajs-2011	208	2	.	.	PUNCT
iajs-2011	209	1	ogunleyehg	ogunleyehg	PROPN
iajs-2011	209	2	,	,	PUNCT
iajs-2011	209	3	a.	a.	NOUN
iajs-2011	209	4	z.	z.	PROPN
iajs-2011	209	5	;	;	PUNCT
iajs-2011	209	6	asaolu	asaolu	NOUN
iajs-2011	209	7	,	,	PUNCT
iajs-2011	209	8	m.	m.	NOUN
iajs-2011	209	9	f.	f.	PROPN
iajs-2011	209	10	evaluation	evaluation	PROPN
iajs-2011	209	11	of	of	ADP
iajs-2011	209	12	macro	macro	ADJ
iajs-2011	209	13	minerals	mineral	NOUN
iajs-2011	209	14	in	in	ADP
iajs-2011	209	15	patients	patient	NOUN
iajs-2011	209	16	with	with	ADP
iajs-2011	209	17	type	type	NOUN
iajs-2011	209	18	ii	ii	NOUN
iajs-2011	209	19	diabetes	diabetes	NOUN
iajs-2011	209	20	mellitus	mellitus	NOUN
iajs-2011	209	21	in	in	ADP
iajs-2011	209	22	southern	southern	PROPN
iajs-2011	209	23	nigeria	nigeria	PROPN
iajs-2011	209	24	.	.	PUNCT
iajs-2011	210	1	int	int	PROPN
iajs-2011	210	2	j	j	PROPN
iajs-2011	210	3	biochem	biochem	PROPN
iajs-2011	210	4	res	res	PROPN
iajs-2011	210	5	rev	rev	PROPN
iajs-2011	210	6	.	.	PROPN
iajs-2011	210	7	2016	2016	NUM
iajs-2011	210	8	,	,	PUNCT
iajs-2011	210	9	9	9	NUM
iajs-2011	210	10	,	,	PUNCT
iajs-2011	210	11	2,1	2,1	NUM
iajs-2011	210	12	-	-	SYM
iajs-2011	210	13	9	9	NUM
iajs-2011	210	14	.	.	NOUN
iajs-2011	210	15	22	22	NUM
iajs-2011	210	16	.	.	PUNCT
iajs-2011	211	1	fard	fard	NOUN
iajs-2011	211	2	,	,	PUNCT
iajs-2011	211	3	a.a	a.a	PROPN
iajs-2011	211	4	.	.	PROPN
iajs-2011	211	5	;	;	PUNCT
iajs-2011	211	6	abbasnezhad	abbasnezhad	VERB
iajs-2011	211	7	,	,	PUNCT
iajs-2011	211	8	p.	p.	NOUN
iajs-2011	211	9	;	;	PUNCT
iajs-2011	211	10	makhdomi	makhdomi	NOUN
iajs-2011	211	11	,	,	PUNCT
iajs-2011	211	12	k.	k.	PROPN
iajs-2011	211	13	;	;	PUNCT
iajs-2011	211	14	salehi	salehi	PROPN
iajs-2011	211	15	.	.	PUNCT
iajs-2011	212	1	m.	m.	NOUN
iajs-2011	212	2	;	;	PUNCT
iajs-2011	212	3	karamdelok	karamdelok	PROPN
iajs-2011	212	4	h.r	h.r	PROPN
iajs-2011	212	5	.	.	PROPN
iajs-2011	212	6	;	;	PUNCT
iajs-2011	213	1	saboory	saboory	PROPN
iajs-2011	213	2	.	.	PUNCT
iajs-2011	214	1	e.	e.	PROPN
iajs-2011	214	2	association	association	PROPN
iajs-2011	214	3	of	of	ADP
iajs-2011	214	4	serum	serum	PROPN
iajs-2011	214	5	prolactin	prolactin	NOUN
iajs-2011	214	6	concentration	concentration	NOUN
iajs-2011	214	7	with	with	ADP
iajs-2011	214	8	renal	renal	ADJ
iajs-2011	214	9	failure	failure	NOUN
iajs-2011	214	10	in	in	ADP
iajs-2011	214	11	diabetic	diabetic	ADJ
iajs-2011	214	12	patients	patient	NOUN
iajs-2011	214	13	.	.	PUNCT
iajs-2011	215	1	rom	rom	PROPN
iajs-2011	215	2	j	j	PROPN
iajs-2011	215	3	diabetes	diabetes	PROPN
iajs-2011	215	4	nutr	nutr	PROPN
iajs-2011	215	5	metab	metab	PROPN
iajs-2011	215	6	dis	dis	PROPN
iajs-2011	215	7	.	.	PROPN
iajs-2011	216	1	2017	2017	NUM
iajs-2011	216	2	,	,	PUNCT
iajs-2011	216	3	24	24	NUM
iajs-2011	216	4	,	,	PUNCT
iajs-2011	216	5	3	3	NUM
iajs-2011	216	6	,	,	PUNCT
iajs-2011	216	7	179	179	NUM
iajs-2011	216	8	-	-	SYM
iajs-2011	216	9	185	185	NUM
iajs-2011	216	10	.	.	PUNCT
iajs-2011	217	1	23	23	NUM
iajs-2011	217	2	.	.	PUNCT
iajs-2011	218	1	jeroen	jeroen	PROPN
iajs-2011	218	2	,	,	PUNCT
iajs-2011	218	3	h.	h.	PROPN
iajs-2011	218	4	f.	f.	PROPN
iajs-2011	218	5	;	;	PUNCT
iajs-2011	218	6	baaij	baaij	NOUN
iajs-2011	218	7	,	,	PUNCT
iajs-2011	218	8	de	de	X
iajs-2011	218	9	.	.	PROPN
iajs-2011	218	10	;	;	PUNCT
iajs-2011	218	11	joost	joost	X
iajs-2011	218	12	,	,	PUNCT
iajs-2011	218	13	g.	g.	PROPN
iajs-2011	218	14	;	;	PUNCT
iajs-2011	218	15	hoenderop	hoenderop	PROPN
iajs-2011	218	16	,	,	PUNCT
iajs-2011	218	17	j.	j.	PROPN
iajs-2011	218	18	;	;	PUNCT
iajs-2011	218	19	rene	rene	PROPN
iajs-2011	218	20	.	.	PUNCT
iajs-2011	219	1	j.	j.	PROPN
iajs-2011	219	2	m.	m.	PROPN
iajs-2011	219	3	bindels	bindel	NOUN
iajs-2011	219	4	.	.	PUNCT
iajs-2011	220	1	magnesium	magnesium	NOUN
iajs-2011	220	2	in	in	ADP
iajs-2011	220	3	man	man	NOUN
iajs-2011	220	4	–	–	PUNCT
iajs-2011	220	5	implication	implication	NOUN
iajs-2011	220	6	for	for	ADP
iajs-2011	220	7	health	health	NOUN
iajs-2011	220	8	and	and	CCONJ
iajs-2011	220	9	disease	disease	NOUN
iajs-2011	220	10	.	.	PUNCT
iajs-2011	221	1	physiol	physiol	PROPN
iajs-2011	221	2	rev	rev	VERB
iajs-2011	221	3	.	.	PROPN
iajs-2011	221	4	2015	2015	NUM
iajs-2011	221	5	,	,	PUNCT
iajs-2011	221	6	95,1	95,1	NUM
iajs-2011	221	7	,	,	PUNCT
iajs-2011	221	8	1	1	NUM
iajs-2011	221	9	-	-	SYM
iajs-2011	221	10	46	46	NUM
iajs-2011	221	11	.	.	PUNCT
iajs-2011	222	1	chemistry	chemistry	NOUN
iajs-2011	222	2	|	|	ADV
iajs-2011	222	3	69	69	NUM
iajs-2011	222	4	ibn	ibn	PROPN
iajs-2011	222	5	al	al	PROPN
iajs-2011	222	6	-	-	PUNCT
iajs-2011	222	7	haitham	haitham	PROPN
iajs-2011	222	8	jour	jour	X
iajs-2011	222	9	.	.	PROPN
iajs-2011	223	1	for	for	ADP
iajs-2011	223	2	pure	pure	ADJ
iajs-2011	223	3	&	&	CCONJ
iajs-2011	223	4	appl	appl	PROPN
iajs-2011	223	5	.	.	PUNCT
iajs-2011	224	1	sci	sci	PROPN
iajs-2011	224	2	.	.	PROPN
iajs-2011	224	3	ihjpas	ihjpa	VERB
iajs-2011	224	4	https://doi.org/10.30526/31.3.2011	https://doi.org/10.30526/31.3.2011	X
iajs-2011	224	5	vol	vol	NOUN
iajs-2011	224	6	.	.	PROPN
iajs-2011	225	1	31	31	NUM
iajs-2011	225	2	(	(	PUNCT
iajs-2011	225	3	3	3	NUM
iajs-2011	225	4	)	)	PUNCT
iajs-2011	225	5	2018	2018	NUM
iajs-2011	225	6	24	24	NUM
iajs-2011	225	7	.	.	PUNCT
iajs-2011	226	1	kang	kang	PROPN
iajs-2011	226	2	,	,	PUNCT
iajs-2011	226	3	y.e	y.e	PROPN
iajs-2011	226	4	.	.	PROPN
iajs-2011	226	5	;	;	PUNCT
iajs-2011	226	6	kim	kim	PROPN
iajs-2011	226	7	,	,	PUNCT
iajs-2011	226	8	j.m	j.m	PROPN
iajs-2011	226	9	.	.	PROPN
iajs-2011	226	10	;	;	PUNCT
iajs-2011	226	11	joung	joung	PROPN
iajs-2011	226	12	,	,	PUNCT
iajs-2011	226	13	k.h	k.h	PROPN
iajs-2011	226	14	.	.	PROPN
iajs-2011	226	15	;	;	PUNCT
iajs-2011	226	16	kim	kim	PROPN
iajs-2011	226	17	,	,	PUNCT
iajs-2011	226	18	h.j	h.j	PROPN
iajs-2011	226	19	.	.	PROPN
iajs-2011	226	20	;	;	PUNCT
iajs-2011	226	21	ku	ku	PROPN
iajs-2011	226	22	,	,	PUNCT
iajs-2011	226	23	b.j	b.j	PROPN
iajs-2011	226	24	.	.	PROPN
iajs-2011	226	25	treatment	treatment	NOUN
iajs-2011	226	26	with	with	ADP
iajs-2011	226	27	gefitinib	gefitinib	NOUN
iajs-2011	226	28	,	,	PUNCT
iajs-2011	226	29	an	an	DET
iajs-2011	226	30	epidermal	epidermal	ADJ
iajs-2011	226	31	growth	growth	NOUN
iajs-2011	226	32	factor	factor	NOUN
iajs-2011	226	33	receptor	receptor	NOUN
iajs-2011	226	34	inhibitor	inhibitor	NOUN
iajs-2011	226	35	,	,	PUNCT
iajs-2011	226	36	decreases	decrease	VERB
iajs-2011	226	37	serum	serum	NOUN
iajs-2011	226	38	cholesterol	cholesterol	NOUN
iajs-2011	226	39	in	in	ADP
iajs-2011	226	40	patients	patient	NOUN
iajs-2011	226	41	with	with	ADP
iajs-2011	226	42	lung	lung	NOUN
iajs-2011	226	43	cancer	cancer	NOUN
iajs-2011	226	44	.	.	PUNCT
iajs-2011	227	1	korean	korean	PROPN
iajs-2011	227	2	j	j	PROPN
iajs-2011	227	3	obes	obes	PROPN
iajs-2011	227	4	.	.	PUNCT
iajs-2011	228	1	2016	2016	NUM
iajs-2011	228	2	,	,	PUNCT
iajs-2011	228	3	25	25	NUM
iajs-2011	228	4	,	,	PUNCT
iajs-2011	228	5	4	4	NUM
iajs-2011	228	6	,	,	PUNCT
iajs-2011	228	7	233	233	NUM
iajs-2011	228	8	-	-	SYM
iajs-2011	228	9	239	239	NUM
iajs-2011	228	10	.	.	PUNCT
iajs-2011	229	1	25	25	NUM
iajs-2011	229	2	.	.	X
iajs-2011	229	3	ortega	ortega	PROPN
iajs-2011	229	4	,	,	PUNCT
iajs-2011	229	5	b.	b.	PROPN
iajs-2011	229	6	;	;	PUNCT
iajs-2011	229	7	dey	dey	PROPN
iajs-2011	229	8	.	.	PROPN
iajs-2011	229	9	j.	j.	PROPN
iajs-2011	229	10	m.	m.	PROPN
iajs-2011	229	11	;	;	PUNCT
iajs-2011	229	12	gardella	gardella	PROPN
iajs-2011	229	13	,	,	PUNCT
iajs-2011	229	14	a.r	a.r	PROPN
iajs-2011	229	15	.	.	PROPN
iajs-2011	229	16	;	;	PUNCT
iajs-2011	229	17	proano	proano	PROPN
iajs-2011	229	18	,	,	PUNCT
iajs-2011	229	19	j.	j.	PROPN
iajs-2011	229	20	;	;	PUNCT
iajs-2011	229	21	vaneerde	vaneerde	PROPN
iajs-2011	229	22	,	,	PUNCT
iajs-2011	229	23	d.	d.	NOUN
iajs-2011	229	24	antibody	antibody	NOUN
iajs-2011	229	25	-	-	PUNCT
iajs-2011	229	26	mediated	mediate	VERB
iajs-2011	229	27	inhibition	inhibition	NOUN
iajs-2011	229	28	of	of	ADP
iajs-2011	229	29	egfr	egfr	NOUN
iajs-2011	229	30	reduces	reduce	VERB
iajs-2011	229	31	phosphate	phosphate	ADJ
iajs-2011	229	32	excretion	excretion	NOUN
iajs-2011	229	33	and	and	CCONJ
iajs-2011	229	34	induces	induce	VERB
iajs-2011	229	35	hyperphosphatemia	hyperphosphatemia	NOUN
iajs-2011	229	36	and	and	CCONJ
iajs-2011	229	37	mild	mild	ADJ
iajs-2011	229	38	hypomagnesemia	hypomagnesemia	ADV
iajs-2011	229	39	in	in	ADP
iajs-2011	229	40	mice	mouse	NOUN
iajs-2011	229	41	.	.	PUNCT
iajs-2011	230	1	physiol	physiol	PROPN
iajs-2011	230	2	rep.2017	rep.2017	PRON
iajs-2011	230	3	,	,	PUNCT
iajs-2011	230	4	5	5	NUM
iajs-2011	230	5	,	,	PUNCT
iajs-2011	230	6	5	5	NUM
iajs-2011	230	7	,	,	PUNCT
iajs-2011	230	8	1	1	NUM
iajs-2011	230	9	-	-	SYM
iajs-2011	230	10	8	8	NUM
iajs-2011	230	11	.	.	NOUN
iajs-2011	230	12	26	26	NUM
iajs-2011	230	13	.	.	X
iajs-2011	231	1	weir	weir	PROPN
iajs-2011	231	2	,	,	PUNCT
iajs-2011	231	3	m.r	m.r	PROPN
iajs-2011	231	4	.	.	PROPN
iajs-2011	231	5	;	;	PUNCT
iajs-2011	231	6	kline	kline	PROPN
iajs-2011	231	7	,	,	PUNCT
iajs-2011	231	8	i.	i.	PROPN
iajs-2011	231	9	;	;	PUNCT
iajs-2011	232	1	xie	xie	PROPN
iajs-2011	232	2	.	.	PUNCT
iajs-2011	233	1	j.	j.	PROPN
iajs-2011	233	2	;	;	PUNCT
iajs-2011	233	3	edwards	edwards	PROPN
iajs-2011	233	4	,	,	PUNCT
iajs-2011	233	5	r.	r.	PROPN
iajs-2011	233	6	;	;	PUNCT
iajs-2011	233	7	usiskin	usiskin	PROPN
iajs-2011	233	8	,	,	PUNCT
iajs-2011	233	9	k.	k.	PROPN
iajs-2011	233	10	effect	effect	NOUN
iajs-2011	233	11	of	of	ADP
iajs-2011	233	12	canagliflozin	canagliflozin	PROPN
iajs-2011	233	13	on	on	ADP
iajs-2011	233	14	serum	serum	NOUN
iajs-2011	233	15	electrolytes	electrolyte	NOUN
iajs-2011	233	16	in	in	ADP
iajs-2011	233	17	patients	patient	NOUN
iajs-2011	233	18	with	with	ADP
iajs-2011	233	19	type	type	NOUN
iajs-2011	233	20	2	2	NUM
iajs-2011	233	21	diabetes	diabetes	NOUN
iajs-2011	233	22	in	in	ADP
iajs-2011	233	23	relation	relation	NOUN
iajs-2011	233	24	to	to	ADP
iajs-2011	233	25	estimated	estimate	VERB
iajs-2011	233	26	glomerular	glomerular	ADJ
iajs-2011	233	27	filtration	filtration	NOUN
iajs-2011	233	28	rate	rate	NOUN
iajs-2011	233	29	(	(	PUNCT
iajs-2011	233	30	egfr	egfr	X
iajs-2011	233	31	)	)	PUNCT
iajs-2011	233	32	curr	curr	PROPN
iajs-2011	233	33	med	med	PROPN
iajs-2011	233	34	res	re	NOUN
iajs-2011	233	35	opin	opin	NOUN
iajs-2011	233	36	.	.	PUNCT
iajs-2011	234	1	2014	2014	NUM
iajs-2011	234	2	,	,	PUNCT
iajs-2011	234	3	30	30	NUM
iajs-2011	234	4	,	,	PUNCT
iajs-2011	234	5	9	9	NUM
iajs-2011	234	6	,	,	PUNCT
iajs-2011	234	7	1759	1759	NUM
iajs-2011	234	8	-	-	SYM
iajs-2011	234	9	1768	1768	NUM
iajs-2011	234	10	.	.	PUNCT